

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(10) **DK/EP 2314629 T4**

(12) Oversættelse af ændret
europæisk patentskrift

-
- (51) Int.Cl.: *C 07 K 16/46 (2006.01)* *A 61 K 39/00 (2006.01)* *A 61 K 39/395 (2006.01)*
A 61 P 31/04 (2006.01) *A 61 P 31/12 (2006.01)* *A 61 P 35/00 (2006.01)*
A 61 P 35/02 (2006.01) *A 61 P 35/04 (2006.01)* *A 61 P 37/00 (2006.01)*
A 61 P 37/06 (2006.01) *A 61 P 43/00 (2006.01)* *C 07 K 16/00 (2006.01)*
C 07 K 16/10 (2006.01) *C 07 K 16/28 (2006.01)* *C 07 K 16/30 (2006.01)*
C 07 K 16/32 (2006.01) *C 12 P 21/00 (2006.01)* *C 12 P 21/02 (2006.01)*
G 01 N 33/50 (2006.01)
- (45) Oversættelsen bekendtgjort den: **2023-02-06**
- (80) Dato for Den Europæiske Patentmyndigheds
bekendtgørelse om opretholdelse af patentet i ændret form: **2022-11-16**
- (86) Europæisk ansøgning nr.: **10186063.3**
- (86) Europæisk indleveringsdag: **2003-07-15**
- (87) Den europæiske ansøgnings publiceringsdag: **2011-04-27**
- (30) Prioritet: **2002-07-18 US 397066 P** **2002-07-18 EP 02077953**
2003-05-27 WO PCT/EP03/50201
- (62) Stamansøgningsnr: **03764997.7**
- (84) Designerede stater: **AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO
SE SI SK TR**
- (73) Patenthaver: **Merus N.V., Yalelaan 62, 3584 CM Utrecht, Holland**
- (72) Opfinder: **Van Berkel, Patricius Hendrikus, Rodenrijseweg 315, 2651 BS Berkel en Rodenrijs, Holland**
Brus, Ronald Hendrik Peter, Leidseweg 193, 2253 AD Voorschoten, Holland
Bout, Abraham, Van Swaanswijckstraat 38, 2751 XL Moerkapelle, Holland
Logtenberg, Ton, Jachtrustlaan 1, 3985 MK Werkhoven, Holland
- (74) Fuldmægtig i Danmark: **CHAS. HUDE A/S, Langebrogade 3B, 1411 København K, Danmark**
- (54) Benævnelse: **REKOMBINANT PRODUKTION AF BLANDINGER AF ANTISTOFFER**
- (56) Fremdragne publikationer:
WO-A-98/50431
**MERCHANT A M ET AL: "An efficient route to human bispecific IgG", NATURE BIOTECHNOLOGY, NATURE
PUB. CO, NEW YORK, NY, US, vol. 16, no. 7, July 1998 (1998-07), pages 677-681, XP002141015, ISSN: 1087-0156**
**LENZ H ET AL: "EXPRESSION OF HETEROBISPECIFIC ANTIBODIES BY GENES TRANSFECTED INTO
PRODUCER HYBRIDOMA CELLS", GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 87, no. 2, 15
March 1990 (1990-03-15), pages 213-218, XP000114191, ISSN: 0378-1119**
**VAUGHAN T J ET AL: "HUMAN ANTIBODIES WITH SUB-NANOMOLAR AFFINITIES ISOLATED FROM A LARGE
NON-IMMUNIZED PHAGE DISPLAY LIBRARY", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 14,
1 March 1996 (1996-03-01), pages 309-314, XP000196144, ISSN: 1087-0156**
WO-A1-01/64929
WO-A1-91/08216

Fortsættes ...

WO-A1-95/17085
 WO-A1-95/17500
 WO-A1-97/42313
 WO-A1-98/39416
 WO-A1-99/45962
 WO-A2-00/63403
 WO-A2-02/18948
 WO-A2-98/50431
 US-A- 5 888 789
 US-A- 6 080 560
 US-A1- 2002 088 016
 US-B2- 9 248 182
 de Wildt et al (1999) J Mol Biol., 285: 895-901
 Nicholson et al (1999) J. Immunol., 163: 6898-6906
 Mendez et al (1997) Nat Genet. 15: 146-56
 Merchant et al (1998) Nat. Biotech. 16: 677-681
 Pollock et al (1999) J Immunol Methods. 231: 147-157
 Larrick and Thomas (2001) Curr. Opin. Biotechnol. 12: 411-418
 Wilmut and Clark (1991) J Reprod Fertil Suppl 43: 265-275
 Schnieke et al (1997) Science, 278: 2130-2133
 Campbell et al, (1996) Nature, 380: 64-66
 Wilmut et al (1997) Nature, 385: 810-813
 Dinnyes et al (2002) Cloning Stem Cells, 4: 81-90
 Hiatt et al (1989) Nature, 342: 76-78
 Peeters et al (2001) Vaccine, 19: 2756-2761
 Giddings et al (2000) Nat. Biotechnol., 18: 1151-1155
 Carter et al (2001) J. Immunol Methods, 248: 7-15
 Segal (2001) J Immunol Methods, 248:1-6
 Nissim et al (1994) EMBO J, 13: 692-698
 Vaughan et al (1996) Nat. Biotech., 14: 309-314
 Kasprzyk et al (1992) Cancer Research, 52: 2771-2776
 Flavell et al (2001) British Journal of Cancer (2001) 84(4):571-578
 Nemazee (2000) Adv. Immunol., 74: 89-126
 Casellas et al (2001) Science 291: 1541-1544
 Radic et al (1991) J. Immunol., 146: 176-182
 De Kruif et al (1995) Proc Natl Acad Sci USA, 92:3938
 Declaration from Ton Logtenberg
 Appeal Brief from US Application No. 13/948,813 filed 20 July 2015
 Declaration from Joel Martin (originally filed as R36)
 Huls et al (1999) Cancer Research 59: 5778-5784 (originally filed as R38)
 Jones et al (2003) Biotechnol Prog. 19: 163-168 - ?High-level expression of recombinant γ G in the human cell line PER.C6*? (originally filed as R41)
 Tada et al (1994) Journal of Biotechnology 33: 157-174
 Phelps et al (1990) Journal of Immunology 145(4): 1200-1204
 Verma et al (1998) Journal of immunological Methods 216: 165-181
 Fussenegger et al (1999) Trends In Biotechnol 17: 35-42

DESCRIPTION

Field of the invention

[0001] The present invention relates to the field of medicine, more in particular to the field of production of antibodies, more in particular to the production of mixtures of antibodies.

Background of the invention

[0002] The essential function of the immune system is the defence against infection. The humoral immune system combats molecules recognized as non-self, such as pathogens, using immunoglobulines. These immunoglobulines, also called antibodies, are raised specifically against the infectious agent, which acts as an antigen, upon first contact (ROITT, Essential Immunology, Blackwell Scientific Publications, fifth edition, 1984). Antibodies are multivalent molecules comprising heavy (H) chains and light (L) chains joined with interchain disulfide bonds. Several isotypes of antibodies are known, including IgG1, IgG2, IgG3, IgG4, IgA, IgD, IgE, and IgM. An IgG contains two heavy and two light chains. Each chain contains constant (C) and variable (V) regions, which can be broken down into domains designated C_{H1} , C_{H2} , C_{H3} , V_H , and C_L , V_L (Fig. 1). Antibody binds to antigen via the variable region domains contained in the Fab portion, and after binding can interact with molecules and cells of the immune system through the constant domains, mostly through the Fc portion.

B-lymphocytes can produce antibodies in response to exposure to biological substances like bacteria, viruses and their toxic products. Antibodies are generally epitope specific and bind strongly to substances carrying these epitopes. The hybridoma technique (Kohler and Milstein 1975) makes use of the ability of B-cells to produce monoclonal antibodies to specific antigens and to subsequently produce these monoclonal antibodies by fusing B-cells from mice exposed to the antigen of interest to immortalized murine plasma cells. This technology resulted in the realization that monoclonal antibodies produced by hybridoma's could be used in research, diagnostics and therapies to treat different kinds of diseases like cancer and auto-immune related disorders.

Because antibodies that are produced in mouse hybridoma's induce strong immune responses in humans, it has been appreciated in the art that antibodies required for successful treatment of humans needed to be less or preferably non-immunogenic. For this, murine antibodies were first engineered by replacing the murine constant regions with human constant regions (referred to as chimeric antibodies). Subsequently, domains between the complementarity determining regions (CDRs) in the variable domains, the so-called framework regions, were replaced by their human counterparts (referred to as humanized antibodies). The final stage in this humanization process has been the production of fully human antibodies.

[0003] In the art, also bispecific antibodies, which have binding specificities for two different antigens, have been described. These are generally used to target a therapeutic or diagnostic

moiety, e.g. T-cell, a cytotoxic trigger molecule or a chelator that binds a radionuclide, that is recognized by one variable region of the antibody to a cell that is recognized by the other variable region of the antibody, e.g. a tumor cell (see for bispecific antibodies Segal et al, 2001).

[0004] Merchant et al (Nature Biotechnology, Vol. 16, No.7 (1998), 677-681) describe the production of a human bispecific IgG, wherein a single light chain was used and heavy chains were remodeled for heterodimerization using engineered disulfide bonds in combination with the "knob-into-hole" technology. A yield of 95% heterodimer was achieved.

[0005] Lenz and Weidle (Gene, Vol. 87, No.2 (1990), 213-218) describe a method for producing heterobifunctional antibodies, wherein cloned genes encoding an antibody of interest are introduced into a hybridoma cell line secreting another antibody of interest. This way, stable cell lines secreting heterobispecific antibodies are obtained.

[0006] One very useful method known in the art to obtain fully human monoclonal antibodies with desirable binding properties employs phage display libraries. This is an *in vitro*, recombinant DNA-based, approach that mimics key features of the humoral immune response (see for phage display methods e.g. CF BARBAS III et al, Phage Display. A laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2001). For the construction of phage display libraries, collections of human monoclonal antibody heavy and light chain variable region genes are expressed on the surface of bacteriophage particles, usually in single chain Fv (scFv) or in Fab format. Large libraries of antibody fragment-expressing phages typically contain more than 10^9 antibody specificities and may be assembled from the immunoglobulin V regions expressed in the B lymphocytes of immunized- or non-immunized individuals. Alternatively, phage display libraries may be constructed from immunoglobulin variable regions that have been partially assembled or rearranged *in vitro* to introduce additional antibody diversity in the library (semi-synthetic libraries) (De Kruif et al, 1995b). For example, *in vitro* assembled variable regions contain stretches of synthetically produced, randomized or partially randomized DNA in those regions of the molecules that are important for antibody specificity. The genetic information encoding the antibodies identified by phage display, can be used for cloning the antibodies in a desired format, e.g. IgG, IgA or IgM, to produce the antibody with recombinant DNA methods (Boel et al, 2000).

An alternative method to provide fully human antibodies uses transgenic mice that comprise genetic material encoding a human immunoglobulin repertoire (Fishwild et al, 1996; Mendez et al, 1997). Such mice can be immunized with a target antigen, and the resulting immune response will produce fully human antibodies. The sequences of these antibodies can be used in recombinant production methods.

[0007] Production of monoclonal antibodies routinely is performed by use of recombinant expression of the nucleic acid sequences encoding the H and L chains of antibodies in host cells (see e.g. EP0120694; EP0314161; EP0481790; US patent 4,816,567; WO 00/63403).

[0008] To date, many different diseases are being treated with either humanized or fully

human monoclonal antibodies. Products based on monoclonal antibodies that are currently approved for use in humans include Herceptin[™] (anti-Her2/Neu), Reopro[™] (anti-Glycoprotein IIB/IIIA receptor), Mylotarg[™] (anti-CD33), Rituxan[™] (Rituximab, anti-CD20), Simulect[™] (anti-CD25), Remicade[™] (anti-TNF), Synagis[™] (anti-RSV), Zenapax[™] (IL2-receptor), CAMPATH[™] (anti-CD52). Despite these successes, there is still room for new antibody products and for considerable improvement of existing antibody products. The use of monoclonal antibodies in cancer treatment has shown that so-called "antigen-loss tumor variants" can arise, making the treatment with the monoclonal antibody less effective. Treatment with the very successful monoclonal antibody Rituximab (anti-CD20) has for instance shown that antigen-loss escape variants can occur, leading to relapse of the lymphoma (Massengale et al, 2002). In the art, the potency of monoclonal antibodies has been increased by fusing them to toxic compounds, such as radionuclides, toxins, cytokines, and the like. Each of these approaches however has its limitations, including technological and production problems and/or high toxicity.

[0009] Furthermore, it appears that the gain in specificity of monoclonal antibodies compared to traditional undefined polyclonal antibodies, goes at the cost of loss of efficacy. In vivo, antibody responses are polyclonal in nature, i.e. a mixture of antibodies is produced because various B-cells respond to the antigen, resulting in various specificities being present in the polyclonal antibody mixture. Polyclonal antibodies can also be used for therapeutic applications, e.g. for passive vaccination or for active immunotherapy, and currently are usually derived from pooled serum from immunized animals or from humans who recovered from the disease. The pooled serum is purified into the proteinaceous or gamma globulin fraction, so named because it contains predominantly IgG molecules. Polyclonal antibodies that are currently used for treatment include anti-rhesus polyclonal antibodies, gamma-globulin for passive immunization, anti-snake venom polyclonal (CroFab), Thymoglobulin[™] for allograft rejection, anti-digoxin to neutralize the heart drug digoxin, and anti-rabies polyclonal. In currently marketed therapeutic antibodies, an example of the higher efficacy of polyclonal antibodies compared to monoclonal antibodies can be found in the treatment of acute transplant rejection with anti-T-cell antibodies. The monoclonal antibodies on the market (anti-CD25 basiliximab) are less efficacious than a rabbit polyclonal antibody against thymocytes (Thymoglobulin[™]) (press releases dated March 12, April 29, and August 26, 2002, on www.sangstat.com). The use of pooled human sera however potentially bears the risk of infections with viruses such as HIV or hepatitis, with toxins such as lipopolysaccharide, with proteinaceous infectious agents such as prions, and with unknown infectious agents. Furthermore, the supply that is available is limited, and insufficient for widespread human treatments. Problems associated with the current application of polyclonal antibodies derived from animal sera in the clinic include a strong immune response of the human immune system against such foreign antibodies. Therefore such polyclonals are not suitable for repeated treatment, or for treatment of individuals that were injected previously with other serum preparations from the same animal species.

[0010] The art describes the idea of the generation of animals with a human immunoglobulin repertoire, which can subsequently be used for immunization with an antigen to obtain

polyclonal antibodies against this antigen from the transgenic animals (WO 01/19394). However, much technological hurdles still will have to be overcome before such a system is a practical reality in larger animals than mice, and it will take years of development before such systems can provide the polyclonal antibodies in a safe and consistent manner in sufficient quantities. Moreover, antibodies produced from pooled sera, whether being from human or animal origin, will always comprise a high amount of unrelated and undesired specificities, as only a small percentage of the antibodies present in a given serum will be directed against the antigen used for immunization. It is for instance known that in normal, i.e. non-transgenic, animals about 1-10% of the circulating immunoglobulin fraction is directed against the antigen used for hyper-immunization, hence the vast majority of circulating immunoglobulins is not specific.

[0011] One approach towards expression of polyclonal antibody libraries has been described (WO 95/20401; US patents 5,789,208 and 6,335,163). A polyclonal library of Fab antibody fragments is expressed using a phage display vector, and selected for reactivity towards an antigen. The selected heavy and light chain variable region gene combinations are transferred in mass, as linked pairs, to a eukaryotic expression vector that provides constant region genes, to obtain a sublibrary of intact polyclonal antibodies. Upon transfection of this sublibrary into myeloma cells, stable clones produce monoclonal antibodies that can be mixed to obtain a polyclonal antibody mixture. While in theory it would be possible to obtain polyclonal antibodies directly from a single recombinant production process using this method by culturing a mixed population of transfected cells, potential problems would occur concerning the stability of the mixed cell population, and hence the consistency of the produced polyclonal antibody mixture. The control of a whole population of different cells in a pharmaceutically acceptable large (i.e. industrial) scale process, is a daunting task. It would seem, that characteristics such as growth rates of the cells and production rates of the antibodies should remain stable for all the individual clones of the non-clonal population in order to keep the ratio of antibodies in the polyclonal antibody mixture more or less constant. Thus, while the need for mixtures of antibodies may have been recognized in the art, no acceptable solutions exist to make mixtures of antibodies economically in a pharmaceutically acceptable way. It is the object of the present invention to provide novel means for producing a mixture of antibodies in recombinant hosts.

Brief description of the figures

[0012]

Fig. 1 Schematic representation of an antibody. The heavy and light chains are paired via interchain disulfide bonds (dotted lines). The heavy chain can be either of the α , γ , μ , δ , or ϵ isotype. The light chain is either λ or κ . An antibody of IgG1 isotype is shown.

Fig. 2 Schematic representation of a bi-specific monoclonal antibody. A bi-specific antibody contains two different functional F(Ab) domains, indicated by the different patterns of the V_H - V_L

regions.

Fig. 3 Sequence alignment of V_L and V_H of K53, UBS-54 and 02-237. DNA sequence of common V_L of UBS54 and K53 is SEQ. ID. NO. 1, while the amino acid sequence is given as SEQ. ID. NO. 2. DNA sequences of V_L of 02-237, and V_H of UBS54, K53 and 02-237 are SEQ. ID. NOs. 3, 5, 7 and 9, respectively, while the amino acid sequences are given in SEQ. ID. NOs. 4, 6, 8 and 10, respectively.

Fig. 4 Overview of plasmids pUBS3000Neo and pCD46_3000 (Neo).

Fig. 5 A. IEF of transiently expressed pUBS3000Neo, pCD46_3000(Neo) and a combination of both. B. The upper part shows a schematic representation of the expected molecules when a single light chain and a single heavy chain are expressed in a cell, leading to monoclonal antibodies UBS-54 or K53. The lower part under the arrow shows a schematic representation of the combinations produced when both heavy chains and the common light chain are co-expressed in a host cell, with theoretical amounts when both heavy chains are expressed at equal levels and pair to each other with equal efficiency. The common light chain is indicated with the vertically striped bars.

Fig. 6. Schematic representation of a method (see e.g. Examples 9). (1) Introduction of nucleic acid sequences encoding one light chain and three different heavy chains capable of pairing to the common light chain to give functional antibodies into host cells; (2) selection of stable clones; (3) clones can be screened for e.g. expression levels, binding; (4) expand clones; (5) production of functional mixtures of antibodies. Some or all of steps 2-5 could be performed simultaneously or in different order.

Fig. 7. Sequence of V_H and V_L of phages directed against CD22 (clone B28), CD72 (clone II-2) and HLA-DR (class II; clone I-2). DNA sequences of V_L of clones B28, II-2 and I-2 are SEQ. ID. NOs. 11, 13 and 15, respectively, while the amino acid sequences are SEQ. ID. NOs. 12, 14 and 16, respectively. DNA sequence of the common light chain of these clones is SEQ. ID. NO. 17, while the amino acid sequence is SEQ. ID. NO. 18.

Fig. 8. Map of pUBS54-IgA (pCRU-L01 encoding human IgA1 against EPCAM).

Fig. 9. Dimeric bi-specific IgA with a single light chain (indicated by horizontally striped bar). The method of the invention will produce a mixture of forms wherein different heavy chains can be paired, and only the most simple form is depicted in this schematic representation. A J-chain is shown to join the two monomers.

Fig. 10. Pentameric multispecific IgM with a single light chain (indicated by horizontally striped bars). The method as described herein may produce a mixture of many different forms wherein different heavy chains can be paired, and only the most simple form when 5 different heavy chains are expressed with a single light chain, and all 5 different heavy chains are incorporated in the pentamer and paired to the same heavy chain, is depicted in this schematic representation. Pentamers with less specificities can also be formed by incorporation of less than 5 different heavy chains. Especially when the J-chain is not expressed, hexamers can

also be obtained.

Fig. 11. Expression of a mixture of human IgG isotypes consisting of a common light chain, but with different binding specificities in a single cell to avoid the formation of bispecific antibodies. The different binding specificities are indicated by the different colours of the VH sequences. The common light chain is indicated with the vertically striped bars. The IgG1 isotype is indicated with the grey Fc, the IgG3 isotype is indicated with the black Fc part.

Fig. 12. DNA and protein sequences of variable domains heavy and light chains of K53, UBS54 and 02-237 IgG.

Fig. 13 Alignment of the variable sequences of the heavy chains of K53, 02-237 and UBS54. CDR1, CDR2 and CDR3 regions are indicated in bold.

Fig. 14 BIACORE analysis of K53 and 02-237. Affinity purified human CD46 from LS174T cells was coupled (640 RU) to CM5 chips (BIACORE BR-1000-14). Binding of 1000 (A), 500 (B), 250 (C), 125 (D), 63 (E), 31 (F), 16 (G), 8 (H) or 0 (I) nM 02-237 or k53 purified from stable PER.C6TM derived cell lines to the CD46 was monitored using a BIACORE 3000 system at 37°C. Using this experimental set-up, a K_d of 9.1×10^{-7} and 2.2×10^{-8} was found for K53 and 02-237, respectively.

Fig. 15 Binding of K53 and 02-237 to LS174T cells. Serial dilutions of purified 02-237 (■), K53 (✕) and the negative control GBSIII (◇) conjugated to biotin were incubated with LS147T cells preincubated with normal human serum to block Fcγ receptor interaction. Binding (MFI, ordinate) was determined by FACS after incubation with streptavidin conjugated-phycoerythrin.

Fig. 16. SDS-PAGE analysis of purified IgG fractions. Three µg purified IgG was analysed on a non-reduced (A) and reduced (B) 4-20% Nupage gel (Novex) according to recommendations of the manufacturer. Proteins were visualized by staining with colloidal blue (Novex cat. No LC6025) according to recommendations of the manufacturer. Clone identity is indicated on top of the SDS-PAGE. Each gel contains a control, which is either purified 02-237 or K53. NR, Non-reduced; R, reduced.

Fig. 17. IEF analysis of purified IgG fractions. Ten µg purified IgG was analysed on an Isogel 3-10 gel (BMA) according to recommendations of the manufacturer. Proteins were visualized by staining with colloidal blue (Novex, cat. No LC6025) according to recommendations of the manufacturer. Clone identity is indicated on top of the IEF. Each gel contains a control, consisting of a 1:1:1 mixture of 02-237, K53 and UBS54.

Fig. 18. IEF analysis of polyclonal mixtures 241, 280, 282, 361 and 402 in comparison to single K53, 02-237 and UBS54. Ten µg purified IgG was analysed on an Isogel 3-10 gel (BMA) according to recommendations of the manufacturer. Proteins were visualized by staining with colloidal blue (Novex, cat. No LC6025) according to recommendations of the manufacturer. IgG identity is indicated on top of the IEF.

Fig. 19. Mass chromatograms of CDR3 peptides of K53, 02-237, UBS54 and the two unique

light chain peptides L1-K53/UBS54 and L1-237 in IgG fraction Poly1-280. On the right-hand side of each mass chromatogram, the isotopic pattern of the peptide is shown. The doubly charged ion at m/z 1058.98 (Mw 2115.96 Da) results from peptide H11-K53. The doubly charged ion at m/z 1029.96 (Mw 2057.92 Da) results from peptide H11-02-237. The triply charged ion at m/z 770.03 (Mw 2307.09 Da) results from peptide H9-UBS54. The doubly charged ion at m/z 1291.08 (Mw 2580.16 Da) results from peptide L1-K53/UBS54. The doubly charged ion at m/z 1278.11 (Mw 2554.22 Da) results from peptide L1-02-237.

Purified IgG was dissolved in a 0.1% RapiGestTM (Waters) in 50 mM NH_4HCO_3 . The disulfides were reduced using 1 M DTT (1,4-dithio-DL-threitol), followed by incubation at 65°C for 30 minutes. Then, for alkylation of all sulfhydryl groups, 1 M iodoacetamide was added, followed by incubation at room temperature for 45 minutes in dark. Alkylation was stopped by addition of 1 M DTT. The buffer was exchanged to 25 mM NH_4HCO_3 , pH 7.5. Finally, the antibodies were digested overnight at 37 °C by addition of a freshly prepared trypsin solution in 25 mM NH_4HCO_3 . The peptide mixture was analysed by LC-MS. The LC-system consisted of a Vydac reversed-phase C18 column, that was eluted by applying a gradient of solvent A (5/95/1 acetonitrile, water, glacial acetic acid v/v/v) and solvent B (90/10/1 acetonitrile, water, glacial acetic acid v/v/v). The LC was on-line coupled to a Q-TOF2 mass spectrometer (Micromass), equipped with an electrospray source operated at 3 kV. Mass spectra were recorded in positive ion mode from m/z 50 to 1500 at a cone voltage of 35 V. The instrumental resolution of >10,000 enabled unambiguous determination of the charge, and therefore the mass of most ions up to at least +7. In this way, all peptides were identified according to their molecular weight. The amino acid sequence of the peptide was confirmed by MS/MS-experiments. MS/MS spectra were recorded in positive ion mode from m/z 50-2000 with collision energy between 20 and 35 eVolts.

Fig. 20. BIACORE analysis of polyclonal 280. Affinity purified human CD46 from LS174T cells was coupled (640 RU) to CM5 chips (BIACORE BR-1000-14). Binding of 1000 (A), 500 (B), 250 (C), 125 (D), 63 (E), 31 (F), 16 (G), 8 (H) or 0 (I) nM Poly1-280 to CD46 was monitored using a BIACORE 3000 system at 37°C.

Fig. 21. IEF analysis of sub-clones from clones poly 1-241, poly 1-280 and poly 1-402 producing a mixture of antibodies. A. Clones poly 1-241 and poly 1-280. Lane 1 contains a pi marker (Amersham, Cat. No. 17-0471-01). Lane 2 contains isolated IgG from the parent clone poly 1-241 (as in Fig. 18). Lanes 3, 4 and 5 respectively contain isolated IgG from 3 independent sub-clones derived from poly 1-241 by limiting dilution. Lane 6 contains isolated IgG from the parent clone poly 1-280 (as in Fig. 18). Lanes 7, 8 and 9 respectively contain isolated IgG from three independent sub-clones derived from poly 1-280 by limiting dilution. B. Clone poly 1-402. Lanes 1 and 7 contain a pi marker. Lane 2 contains isolated IgG from the parent clone poly 1-402 (as in Fig. 18). Lanes 3, 4 and 5 respectively contain isolated IgG from 3 independent sub-clones derived from poly 1-402 by limiting dilution. Lane 6 contains a control (a 1:1:1 mixture of 02-237, K53 and UBS54).

Fig. 22. FACS analysis of mixtures of antibodies produced from sub-clones of poly 1-241 (A), poly 1-280 (B) and poly 1-402 (C). Binding of the mixtures of antibodies to cells transfected with cDNA of CD46, EpCAM, or a negative control (CD38), was determined with FACS

analysis, and mean fluorescent intensity (MFI) is shown for the various parent clones and three independent sub-clones of each. Control antibodies GBS-III (negative control), anti-CD72 (02-004; negative control) and the single antibodies UBS54, 02-237 and K53 are also included.

Summary of the invention

[0013] In one aspect the present invention provides for a method for identifying at least one host cell clone that produces a mixture of antibodies, wherein said mixture of antibodies has a desired effect according to a functional assay, the method comprising the steps of:

1. (i) providing a host cell with nucleic acid sequence encoding one light chain and nucleic acid sequences encoding two different heavy chains, wherein said heavy and light chains are capable of pairing with each other;
2. (ii) culturing at least one clone of said host cell under conditions conducive to expression of said nucleic acid sequences;
3. (iii) screening said at least one clone of the host cell for production of a mixture of antibodies having the desired effect by a functional assay; and
4. (iv) identifying at least one clone that produces a mixture of antibodies having the desired effect.

A further aspect of the invention is the elimination of the production of potentially non-functional light-heavy chain pairing by using pre-selected combinations of heavy and light chains. It has been recognized that phage display libraries built from a single light chain and many different heavy chains can encode antibody fragments with very distinct binding properties. This feature can be used to find different antibodies having the same light chain but different heavy chains, against the same target or different targets, wherein a target can be a whole antigen or an epitope thereof. Such different targets may for instance be on the same surface (e.g. cell or tissue). Such antibody fragments obtained by phage display can be cloned into vectors for the desired format, e.g. IgG, IgA or IgM, and the nucleic acid sequences encoding these formats can be used to transfect host cells. In one approach, H and L chains can be encoded by different constructs that, upon transfection into a cell wherein they are expressed, give rise to intact Ig molecules. When different H chain constructs are transfected into a cell with a single L chain construct, H- and L-chains will be assembled to form all possible combinations. However, in contrast to approaches where different light chains are expressed such as for the production of bispecific antibodies, this method will result only in functional binding regions. It would be particularly useful when the host, e.g. a single cell line, is capable of expressing acceptable levels of recombinant antibodies, without the necessity to first amplify in said cell the nucleic acid sequences encoding the antibodies. The advantage is that cell lines with only a limited copy number of said nucleic acids are expected to be genetically more stable, because there will be less recombination between the sequences encoding the heavy chains, than in cell lines where a multitude of these copies is present. A cell line suitable for use in the methods

according to the invention is the human cell line PER.C6[™]. Using this method a mixture of antibodies with defined specificities can be produced from a single cell clone in a safe, controlled, and consistent manner.

[0014] The invention provides a method of producing a mixture of antibodies, comprising the step of:

1. (i) culturing a host cell clone identified by a method according to the invention under conditions conducive to expression of the nucleic acids encoding the one light chain and the two different heavy chains.

[0015] In a preferred aspect, the recombinant host cell comprises a nucleic acid sequence encoding a common light chain that is capable of pairing with said two different heavy chains, such that the produced antibodies comprise a common light chain. Obviously, those of skill in the art will recognize that "common" also refers to functional equivalents of the light chain of which the amino acid sequence is not identical. Many variants of said light chain exist wherein mutations (deletions, substitutions, additions) are present that do not materially influence the formation of functional binding regions.

[0016] Methods of the invention can be used to prepare a mixture of antibodies comprising a common light chain and two different heavy chains with a different variable region, wherein the two different heavy chains are capable of pairing to said common light chain, and wherein said heavy chains further differ in their constant regions sufficiently so that the amount of bispecific antibodies is decreased as compare to the theoretical percentage of bispecific antibodies. In one embodiment, the light chains of such mixtures have a common sequence. Preferably, the mixture of antibodies is more efficacious than the individual antibodies it comprises, more preferably, the mixture acts synergistically in a functional assay.

[0017] Independent clones obtained from the transfection of nucleic acid sequences encoding a light chain and more than one heavy chain may express the different antibodies in the mixture at different levels. It is another aspect of the invention to select a clone using a functional assay, for the most potent mixture of antibodies. The invention therefore provides a method for identifying at least one host cell clone that produces a mixture of antibodies, wherein said mixture of antibodies has a desired effect according to a functional assay, the method comprising the steps of: (i) providing a host cell with nucleic acid sequence encoding one light chain and nucleic acid sequences encoding two different heavy chains, wherein said heavy and light chains are capable of pairing with each other; (ii) culturing at least one clone of said host cell under conditions conducive to expression of said nucleic acid sequences; (iii) screening said at least one clone of the host cell for production of a mixture of antibodies having the desired effect by a functional assay; and (iv) identifying at least one clone that produces a mixture of antibodies having the desired effect. This method according to the invention can be performed using high-throughput procedures, if desired. The clones identified by the method can be used to produce antibody mixtures according to the invention.

[0018] Mixtures of antibodies prepared using the methods of the invention can be used in the treatment or diagnosis and for the preparation of a medicament for use in the treatment or diagnosis of a disease or disorder in a human or animal subject.

[0019] The invention further provides a method according to the invention for producing a mixture of antibodies comprising different isotypes from a single host cell clone.

[0020] The invention further provides a method according to the invention for identifying a mixture of antibodies having a desired effect in a functional assay.

Detailed description of the invention

[0021] The term "antibody" as used herein means a polypeptide containing one or more domains that bind an epitope on an antigen, where such domains are derived from or have sequence identity with the variable region of an antibody. The structure of an antibody is schematically represented in Fig. 1. Examples of antibodies include full length antibodies, antibody fragments, bispecific antibodies, immunoconjugates, and the like. An antibody according to the invention may be isotype IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgE, IgM, and the like, or a derivative of these. Antibody fragments include Fv, Fab, Fab', F(ab')₂ fragments, and the like. Antibodies can be of any origin, including murine, of more than one origin, i.e. chimeric, humanized, or fully human antibodies. Immunoconjugates comprise antigen binding domains and a non-antibody part such as a toxin, a radiolabel, an enzyme, and the like. An "antigen binding domain" preferably comprises variable regions of a heavy and a light chain, and is responsible for specific binding to an antigen of interest. Recombinant antibodies are prepared by expressing both a heavy and a light chain in a host cell. Similarly, by expressing two chains with their respective light chains (or a common light chain), wherein each heavy chain/light chain has its own specificity, so-called "bispecific" antibodies can be prepared. "Bispecific antibodies" comprise two non-identical heavy-light chain combinations (Fig. 2), and both antigen binding regions of a bispecific antibody may recognize different antigens or different epitopes on an antigen.

[0022] A "common light chain" refers to light chains which may be identical or have amino acid sequence differences. Said light chains may comprise mutations which do not alter the specificity of the antibody when combined with the same heavy chain, without departing from the scope of the present invention. It is for instance possible within the scope of the definition of common light chains as used herein, to prepare or find light chains that are not identical but still functionally equivalent, e.g. by introducing and testing conservative amino acid changes, changes of amino acids in regions that do not or only partly contribute to binding specificity when paired with the heavy chain, and the like. It is an aspect of the present invention to use as common light chain one identical light chain to combine with different heavy chains to form antibodies with functional antigen binding domains. The use of one common light chain avoids

the formation of heterodimers in which pairing of light and heavy chains results in antigen binding domains that are not functional, in other words which are not capable of binding to the target antigen or antigens. The use of a common light chain and two heavy chains has been proposed by (Merchant et al, 1998; WO 98/50431) for a different purpose, viz. to *increase* the formation of functional bispecific antibodies at the expense of antibody mixture complexity. These publications teach a method for preferentially producing one defined and desired bispecific antibody, thereby *minimizing* the complexity of the produced mixture. Hence, Merchant specifically teaches to prevent the production of monospecific antibodies, because these are undesired byproducts in the process for bispecific antibody production described in those publications. Clearly, there is no teaching in the prior art to prepare a complex mixture of antibodies from a recombinant host cell avoiding the formation of non-functional binding domains or the benefits thereof, let alone how. In the method according to the present invention, two different heavy chains that are capable of pairing with the common light chain are expressed.

[0023] "Different heavy chains" according to the invention may differ in the variable region and have the same constant region. In other embodiments, where it is clear from the context, they may have the same variable region and differ in the constant region, e.g. be of a different isotype. The use of a mixture of antibodies having different constant regions, such as the Fc-portion, may be advantageous if different arms of the immune system are to be mobilized in the treatment of the human or animal body. In yet other embodiments, also to be clear from the context, both the variable and the constant regions may differ.

[0024] A "mixture of antibodies" according to the invention comprises at least two non-identical antibodies, but may comprise 3 different antibodies, and may resemble a polyclonal or at least an oligoclonal antibody mixture with regard to complexity and number of functional antigen binding molecules. The mixtures produced according to the present invention usually will comprise bispecific antibodies. If desired, formation of monospecific antibodies in the mixture can be favoured over the formation of bispecific antibodies. When n heavy chains and one common light chain are expressed according to the invention in a host cell at equal levels, the theoretical percentage of bispecific antibodies produced by the method according to the invention is $(1-1/n)*100\%$. The total number of different antibodies in the mixture produced by the method according to the invention is theoretically $n+\{(n^2-n)/2\}$, of which $(n^2-n)/2$ are bispecific antibodies. Distortion of the ratio of expression levels of the different heavy chains may lead to values deviating from the theoretical values. The amount of bispecific antibodies can also be decreased, compared to these theoretical values, if not all heavy chains pair with equal efficiency. It is for instance possible to engineer the heavy chains, e.g. by introducing specific and complementary interaction surfaces between selected heavy chains, to promote homodimer pairing over heterodimer pairing, contrary to what has been proposed by Merchant, *supra*. Heavy chains may also be selected so as to minimize heterodimer formation in the mixture. A special form of this embodiment involves heavy chains of two or more different isotypes (e.g. IgG1, IgG3, IgA). When heavy chains of different isotype are expressed in the same host cell in accordance with the present invention and one light chain that can pair to these heavy chains, the amount of bispecific antibodies will be reduced, possibly to very low

or even to undetectable levels. Thus, when bispecific antibodies are less desirable, it is possible to produce a mixture of antibodies according to the invention, wherein a nucleic acid sequence encoding a common light chain and nucleic acid sequences encoding two different heavy chains with a different variable region capable of pairing to said common light chain are expressed in a recombinant host, and wherein said heavy chains further differ in their constant regions sufficiently to reduce or prevent pairing between the different heavy chains. The mixtures of antibodies according to the invention may be produced from a clone that was derived from a single host cell, i.e. from a population of cells containing the same recombinant nucleic acid sequences.

[0025] It will be understood that the different heavy chains can be encoded on separate nucleic acid molecules, but may also be present on one nucleic acid molecule comprising different regions encoding said two heavy chains. The nucleic acid molecules usually encode precursors of the light and/or heavy chains, which when expressed are secreted from the host cells, thereby becoming processed to yield the mature form. These and other aspects of expressing antibodies in a host cell are well known to those having ordinary skill in the art.

[0026] A "recombinant host cell" as used herein is a cell comprising one or more so-called transgenes, i.e. recombinant nucleic acid sequences not naturally present in said cell. These transgenes are expressed in said host cell to produce recombinant antibodies encoded by these nucleic acid sequences, when these cells are cultured under conditions conducive to expression of said nucleic acid sequences. The host cell can be present in the form of a culture from a clone that is derived from a single host cell wherein the transgenes have been introduced. To obtain expression of nucleic acid sequences encoding antibodies, it is well known to those skilled in the art that sequences capable of driving such expression can be functionally linked to the nucleic acid sequences encoding the antibodies. Functionally linked is meant to describe that the nucleic acid sequences encoding the antibody fragments or precursors thereof is linked to the sequences capable of driving expression such that these sequences can drive expression of the antibodies or precursors thereof. Useful expression vectors are available in the art, e.g. the pcDNA vector series of Invitrogen. Where the sequence encoding the polypeptide of interest is properly inserted with reference to sequences governing the transcription and translation of the encoded polypeptide, the resulting expression cassette is useful to produce the polypeptide of interest, referred to as expression. Sequences driving expression may include promoters, enhancers and the like, and combinations thereof. These should be capable of functioning in the host cell, thereby driving expression of the nucleic acid sequences that are functionally linked to them. Promoters can be constitutive or regulated, and can be obtained from various sources, including viruses, prokaryotic, or eukaryotic sources, or artificially designed. Expression of nucleic acids of interest may be from the natural promoter or derivative thereof or from an entirely heterologous promoter. Some well-known and much used promoters for expression in eukaryotic cells comprise promoters derived from viruses, such as adenovirus, e.g. the E1A promoter, promoters derived from cytomegalovirus (CMV), such as the CMV immediate early (IE) promoter, promoters derived from Simian Virus 40 (SV40), and the like. Suitable promoters can also be derived from eukaryotic cells, such as methallothionein (MT) promoters, elongation

factor 1 α (EF-1 α) promoter, actin promoter, an immunoglobulin promoter, heat shock promoters, and the like. Any promoter or enhancer/promoter capable of driving expression of the sequence of interest in the host cell is suitable in the invention. In one embodiment the sequence capable of driving expression comprises a region from a CMV promoter, preferably the region comprising nucleotides -735 to +95 of the CMV immediate early gene enhancer/promoter. The skilled artisan will be aware that the expression sequences used in the invention may suitably be combined with elements that can stabilize or enhance expression, such as insulators, matrix attachment regions, STAR elements (WO 03/004704), and the like. This may enhance the stability and/or levels of expression.

Protein production in recombinant host cells has been extensively described, e.g. in *Current Protocols in Protein Science*, 1995, Coligan JE, Dunn BM, Ploegh HL, Speicher DW, Wingfield PT, ISBN 0-471-11184-8; Bendig, 1988. Culturing a cell is done to enable it to metabolize, and/or grow and/or divide and/or produce recombinant proteins of interest. This can be accomplished by methods well known to persons skilled in the art, and includes but is not limited to providing nutrients for the cell. The methods comprise growth adhering to surfaces, growth in suspension, or combinations thereof. Several culturing conditions can be optimized by methods well known in the art to optimize protein production yields. Culturing can be done for instance in dishes, roller bottles or in bioreactors, using batch, fed-batch, continuous systems, hollow fiber, and the like. In order to achieve large scale (continuous) production of recombinant proteins through cell culture it is preferred in the art to have cells capable of growing in suspension, and it is preferred to have cells capable of being cultured in the absence of animal- or human-derived serum or animal- or human-derived serum components. Thus purification is easier and safety is enhanced due to the absence of additional animal or human proteins derived from the culture medium, while the system is also very reliable as synthetic media are the best in reproducibility.

[0027] "Host cells" may be any host cell capable of expressing recombinant DNA molecules, including bacteria such as *Escherichia* (e.g. *E.coli*), *Enterobacter*, *Salmonella*, *Bacillus*, *Pseudomonas*, *Streptomyces*, yeasts such as *S.cerevisiae*, *K.lactis*, *P.pastoris*, *Candida*, or *Yarrowia*, filamentous fungi such as *Neurospora*, *Aspergillus oryzae*, *Aspergillus nidulans* and *Aspergillus niger*, insect cells such as *Spodoptera frugiperda* SF-9 or SF-21 cells, mammalian cells such as Chinese hamster ovary (CHO) cells, BHK cells, mouse cells including SP2/0 cells and NS-0 myeloma cells, primate cells such as COS and Vero cells, MDCK cells, BRL 3A cells, hybridomas, tumor-cells, immortalized primary cells, human cells such as W138, HepG2, HeLa, HEK293, HT1080 or embryonic retina cells such as PER.C6[™], and the like. Often, the expression system of choice will involve a mammalian cell expression vector and host so that the antibodies are appropriately glycosylated. A human cell line, preferably PER.C6[™], can advantageously be used to obtain antibodies with a completely human glycosylation pattern. The conditions for growing or multiplying cells (see e.g. *Tissue Culture*, Academic Press, Kruse and Paterson, editors (1973)) and the conditions for expression of the recombinant product may differ somewhat, and optimization of the process is usually performed to increase the product yields and/or growth of the cells with respect to each other, according to methods generally known to the person skilled in the art. In general, principles, protocols, and practical techniques for maximizing the productivity of mammalian cell cultures can be found in

Mammalian Cell Biotechnology: a Practical Approach (M. Butler, ed., IRL Press, 1991). Expression of antibodies in recombinant host cells has been extensively described in the art (see e.g. EP0120694; EP0314161; EP0481790; EP0523949; US patent 4816567; WO 00/63403). The nucleic acid molecules encoding the light and heavy chains may be present as extrachromosomal copies and/or stably integrated into the chromosome of the host cell. With regard to stability of production, the latter is preferred.

[0028] The antibodies are expressed in the cells, and may be recovered from the cells or preferably from the cell culture medium, by methods generally known to persons skilled in the art. Such methods may include precipitation, centrifugation, filtration, size-exclusion chromatography, affinity chromatography, cation- and/or anion-exchange chromatography, hydrophobic interaction chromatography, and the like. For a mixture of antibodies comprising IgG molecules, protein A or protein G affinity chromatography can be suitably used (see e.g. US patents 4,801,687 and 5,151,504).

[0029] In one embodiment, at least two antibodies from the mixture produced according to the invention comprise a heavy-light chain dimer having different specificities and/or affinities. The specificity determines which antigen or epitope thereof is bound by the antibody. The affinity is a measure for the strength of binding to a particular antigen or epitope. Specific binding is defined as binding with an affinity (K_a) of at least 5×10^4 liter/mole, more preferably 5×10^5 , more preferably more than 5×10^6 , still more preferably 5×10^7 , or more. Typically, monoclonal antibodies may have affinities which go up to 10^{10} liter per mole, or even higher. The mixture of antibodies produced according to the methods of the present invention may contain at least two antibodies that bind to different epitopes on the same antigen molecule and/or may contain at least two antibodies that bind to different antigen molecules present in one antigen comprising mixture. Such an antigen comprising mixture may be a mixture of partially or wholly purified antigens such as toxins, membrane components and proteins, viral envelope proteins, or it may be a healthy cell, a diseased cell, a mixture of cells, a tissue or mixture of tissues, a tumor, an organ, a complete human or animal subject, a fungus or yeast, a bacteria or bacterial culture, a virus or virus stock, combinations of these, and the like. Unlike monoclonal antibodies that are able to bind to a single antigen or epitope only, the mixture of antibodies described herein may therefore have many of the advantages of a polyclonal or oligoclonal antibody mixture.

[0030] It is preferred that the host cell is capable of high-level expression of human immunoglobulin, i.e. at least 1 pg/cell/day, preferably at least 10 pg/cell/day and even more preferably at least 20 pg/cell/day or more without the need for amplification of the nucleic acid molecules encoding the heavy and light chains in said host cell. Preferably, host cells contain in their genome between 1 and 10 copies of each recombinant nucleic acid to be expressed. In the art, amplification of the copy number of the nucleic acid sequences encoding a protein of interest in e.g. CHO cells can be used to increase expression levels of the recombinant protein by the cells (see e.g. Bendig, 1988; Cockett et al, 1990; US patent 4,399,216). This is currently a widely used method. However, a significant time-consuming effort is required before a clone with a desired high copy number and high expression levels has been established, and

moreover clones harbouring very high copy numbers (up to hundreds) of the expression cassette often are unstable (e.g. Kim et al., 1998). It is therefore preferred to use host cells that do not require such amplification strategies for high-level expression of the antibodies of interest. This allows fast generation of stable clones of host cells that express the mixture of antibodies as described herein in a consistent manner. We provide evidence that host cells can be obtained, subcloned and further propagated for at least around 30 cell divisions (population doublings) while expressing the mixture of antibodies in a stable manner, in the absence of selection pressure. Therefore, in certain aspects the methods of the invention include culturing the cells for at least 20, preferably 25, more preferably 30 population doublings, and in other aspects the host cells according to the invention have undergone at least 20, preferably 25, more preferably 30 population doublings and are still capable of expressing a mixture of antibodies as described herein.

[0031] Preferably host cells are derived from human retina cells that have been immortalized or transformed with adenoviral E1 sequences. A particularly preferred host cell according to methods of the present invention is PER.C6[™] as deposited under ECACC no. 96022940, or a derivative thereof. PER.C6-derived clones can be generated fast, usually contain a limited number of copies (about 1-10) of the transgene, and are capable of high-level expression of recombinant antibodies (Jones et al, 2003). Therefore, such clones are expected to maintain a stable copy number over many generations, which is an advantage in the production of biopharmaceuticals. PER.C6[™] cells have been extensively characterized and documented, demonstrating good process of scaling up, suspension growth and growth factor independence. Furthermore, PER.C6[™] can be incorporated into a suspension in a highly reproducible manner, making it particularly suitable for large-scale production. In this regard, the PER.C6[™] cell line has been characterized for bioreactor growth, where it can grow to very high densities. The use of PER.C6[™] for recombinant production of antibodies has been described in detail in publication WO 00/63403 and in (Jones et al., 2003).

[0032] Methods of the invention can be used to prepare a mixture of antibodies comprising a common light chain and two different heavy chains with a different variable region, wherein the two different heavy chains are capable of pairing to said common light chain, and wherein said heavy chains further differ in their constant regions sufficiently so that the amount of bispecific antibodies is decreased as compared to the theoretical percentage of bispecific antibodies.

[0033] Use of a mixture of antibodies that is obtainable by a method according to the invention is also described herein. Such mixtures of antibodies are expected to be more effective than the sole components it comprises, in analogy to polyclonal antibodies usually being more effective than monoclonal antibodies to the same target. Such mixtures can be prepared against a variety of target antigens or epitopes.

[0034] Methods of the invention can be used to prepare a mixture of antibodies wherein two different heavy chains are paired to light chains in the form of antibodies. Preferably, the light chains of the antibodies in said mixtures have a common light chain. The mixtures may

comprise bispecific antibodies. The mixtures may be produced from a clone that was derived from a single host cell, i.e. from a population of cells containing the same recombinant nucleic acid sequences. The optimal mixture for a certain purpose may be determined empirically by methods known to the person skilled in the art, or by methods disclosed herein. Such mixtures may have several of the advantages of a polyclonal antibody mixture, without the disadvantages usually inherently associated with polyclonal antibody mixtures, because of the manner in which they are produced. It is furthermore expected that the mixture of antibodies is more efficacious than separate monoclonal antibodies. Therefore the dosage, and hence the production capacity required, may be less for the mixtures of antibodies than for monoclonal antibodies.

[0035] It has for instance been described that although no single monoclonal antibody to botulinum neurotoxin (BoNT/A) significantly neutralized toxin, a combination of three such monoclonal antibodies (oligoclonal antibody) neutralized 450,000 50% lethal doses of BoNT/A, a potency 90 times greater than human hyperimmune globulin (Nowakowski et al, 2002). This result demonstrates that oligoclonal mixtures of antibodies comprising only 2 to 3 different specificities may have very high potency.

[0036] Furthermore, the chances of a mixture of antibodies losing its activity due to target or epitope loss is reduced, when compared to a single monoclonal antibody. In particular embodiments, 2, or 3, of the antibodies present in the mixture as described herein have different specificities. Said different specificities may be directed to different epitopes on the same antigen and/or may be directed to different antigens present in one antigen comprising mixture. The mixture of antibodies further may also comprise 2, or 3 antibodies having different affinities for the same epitope. Antibodies with differing affinities for the same epitope may for instance be generated by methods of affinity maturation, known to the person skilled in the art. The mixture of antibodies produced according to the methods of the invention has an effect that is greater than the effect of each individual monospecific antibody present in said mixture. Said effect can be measured in a functional assay. A "functional assay" according to the present invention is an assay that can be used to determine one or more desired parameters of the antibody or the mixture of antibodies subject to the assay conditions. Suitable functional assays may be binding assays, apoptosis assays, antibody dependent cellular cytotoxicity (ADCC) assays, complement dependent cytotoxicity (CDC) assays, inhibition of cell growth or proliferation (cytostatic effect) assays, cell killing (cytotoxic effect) assays, cell signaling assays, assays for measuring inhibition of binding of pathogen to target cell, assays to measure the secretion of vascular endothelial growth factor (VEGF) or other secreted molecules, assays for bacteriostasis, bactericidal activity, neutralization of viruses, assays to measure the attraction of components of the immune system to the site where antibodies are bound, including in situ hybridization methods, labeling methods, and the like. Clearly, also in vivo assays such as animal models, including mouse tumor models, models of autoimmune disease, virus-infected or bacteria-infected rodent or primate models, and the like, can be used for this purpose. The efficacy of a mixture of antibodies can be compared to individual antibodies in such models by methods generally known to the person skilled in the art.

[0037] It is another aspect of the present invention to provide a method for identifying at least one host cell clone that produces a mixture of antibodies, wherein said mixture of antibodies has a desired effect according to a functional assay, the method comprising the steps of: (i) providing a host cell comprising a nucleic acid sequence encoding one light chain and nucleic acid sequence or sequences encoding two different heavy chains, wherein said heavy and light chains are capable of pairing with each other; (ii) culturing at least one clone of said host cell under conditions conducive to expression of said nucleic acid sequences; (iii) screening said at least one clone of the host cell for production of a mixture of antibodies having the desired effect by a functional assay; and (iv) identifying at least one clone that produces a mixture of antibodies having the desired effect. Preferably, said host cell comprises a nucleic acid sequence encoding a common light chain that is capable of pairing with said two different heavy chains, such that produced antibodies comprise common light chains, as described above. In specific embodiments said culturing in step (ii) and said screening in step (iii) of the method is performed with at least two clones. The method may optionally include an assay for measuring the expression levels of the antibodies that are produced, which assay may be during or after step (ii) according to the method, or later in the procedure. Such assays are well known to the person skilled in the art, and include protein concentration assays, immunoglobulin specific assays such as ELISA, RIA, DELFIA, and the like. Functional assays useful for the method according to the invention may be assays for apoptosis, ADCC, CDC, cell killing, inhibition of proliferation, virus neutralization, bacterial opsonization, receptor-mediated signaling, cell signaling, bactericidal activity, and the like. Useful screening assays for anti-cancer antibodies have for instance been described in US patent 6,180,357. Such assays may also be used to identify a clone according to the method of the present invention. It is for instance possible to use enzyme linked immunosorbent assays (ELISAs) for the testing of antibody binding to their target. Using such assays, it is possible to screen for antibody mixtures that most avidly bind the target antigen (or mixture of target antigens against which the mixture of antibodies is to be tested). Another possibility that can be explored is to directly screen for cytotoxicity or cytostatic effects. It is possible that upon such a different screen, other or the same clones producing mixtures of antibodies will be chosen than with the ELISA mentioned above. The screening for cell killing or cessation of growth of cancerous cells may be suitably used according to the invention. Cell death can be measured by various endpoints, including the absence of metabolism or the denaturation of enzymes. In one possible embodiment of the present invention, the assay is conducted by focusing on cytotoxic activity toward cancerous cells as an endpoint. For this assay, a live/dead assay kit, for example the LIVE/DEAD Viability/Cytotoxicity Assay Kit (L-3224) by Molecular Probes, can suitably be used. Other methods of assessing cell viability, such as trypan blue exclusion, ⁵¹Cr release, Calcein-AM, Alamar Blue™, LDH activity, and similar methods can also be used. The assays may also include screening of the mixture of antibodies for specificity to the desired antigen comprising tissue. The antibodies described herein may have a limited tissue distribution. It is possible to include testing the mixtures of antibodies against a variety of cells, cell types, or tissues, to screen for mixtures of antibodies that preferably bind to cells, cell types or tissues of interest. Irrespective of a functional assay as described above, ways to determine the identity of the antibodies expressed by a clone are described herein, using methods such as iso-electric focusing (IEF), mass-spectrometry (MS), and the like. It is therefore possible to use MS and/or

IEF in selecting a clone that expresses a mixture of antibodies described herein.

[0038] When monoclonal antibodies are produced by recombinant host cells, a screening step is usually performed to assess expression levels of the individual clones that were generated. The addition of more heavy chains to produce mixtures adds a level of complexity to the production of antibodies. When host cells are transfected with nucleic acid molecules encoding the light and heavy chains that will form the mixture of antibodies desired, independent clones may arise containing the same genetic information, but nevertheless differing in expression levels, thereby producing different ratios of the encoded antibodies, giving rise to different mixtures of antibodies from the same genetic repertoire. The method according to the invention is useful for identifying a clone that produces an optimal mixture for a certain purpose.

[0039] The culturing and/or screening according to steps (ii) and (iii) respectively, may be suitably performed using high-throughput procedures, optionally in an automated fashion. Clones can e.g. be cultured in 96-well or other multi-well plates, e.g. in arrayed format, and screened for production of a desired mixture. Robotics may be suitably employed for this purpose. Methods to implement high-throughput culturing and assays are generally available and known to the person skilled in the art. It will be clear that also for this method, it is beneficial to use host cells capable of high level expression of proteins, without the need for amplification of the nucleic acid encoding said proteins in said cell. In one embodiment, said host cell is derived from a human embryonic retinoblast cell, that has been immortalized or transformed by adenoviral E1 sequences. In a preferred embodiment, said cell is derived from PER.C6TM. This cell line has already been shown to be amenable to high-throughput manipulations, including culturing (WO 99/64582).

[0040] In specific embodiments of the present invention, said mixture of antibodies according to the method of identifying at least one host cell as described herein, comprises at least 2, or 3 antibodies having different specificities and/or affinities.

[0041] A potential advantage of the method will be that it will allow exploring many possible combinations simultaneously, the combinations inherently including the presence of bispecific antibodies in the produced mixture. Therefore more combinations can be tested than by just mixing purified known monoclonal antibodies, both in number of combinations and in ratios of presence of different antibodies in these combinations.

[0042] The clone that has been identified by the method according to the invention, can be used for producing a desired mixture of antibodies. It is therefore another aspect of the present invention to provide a method of producing a mixture of antibodies, the method comprising the step of: culturing a host cell clone identified by the method of identifying at least one host cell clone that produces a mixture of antibodies according to the invention, said culturing being under conditions conducive to expression of the nucleic acid molecules encoding the one light chain and the two different heavy chains. The produced antibodies may be recovered from the host cells and/or from the host cell culture, e.g. from the culture medium. The mixture of

antibodies can be recovered according to a variety of techniques known to the person skilled in the art. A mixture of antibodies that is obtainable by the method according to the invention, described above can be used for a variety of purposes, such as in treatment or diagnosis of disease, and may replace, or be used in addition to, monoclonal or polyclonal antibodies.

[0043] The methods according to the present invention may suitably use nucleic acid molecules for encoding the antibodies, which nucleic acid molecules have been obtained by any suitable method, including in vivo, e.g. immunization, methods or in vitro, e.g. antibody display methods (A. Plückthun et al, In vitro selection and evolution of proteins. In: Adv. Prot. Chem., F.M. Richards et al, Eds, Academic Press, San Diego, 2001, vol 55: 367-403), such as phage display, ribosome display or mRNA display (C. Schaffitzel et al., In vitro selection and evolution of protein-ligand interactions by ribosome display. In: Protein-Protein Interactions. A Molecular Cloning Manual, E. Golemis, Ed., Cold Spring Harbor Laboratory Press, New York, 2001, pp 535-567), and yeast display (e.g. WO 99/36569). Methods of identifying antibodies to a certain target, which target may be a known antigen or an unknown antigen present in an antigenic mixture, by phage display are known to the person skilled in the art. In general, a library of phages that express an antigen binding domain or derivative thereof on their surface, said antigen binding domain encoded by genetic material present in said phages, is incubated with the antigen or antigen mixture of interest, after which binding of a subpopulation of the phages that display antigen binding sites binding to the desired antigen is obtained whereas the non-binding phages are discarded. Such selection steps may be repeated one, two, or more times to obtain a population of phages that are more or less specific for the antigen of interest. Phage display methods to obtain antibodies, parts or derivatives thereof have been extensively described in e.g. (CF Barbas III et al, Phage Display. A laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2001). The library used for such screening may be generated by using the genetic information of one or more light chains, combined with genetic information encoding a plurality of heavy chains. The library described by De Kruif et al. (1995b) comprises 7 light chains. Therefore, in a panel of phages binding to a target, which can e.g. be obtained by methods described in De Kruif et al (*supra*); US patent 6,265,150; not more than 7 different light chains will be represented, and if the panel is large enough, several phages with the same light chain coupled to unrelated heavy chains may be found. Such phages can be used to obtain the nucleic acid molecules useful in the methods according to the present invention.

[0044] In one embodiment of the method for producing a mixture of antibodies, the nucleic acid sequence or sequences encoding at least one common light and/or heavy chains have been obtained by a method comprising at least one antibody display selection step.

The antibody display library may be a phage display library, a ribosome display library, an mRNA display library, or a yeast display library. The selection step may optionally be repeated one or more times.

The nucleic acid sequences encoding the antibodies obtained by the phage display, ribosome display or yeast display method may be converted to encode any desired antibody format such as IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgD, IgE, before introducing them into a host cell, using standard molecular cloning methods and means known to the person skilled in the art (e.g.

described in Boel et al, 2000).

[0045] It will be clear to the skilled person that libraries in which only one light chain is represented are especially useful in light of the present invention, since all antibodies that can be obtained from such a library, will have a common light chain that is functional in binding target antigen with each of the heavy chains. In other words, the formation of non-functional light chain-heavy chain dimers is avoided. Phage antibody display libraries having extensive H chain repertoires and unique or very few L chain sequences have been disclosed in the art (Nissim et al, 1994; Vaughan et al, 1996). In general, the specificity of an antibody appears to be determined to a large extent by its heavy chain. It is even possible to screen for and identify light chains that do not contribute significantly to binding of the antibody, which light chains also could be suitably used according to the invention. It may also be possible to follow the teachings of the present disclosure, but use one heavy chain and vary the light chains. However, the use of a common light chain and different heavy chains appears preferable, and the following observations support the idea that the specificity of an antibody appears to be dominated by its heavy chain sequence. In the process of receptor editing, a mechanism of B-cells to monitor if their immunoglobulin receptor encodes a potentially harmful autoantibody, B-cells expressing an autoantibody replace the expressed heavy chain with another heavy chain while retaining the expressed light chain. Thus, a new antibody specificity is generated that does not encode an autoantibody. This shows that a single light chain can successfully dimerize with multiple heavy chains to form different antibody specificities (Nemazee, 2000; Casellas et al, 2001). Series of transfected cell lines using a single heavy chain gene with different light chain genes have been reported, the antibodies produced to a large extent maintaining their specificity, regardless of the light chain (Radic et al, 1991). Different antibodies have been obtained from a library that has been constructed using a single light chain (Nissim et al, 1994). We have obtained several antibodies from the library described by De Kruif et al (1995), which was constructed using 7 light chains, that have the same light chain but different specificities (see e.g. example 1: antibodies binding to EpCAM and to CD46, described in WO 01/48485 and WO 02/18948, respectively). Besides screening a phage library against a target, it will be also possible to start with an antibody that has already proven its merits, and use the light chain of this antibody in the preparation of a library of heavy chains combined with this particular light chain only, according to methods known to the person skilled in the art, such as phage display. Using this strategy, a monoclonal antibody can be used to obtain a mixture of antibodies according to the invention, functionally resembling a polyclonal or oligoclonal antibody to the same target. Alternatively, a method reminiscent of the method described by Jespers et al (1994) to obtain a human antibody based on a functional rodent antibody can be used. The heavy chain of a known antibody of non-human origin is first cloned and paired as a template chain with a repertoire of human light chains for use in phage display, after which the phages are selected for binding to the antigen or mixture of antigens. The selected light chain is in turn paired with a repertoire of human heavy chains displayed on a phage, and the phages are selected again to find several heavy chains that when paired with the light chain are able to bind to the antigen or mixture of antigens of interest. This enables creating a mixture of human antibodies against a target for which thus far only a non-human monoclonal antibody is described. It is possible that a mixture as described herein already has

beneficial functional effects when the individual antibodies do not have high affinities for the target, whereas high affinities are often required for monoclonal antibodies to be effective. This would have the advantage that affinity maturation may be required in less instances for methods and mixtures according to the present disclosure than when an approach with monoclonal antibodies is envisaged.

[0046] The heavy and light chain coding sequences can be introduced simultaneously or consecutively into the host cell. It is also possible to prepare a host cell comprising a recombinant nucleic acid encoding a light chain of an antibody. Such a cell can for instance be obtained by transfection of said nucleic acid, and optionally a clone can be identified that has a high expression of the light chain. An established clone may then be used to add genetic information encoding 2 heavy chains of the invention by introducing the nucleic acid molecules encoding these into cells of the clone that already contains the light chain. The nucleic acid molecules encoding the heavy chains may be introduced into said host cell concomitantly. It is of course also possible to introduce them consecutively, e.g. by using different selection markers, which can be advantageous if not all heavy chains can be introduced simultaneously because the cells do not take up enough copies of recombinant nucleic acid molecules. Methods to introduce recombinant nucleic acid molecules into host cells are well known to the person skilled in the art, and include transfection, electroporation, calcium phosphate precipitation, virus infection, and the like. The skilled person has several possibilities to introduce more vectors with nucleic acid sequences of interest into the same host cell, see e.g. Sambrook, Fritsch and Maniatis, *Molecular Cloning: A Laboratory Manual*, 2nd edition, 1989; *Current Protocols in Molecular Biology*, Ausubel FM, et al, eds, 1987; the series *Methods in Enzymology* (Academic Press, Inc.). Suitable dominant selection markers for introducing nucleic acids into eukaryotic host cells according to the invention may be G418 or neomycin (geneticin), hygromycin or mycophenolic acid, puromycin, and the like, for which genes encoding resistance are available on expression vectors. Further possibilities include for instance the use of vectors containing DHFR genes or glutamate synthetase to select in the presence of methotrexate in a DHFR⁻ cell or the absence of glutamine in a glutamine auxotroph, respectively. The use of expression vectors with different selection markers enables subsequent transfections with heavy chain sequences of interest into the host cell, which already stably contains other heavy chains introduced previously by use of other selection markers. It is also possible to use selection markers that can be used more than once, e.g. when containing mutations, introns, or weakened promoters that render them concentration dependent (e.g. EP0724639; WO01/32901; US patent 5,733,779). Alternatively, a selection marker may be re-used by deleting it from the host cell after use, e.g. by site-specific recombination. A selectable marker located between sequences recognized by a site-specific recombinase, e.g. lox-sites or FRT-sites, is used for the generation of the first stable transfectant (see for Cre-lox site-specific recombination Wilson and Kola, 2001). Subsequently, the selectable marker is excised from the host cell DNA by the matching site-specific recombinase, e.g. Cre or FIp. A subsequent transfection can suitably use the same selection marker.

Different host cell clones each comprising the genetic information encoding a different light chain may be prepared. If the antibodies are identified by an antibody display method, it is thus

possible to prepare several host cells, each comprising one light chain present in the antibody display library. After identifying antibodies that bind to a target using antibody display, the nucleic acid molecules encoding the heavy chains can be introduced into the host cell containing the common light chain that is capable of pairing to the heavy chains.

[0047] In case it would appear that a recombinant host cell described herein does not express sufficient light chain to dimerize with all of the expressed two heavy chains, extra copies of the nucleic acid molecules encoding the light chain may be transfected into the cell.

[0048] Besides random integration after transfection, methods to integrate the transgenes in predetermined positions of the genome resulting in favorable expression levels, can also be used. Such methods may for instance employ site-specific integration by homologous recombination (see e.g. WO 98/41645), or make use of site-specific recombinases (Gorman and Bullock, 2000).

[0049] Besides cell culture as a production system for recombinant proteins, the art also discloses the use of transgenic animals, transgenic plants, and for instance transgenic chickens to produce proteins in the eggs, and the like to produce recombinant proteins of interest (Pollock et al, 1999; Larrick and Thomas, 2001; WO 91/08216). These usually comprise the recombinant gene or genes encoding one or more proteins of interest in operable association with a tissue-specific promoter. It has for instance been shown that recombinant antibodies can be produced at high levels in the milk of transgenic animals, that contain the nucleic acids encoding a heavy and a light chain behind a mammary gland specific promoter (e.g. Pollock et al, 1999; WO 95/17085). Particularly useful in this respect are cows, sheep, goats, pigs, rabbits, mice, and the like, which can be milked to obtain antibodies. Useful promoters are the casein promoters, such as the β -casein promoter, the α S1-casein promoter, the whey acidic protein (WAP) promoter, the β -lactoglobulin promoter, the α -lactalbumin promoter, and the like. Production of biopharmaceutical proteins in the milk of transgenic mammals has been extensively described (e.g. Pollock et al, 1999). Besides mammary gland specific promoters, also other tissue-specific promoters may be used, directing the expression to the blood, urine, saliva, and the like. The generation of transgenic animals comprising recombinant nucleic acid molecules has been extensively documented, and may include micro-injection of oocytes (see e.g. Wilmut and Clark, 1991), nuclear transfer after transfection (e.g. Schnieke et al, 1997), infection by recombinant viruses (e.g. US patent 6291740), and the like. Nuclear transfer and cloning methods for mammalian cells are known to the person skilled in the art, and are e.g. described in (Campbell et al, 1996; Wilmut et al, 1997; Dinnyes et al, 2002; WO 95/17500; WO 98/39416). It is nowadays possible to clone most of these animals, to generate lines of animals that are genetically identical, which renders it possible for a person skilled in the art to create such a line once an individual animal producing the desired mixture of antibodies has been identified. Alternatively, classical breeding methods can be used to generate transgenic offspring. Strategies for the generation of transgenic animals for production of recombinant proteins in milk are described in Brink et al, 2000.

[0050] Transgenic plants or plant cells producing antibodies have also been described (Hiatt et

al, 1989; Peeters et al, 2001), and useful plants for this purpose include corn, maize, tobacco, soybean, alfalfa, rice, and the like. Constitutive promoters that can for instance be used in plant cells are the CaMV 35S and 19S promoters, *Agrobacterium* promoters *nos* and *ocs*. Other useful promoters are light inducible promoters such as *rbcS*. Tissue-specific promoters can for instance be seed-specific, such as promoters from zein, napin, beta-phaseolin, ubiquitin, or tuber-specific, leaf-specific (e.g. useful in tobacco), root-specific, and the like. It is also possible to transform the plastid organelle by homologous recombination, to express proteins in plants. Methods and means for expression of proteins in recombinant plants or parts thereof, or recombinant plant cell culture, are known to the person skilled in the art and have been for instance described in (Giddings et al, 2000; WO 01/64929; WO 97/42313; US patents 5888789, 6080560; See for practical guidelines: *Methods In Molecular Biology* vol. 49 "Plant Gene Transfer And Expression Protocols", Jones H, 1995). Other transgenic systems for producing recombinant proteins have also been described, including the use of transgenic birds to produce recombinant proteins in eggs (e.g WO 97/47739), and the use of transgenic fish (e.g. WO 98/15627), and can be used in combination with the teachings of the present invention to obtain mixtures of antibodies. It is also possible to use an in vitro transcription/translation or in vitro translation system for the expression of mixtures of antibodies. It will be clear to the skilled person that the teachings of the current invention will allow producing mixtures of antibodies in systems where recombinant nucleic acid encoding the light chain and heavy chains can be introduced and expressed. Preferably such systems are able to produce antibodies encoded by said nucleic acid sequences, without the use of amplification of said nucleic acid sequences in said systems. In another aspect, a cell from a transgenic non-human animal or a transgenic plant is used. Such cells can be used to generate the animals or plants, using techniques known to the person skilled in the art, such as nuclear transfer or other known methods of cloning whole organisms from single cells. These cells may also be obtained by introducing the light and at least two heavy chain sequences into isolated cells of non-human animals or plants, which cells are capable of becoming part of a transgenic animal or plant. Particularly useful for such purposes are embryonic stem cells. These can contribute to the germ line, and therefore the genetic information introduced into such cells can be passed to future generations. In addition, plant cell cultures of cotton, corn, tomato, soybean, potato, petunia, and tobacco can be utilized as hosts, when transformed with the nucleic acid molecules encoding the light chain and the heavy chains, e.g. by use of the plant transforming bacterium *Agrobacterium tumefaciens* or by particle bombardment, or by infecting with recombinant plant viruses.

[0051] Methods of the invention can be used to prepare a pharmaceutical composition comprising a mixture of recombinantly produced antibodies and a suitable carrier, wherein two different heavy chains and one common light chain are represented in said mixture of recombinantly produced antibodies, and whereby the two different heavy chains are capable of pairing with said one common light chain. Pharmaceutically acceptable carriers as used herein are exemplified, but not limited to, adjuvants, solid carriers, water, buffers, or other carriers used in the art to hold therapeutic components, or combinations thereof. Said mixture may comprise bispecific antibodies. Said mixture may be produced from a clone that was derived from a single host cell, i.e. from a population of cells containing the same recombinant nucleic

acid molecules. The term "recombinantly produced" as used herein refers to production by host cells that produce antibodies encoded by recombinant nucleic acids introduced in such host cells or ancestors thereof. It does therefore not include the classical method of producing polyclonal antibodies, whereby a subject is immunized with an antigen or antigen comprising mixture, after which the antibodies produced by this subject are recovered from the subject, e.g. from the blood.

[0052] Methods of the invention can be used to prepare a mixture of antibodies for use in the treatment or diagnosis of a disease or disorder in a human or animal subject. In another aspect, the mixture of antibodies can be used for the preparation of a medicament for use in the treatment or diagnosis of a disease or disorder in a human or animal subject. The mixtures may comprise bispecific antibodies, and may be recombinantly produced from a clone that was derived from a single host cell, i.e. from a population of cells containing the same recombinant nucleic acid molecules. The targets may be used to screen an antibody display library, as described supra, to obtain 2, 3, 4, 5, 6, 7, 8, 9, 10, or more antibodies comprising a common light chain that bind to the target, and produce a mixture of these according to the teachings of the present disclosure. Virtually any area of medicine where monoclonal antibodies can be used is amenable for the use of the mixtures according to the invention. This can e.g. include treatment of auto-immune diseases and cancer, including solid tumors of the brain, head- and neck, breast, prostate, colon, lung, and the like, as well as hematologic tumors such as B-cell tumors. Neoplastic disorders which can be treated with the mixtures described herein include leukemias, lymphomas, sarcomas, carcinomas, neural cell tumors, squamous cell carcinomas, germ cell tumors, metastases, undifferentiated tumors, seminomas, melanomas, myelomas, neuroblastomas, mixed cell tumors, neoplasias caused by infectious agents, and other malignancies. Targets for the antibody mixtures may include, but are not limited to, the HER-2/Neu receptor, other growth factor receptors such as VEGFR1 and VEGFR2 receptor, B-cell markers such as CD19, CD20, CD22, CD37, CD72, etc, T-cell markers such as CD3, CD25, etc, other leukocyte cell surface markers such as CD33 or HLA-DR, etc, cytokines such as TNF, interleukins, receptors for these cytokines such as members of the TNF receptor family, and the like. It is anticipated that the use of such mixtures of antibodies in the treatment of cancerous tissues or other complex multi-antigen comprising cells such as microorganisms or viruses will give rise to less occurrence of epitope-loss escape variants than the use of single monoclonal antibodies. Several treatments nowadays use polyclonal mixtures of antibodies, which are derived from immunized humans or animals. These treatments may be replaced by use of the mixtures disclosed herein. Use of these mixtures can also include use in graft-versus-host rejections, known in the art of transplantation, e.g. by use of anti-thymocyte antibodies. It is anticipated that the mixtures of antibodies are superior to monoclonal antibodies in the treatment of complex antigens or antigen comprising mixtures such as bacteria or viruses. Therefore, use as described herein, can also include use against strains of bacteria and fungi, e.g. in the treatment of infectious diseases due to pathogenic bacteria such as multidrug resistant *S.aureus* and the like, fungi such as *Candida albicans* and *Aspergillus* species, yeast and the like. The mixtures described herein may also be used for post exposure prophylaxis against viruses, such as members of the genus *Lyssavirus* e.g. rabies virus, or for therapeutic or prophylactic use against viruses such as *Varicella-Zoster Virus*, *Adenoviruses*,

Respiratory Syncytium Virus, Human Immunodeficiency Virus, Human Metapneumovirus, Influenzavirus, West Nile Virus, the virus causing Severe Acute Respiratory Syndrome (SARS), and the like. Mixtures described herein can also be used to protect against agents, both bacteria and viruses, and against toxic substances that are potential threats of biological warfare. Therefore, use as described herein, can also include use against strains of bacteria such as *Bacillus anthracis*, *Clostridium botulinum* toxin, *Clostridium perfringens* epsilon toxin *Yersinia Pestis*, *Francisella tularensis*, *Coxiella burnetii*, *Brucella* species, *Staphylococcus enterotoxin B*, or against viruses such as Variola major, alphaviruses causing meningoencephalitis syndromes (EEEV, VEEV, and WEEV), viruses known to cause hemorrhagic fevers such as Ebola, Marburg and Junin virus or against viruses such as Nipah virus, Hantaviruses, Tickborne encephalitis virus and Yellow fever virus or against toxins e.g. Ricin toxin from *Ricinus communis* and the like. Use of the mixtures as described herein, can also include use against unicellular or multicellular parasites. Recombinant mixtures of antibodies according to the invention may become a safe alternative to polyclonal antibodies obtained from pools of human sera for passive immunization, or from sera of hyper-immunized animals. The mixtures may be more efficacious than recombinant monoclonal antibodies in various therapeutic applications, including cancer, allergy, viral diseases, chronic inflammation, and the like.

It has been described that homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells (Ghetie et al, 1997). Possibly, when antibodies against receptors or other surface antigens on target cells, such as tumor cells or infectious microorganisms, are produced according to the present invention, the bispecific antibodies present in mixtures described herein, may also crosslink different receptors or other antigens on the surface of target cells, and therefore such mixtures may be very suitable for killing such cells. Alternatively, when bispecific antibodies are less desirable, the present invention also provides methods to recombinantly produce mixtures of antibodies comprising mainly monospecific antibodies. It has been described that the efficacy of treatment with Rituximab[™] (anti-CD20 monoclonal antibody) was increased when anti-CD59 antibodies were added (Herjunpaa et al, 2000). Therefore, it is expected that inclusion of antibodies against CD59 in a mixture according to the invention comprising anti-tumor antibodies in the form of B-cell receptor recognizing antibodies increases the sensitivity of tumor cells to complement attack. It has also been shown that a triple combination cocktail of anti-CD19, anti-CD22, and anti-CD38-saporin immunotoxins is much more effective than the individual components in the treatment of human B-cell lymphoma in an immunodeficient mouse model (Flavell et al, 1997). Many other combinations may also be feasible and can be designed by the person skilled in the art. In general, the use of antibody mixtures that are capable of recognizing multiple B-cell epitopes will likely decrease the occurrence of escape variants.

[0053] Another possible target is a transmembrane tyrosine kinase receptor, encoded by the Her-2/Neu (ErbB2) proto-oncogene (see e.g. US patents 5,772,997 and 5,783,186 for anti-Her2 antibodies). Her-2 is overexpressed on 30% of highly malignant breast cancers, and successful antibodies against this target, marketed under the name Herceptin[™] (Trastuzumab), have been developed. It has been shown that targeting multiple Her-2

epitopes with a mixture of monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo (Spiridon et al, 2002). Her-2 may therefore be a good target for antibody mixtures described herein. Antibodies useful for this purpose can be obtained by methods described herein, including antibody display methods.

[0054] Human antibodies are capable of eliciting effector function via binding to immunoglobulin receptors on immune effector cells. Human IgG, and in particular IgG₁ and IgG₃, fix complement to induce CDC and interact with Fcγ receptors to induce antibody dependent cell mediated cytotoxicity (ADCC), phagocytosis, endocytosis, induction of respiratory burst and release of inflammatory mediators and cytokines. Human IgA interacts with FcαR, also to result in efficient activation of ADCC and phagocytosis of target cells. Hence, due to the differential distribution of FcγR and FcαR on peripheral blood cells (Huls et al., 1999), using a mixture of antibodies directed against the target and consisting of both IgG and IgA would potentially maximize the recruitment and activation of different immune effector cells. Such a mixture of both IgG and IgA could be obtained by producing the IgG and IgA monoclonal antibody in a separate production process using two distinct production cell lines, but could also be obtained from a single cell line producing both the IgG and the IgA monoclonal antibody. This would have the advantage that only a single production process has to be developed. Thus when different heavy chains are mentioned, also heavy chains differing in their constant regions are encompassed in the invention. The principle of using a common light chain can also be used for the production of a mixture of isotypes from a host cell. It is therefore yet another aspect of the present disclosure to use a method for producing a mixture of antibodies comprising different isotypes from a host cell, the method comprising the step of: culturing a host cell comprising a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding two heavy chains of different isotype that are capable of pairing with said light chain, under conditions conducive to expression of said nucleic acid sequences. According to this aspect of the disclosure, different heavy chains may have identical variable regions, and only differ in their constant regions (i.e. be of different isotype and have the same specificity). In a particular embodiment, said isotypes comprise at least an IgG and an IgA and/or IgM, preferably IgG₁ or IgG₃ and IgA. Other combinations of IgG₁, IgG₂, IgG₃ and IgG₄ can also be used. In these embodiments, bispecific antibodies will not be produced because the variable regions are the same.

[0055] In other embodiments according to this aspect of the disclosure, not only the constant regions of the heavy chains may differ, but also the variable regions, thereby giving rise to different specificities, paired with the same light chain. When bispecific antibodies are not desired for a given purpose, e.g. because the mixtures of antibodies are less efficacious because of the presence of the bispecific antibodies, it is possible to use two heavy chains combined with the common light chain according to the invention wherein said heavy chains differ sufficient in their constant regions to reduce or prevent pairing between the different heavy chains, e.g. by using heavy chains of different isotypes, e.g. an IgG₁ and an IgG₃ (see Fig. 11 for a schematic representation). It is anticipated that the heavy chains of different isotype will pair much less efficient, if at all, compared to the same heavy chains. Alternatively, it is also possible to engineer the different heavy chains in their constant region such that

homodimerization is favored over heterodimerization, e.g. by introducing self-complementary interactions (see e.g. WO 98/50431 for possibilities, such as "protuberance-into-cavity" strategies (see WO 96/27011)). It is therefore another aspect of the present invention to provide a method for producing a mixture of antibodies in a recombinant host, the method including the step of: expressing in a recombinant host cell a nucleic acid sequence encoding a common light chain and nucleic acid sequences encoding two different heavy chains that differ in the variable region and that are capable of pairing with said common light chain, and wherein said heavy chains further differ in their constant regions sufficiently to reduce or prevent pairing between the different heavy chains. In one embodiment, said heavy chains are of different isotype. Mixtures of antibodies obtainable by this method are also embodied in the present invention. Such mixtures will comprise mainly monospecific antibodies.

[0056] The teachings herein can also be used to obtain novel multispecific antibodies or mixtures thereof. Dimerization of the IgA molecules can be enhanced by co-expressing J-chain (Yoo et al, 1999). Said dimeric IgA antibodies have two specificities (see Fig. 9 for a schematic representation of one possible form produced and present in the mixture). Up to five specificities can be comprised in an IgM pentamer in the presence of J-chain, and up to six in an IgM hexamer in the absence of J-chain (Yoo et al, 1999). Therefore 3, 4, 5, or 6 IgM heavy chains may be co-expressed with the common light chain. See Fig. 10 for a schematic representation of one of the possible forms that can be produced and present in the mixture, when five different heavy chains are expressed with a common light chain. Hence IgA dimers, IgM pentamers or hexamers having at least two different specificities can be produced from a clone of a single host cell according to the disclosure. Such molecules, harbouring antigen binding regions with different specificities, can bind different epitopes on the same antigen, different antigens on one cell, or different antigens on different cells, thereby crosslinking the antigens or cells.

Examples

[0057] The following examples are provided to illustrate the present disclosures, and are not to be construed in any way to limit the scope of the invention. The practice of this invention will employ, unless otherwise indicated, conventional techniques of immunology, molecular biology, microbiology, cell biology, and recombinant DNA, which are within the skill of the art. See e.g. SAMBROOK, FRITSCH and MANIATIS, *Molecular Cloning: A Laboratory Manual*, 2nd edition, 1989; *Current Protocols in Molecular Biology*, Ausubel FM, et al, eds, 1987; the series *Methods in Enzymology* (Academic Press, Inc.); *PCR2: A Practical Approach*, MacPherson MJ, Hams BD, Taylor GR, eds, 1995; *Antibodies: A Laboratory Manual*, Harlow and Lane, eds, 1988.

Example 1 Production of a mixture of monoclonal antibodies with a common light chain and two different heavy chain variable regions in a single cell

[0058] Clone UBS-54 and Clone K53 were previously isolated by selections on the colorectal cell line SW40 (Huls et al., 1999) and on a heterogeneous mixture of mononuclear cells of a patient with multiple myeloma (WO 02/18948), respectively, with a semi-synthetic library (de Kruif et al., 1995b). Further studies revealed that clone UBS-54 and K53 bound to the EP-CAM homotypic adhesion molecule (Huls et al., 1999) and the membrane cofactor protein CD46 (WO 02/18948), respectively. DNA sequencing of the clones revealed that they were unique in the Heavy chain CDRs, but that they contained an identical light chain sequence (Fig. 3). The V_H and V_L of clones UBS-54 and K53 were inserted into an expression vector containing the HAVT20 leader sequence and all the coding sequences for the constant domains of a human IgG1 with a Kappa light chain by a method essentially as described (Boel et al, 2000), which resulted in plasmids pUBS3000Neo and pCD46_3000(Neo) (Fig. 4). These plasmids were transiently expressed either alone or in combination in PER.C6™ cells. In brief, each 80 cm² flask was transfected by incubation for 4 hours with 140 µl lipofectamine + 10 µg DNA (either pUBS3000Neo, pCD46_3000(Neo) or 10 µg of both) in serum-free DMEM medium at 37°C. After 4 hours, this was replaced with DMEM + 10% FBS, and the cells were grown overnight at 37°C. Cells were then washed with PBS and the medium was replaced with Excell 525 medium (JRH Bioscience). The cells were allowed to grow at 37°C for 6 days, after which the cell culture supernatant was harvested. Human IgG specific ELISA analysis (described in WO 00/63403) indicated that IgG was present at approximately 10 µg/ml for all flasks containing expression plasmids. No IgG1 was present in a control flask which was not transfected with expression plasmid.

Human IgG from each supernatant was subsequently purified using Protein A affinity chromatography (Hightrap Protein A HP, cat.no. 1-040203) according to standard procedures, following recommendations of the manufacturer (Amersham Biosciences). After elution, samples were concentrated in a Microcon YM30 concentrator (Amicon) and buffer exchanged to 10 mM sodium phosphate, pH 6.7. Twelve µg of purified IgG was subsequently analyzed on Isoelectric focusing gels (Serva Pre-cast IEF gels, pH range 3-10, cat.no. 42866). The samples were loaded on the low pH side and after focussing stained with colloidal blue (Fig. 5). Lane 1 shows transiently expressed K53, Lane 2 shows transiently expressed UBS-54 and Lane 3 shows the IgG sample of the cells in which both antibodies were cotransfected. Clearly, K53 and UBS-54 each have a unique pi profile and the sample from the cotransfection showed other unique isoforms, with the major isoform having a pi in between those of K53 and UBS-54. This is also anticipated on the basis of the theoretic pi when calculated with the ProtParam tool provided on the Expasy homepage (<http://www.expasy.ch>; Appel et al., 1994). K53 and UBS-54 have a theoretic pi of 8.24 and 7.65, respectively, whereas an isoform representing a heterodimer of one UBS-54 heavy chain and one K53 heavy chain has a theoretical pi of 8.01. Assembly of such a heterodimer can only occur when a single cell translates both the heavy chain of K53 and the heavy chain of UBS-54 and assembles these into a full length IgG molecule together with the common light chain.

Therefore, this experiment shows that it is possible to express two unique human IgG molecules in a single cell and that a heterodimer consisting of these two unique binding specificities is also efficiently formed.

Example 2 Production of a mixture of antibodies against human B-cell markers in a

PER.C6TM cell line derived clone.

[0059] A method for producing a mixture of antibodies, using expression in a recombinant host cell of a single light chain and three different heavy chains capable of pairing to the single light chain to form functional antibodies, is exemplified herein and is schematically shown in Fig. 6. Phages encoding antibodies capable of binding proteins present on human B-cells, i.e. CD22, CD72 and Major Histocompatibility Complex (MHC) class II (further referred to as HLA-DR) were previously isolated from a semi-synthetic phage library (de Kruif et al., 1995; van der Vuurst de Vries & Logtenberg, 1999). DNA sequencing of the V_H and V_L sequences of the phages clone B28 (anti-CD22), clone I-2 (anti-HLA-DR) and clone II-2 (anti-CD72) revealed that they all contain a unique V_H sequence, but a common light chain sequence (V_L3) with an identical CDR region (Fig. 7).

The V_H and V_L sequences of clones B28, I-1 and II-2 are cloned behind the HAVT20 leader sequences of an expression plasmid comprising a heavy chain. An example of such a plasmid is pCRU-K01 (contains kappa heavy chain sequences, that can easily be interchanged for lambda heavy chain sequences if desired, by a person skilled in the art), as deposited at the ECACC under number 03041601. The cloning gives rise to plasmids encoding a full length human IgG₁ with binding specificities for CD22, CD72 and HLA-DR. These plasmids will further be referred to as pCRU-CD22, pCRU-CD72 and pCRU-HLA-DR, respectively.

Stable PER.C6TM derived cell lines are generated, according to methods known to the person skilled in the art (see e.g. WO 00/63403), the cell lines expressing antibodies encoded by genetic information on either pCRU-CD22, pCRU-CD72 or pCRU-HLA-DR and a cell line expressing antibodies encoded by all three plasmids. Therefore, PER.C6TM cells are seeded in DMEM plus 10% FBS in tissue culture dishes (10 cm diameter) or T80 flasks with approximately 2.5×10^6 cells per dish and kept overnight under their normal culture conditions (10% CO₂ concentration and 37°C). The next day, transfections are performed in separate dishes at 37°C using Lipofectamine (Invitrogen Life Technologies) according to standard protocols provided by the manufacturer, with either 1-2 µg pCRU-CD22, 1-2 µg pCRU-CD72, 1-2 µg pCRU-HLA-DR or 1 µg of a mixture of pCRU-CD22, pCRU-CD72 and pCRU-HLA-DR. As a control for transfection efficiency, a few dishes are transfected with a LacZ control vector, while a few dishes will be not transfected and serve as negative controls.

After 4 to 5 hours, cells are washed twice with DMEM and refed with fresh medium without selection. The next day, medium are replaced with fresh medium containing 500 µg/ml G418. Cells are refreshed every 2 or 3 days with medium containing the same concentrations of G418. About 20-22 days after seeding, a large number of colonies are visible and from each transfection at least 300 are picked and grown via 96-well and/or 24-well via 6-well plates to T25 flasks. At this stage, cells are frozen (at least 1, but usually 4 vials per sub-cultured colony) and production levels of recombinant human IgG antibody are determined in the supernatant using an ELISA specific for human IgG₁ (described in WO 00/63403). Also, at this stage G418 is removed from the culture medium and never re-applied again. For a representative number of colonies larger volumes will be cultured to purify the recombinant human IgG₁ fraction from

the conditioned supernatant using Protein A affinity chromatography according to standard procedures. Purified human IgG₁ from the various clones is analyzed on SDS-PAGE, Iso-electric focusing (IEF) and binding to the targets CD22, CD72 and HLA-DR using cell transfectants expressing these human antigens on their cell surface (transfectants expressing CD72 and HLA-DR have been described by van der Vuurst-de Vries and Logtenberg, 1999; a CD22 transfectant has been prepared according to similar standard procedures in PER.C6TM). Colonies obtained from the co-transfection with pCRU-CD22, pCRU-CD72 and pCRU-HLA-DR are screened by PCR on genomic DNA for the presence or absence of each of the three constructs. The identity of the PCR products is further confirmed by DNA sequencing.

Next, it is demonstrated that a clonal cell line accounts for the production of each of the three binding specificities, i.e. proving that a single cell is able to produce a mixture of more than two functional human IgG's. Therefore, a limited number of colonies, which screened positive for the production of each of the three binding specificities (both by PCR at the DNA level as well as in the specified binding assays against CD22, CD72 and HLA-DR), are subjected to single cell sorting using a fluorescence activated cell sorter (FACS) (Becton & Dickinson FACS VANTAGE SE). Alternatively, colonies are seeded at 0.3 cells/well to guarantee clonal outgrowth. Clonal cell populations, hereafter designated as sub-clones, are refreshed once a week with fresh medium. Sub-clones are grown and transferred from 96-wells via 24- and 6-wells plates to T25 flasks. At this stage, sub-clones are frozen (at least 1, but usually 4 vials per sub-clone) and production levels of recombinant human IgG₁ antibody are determined in the supernatant using a human IgG₁ specific ELISA. For a representative number of sub-clones, larger volumes are cultured to purify the recombinant human IgG₁ fraction from the conditioned supernatant using Protein A affinity chromatography according to standard procedures.

Purified human IgG₁ from the various sub-clones is subsequently analyzed as described above for human IgG₁ obtained from the parental clones, i.e. by SDS-PAGE, Iso-electric focusing (IEF) and binding to the targets CD22, CD72 and HLA-DR. Sub-clones will also be screened by PCR on genomic DNA for the presence or absence of each of the three constructs pCRU-CD22, pCRU-CD72 and pCRU-HLA-DR. The identity of the PCR products is further confirmed by DNA sequencing.

Other methods such as Southern blot and/or FISH can also be used to determine whether each of the three constructs are present in the clonal cell line.

Sub-clones that are proven to be transgenic for each of the three constructs are brought into culture for an extensive period to determine whether the presence of the transgenes is stable and whether expression of the antibody mixture remains the same, not only in terms of expression levels, but also for the ratio between the various antibody isoforms that are secreted from the cell. Therefore, the sub-clone culture is maintained for at least 25 population doubling times either as an adherent culture or as a suspension culture. At every 4-6 population doublings, a specific production test is performed using the human IgG specific ELISA and larger volumes are cultured to obtain the cell pellet and the supernatant. The cell pellet is used to assess the presence of the three constructs in the genomic DNA, either via PCR, Southern blot and/or FISH. The supernatant is used to purify the recombinant human IgG₁ fraction as described supra. Purified human IgG₁ obtained at the various population

doublings is analyzed as described, i.e. by SDS-PAGE, Iso-electric focusing (IEF) and binding to the targets CD22, CD72 and HLA-DR using cell transfectants expressing these antigens.

Example 3 Screening of clones expressing multiple human IgGs for the most potent mixture of functional human IgGs

[0060] Functionality of the antibody mixture is analyzed in cell-based assays to determine whether the human IgG₁ mixture inhibits proliferation and/or induces apoptosis of B-cell lines, such as for example Ramos. Other cell lines can also be used. In addition the antibody mixtures are analyzed for their potential to induce antibody dependent cellular toxicity and complement dependent cytotoxicity of for example Ramos cells.

In each of the following experiments the functionality of the antibody mixture recognizing the targets CD22, CD72 and HLA-DR is analyzed and can be compared to each of the individual IgG1 antibodies and to an equimolar combination of the three individual IgG1 specificities.

[0061] To assess the ability of the antibody mixtures to inhibit the proliferation of Ramos cells, these cells are incubated in 96-well plates ($0.1 - 1.0 \times 10^5/\text{ml}$) with several concentrations (5 - 20 $\mu\text{g}/\text{ml}$) of the antibody mixtures against CD22, CD72 and HLA-DR for 24 hours. The proliferation of the cells is measured by ^3H -thymidine incorporation during another 16 hours of culture. Inhibition of growth is determined by plotting the percentage of ^3H -thymidine incorporation compared to untreated cells (taken as 100% reference value).

[0062] To analyze apoptosis induction of Ramos cells, these cells are stimulated in 48-well plates ($0.2 - 1.0 \times 10^6/\text{ml}$) with several concentrations (5 - 20 $\mu\text{g}/\text{ml}$) of the antibody mixtures against the targets CD22, CD72 and HLA-DR for 24 or 48 hours. After the incubation period the phosphatidyl serine exposure on apoptotic cells is analyzed (Koopman G et al, 1994). Therefore, the cells are harvested, washed twice with PBS and are incubated at RT for 10 min with 100 μl FITC-labelled annexin V (Caltag) diluted 1:25 in annexin V binding buffer (Caltag). Prior to the analysis of the samples by flow cytometry (FACSCalibur, Becton Dickinson, San Jose, CA) propidium iodide (PI)(Sigma) is added to a final concentration of 5 $\mu\text{g}/\text{ml}$ to distinguish necrotic cells (annexin V-/PI+) from apoptotic cells (annexin V+/PI-, early apoptotic cells; annexin V+/PI+, late apoptotic cells).

In an alternative assay, apoptosis is induced by crosslinking the antibody mixtures against CD22, CD72 and HLA-DR on the cell surface of Ramos cells with 25 $\mu\text{g}/\text{ml}$ of F(ab)₂ of goat-anti-human (Fc-specific) polyclonal antibodies (Jackson Immunoresearch Laboratories, West Grove, PA) during the incubation period.

In another alternative assay, apoptosis is induced by incubating the Ramos cells with several concentrations (5 - 20 $\mu\text{g}/\text{ml}$) of the antibody mixtures against CD22, CD72 and HLA-DR while co-incubating them with the chemosensitizing agents doxorubicin (Calbiochem) or dexamethasone (UMCU, Utrecht, the Netherlands).

[0063] Antibody Dependent Cellular Cytotoxicity of the antibody mixtures is analyzed using peripheral blood mononuclear cells as effector cells in a standard ^{51}Cr release assay (Huls et al, 1999). To this purpose, $1-3 \times 10^6$ Ramos cells are labelled with 100 μCi (Amersham, Buckinghamshire, UK) for 1 hour at 37°C . After three washes with medium, the Ramos target cells are plated in U bottom 96 well plates at 5×10^3 cells/well. Peripheral blood mononuclear cells that are obtained from healthy donors by Ficoll-Hypaque density gradients are then added to each well at effector:target ratios ranging from 80:1 to 10:1 in triplicate. The cells are incubated at 37°C in the presence of various concentrations of the antibody mixtures (5 - 20 $\mu\text{g/ml}$) in a final volume of 200 μl . After 4 hours of incubation part of the supernatant is harvested and ^{51}Cr release is measured. The percentage of specific lysis is calculated using the following formula: % specific lysis = $\frac{[\text{experimental cpm} - \text{spontaneous cpm}]}{[\text{maximal cpm} - \text{spontaneous cpm}]} \times 100\%$. Maximal ^{51}Cr release is determined by adding triton X-100 to a final concentration of 1% to the target cells and spontaneous release is determined after incubation of the target cells with medium alone.

Complement dependent cytotoxicity is determined in a similar assay. Instead of the effector cells, now 50 μl human serum is added to the target cells. Subsequently, the assay is performed in the same manner.

Alternatively, ADCC and CDC of the antibody mixtures is determined using a Europium release assay (Patel and Boyd, 1995) or using an LDH release assay (Shields et al, 2001).

Example 4 Use of phage display to isolate multiple phages with an identical V_L sequence against a predefined target (Her-2), and production in a recombinant host cell of a mixture of antibodies capable of binding this target.

[0064] Phages displaying scFv fragments capable of binding multiple epitopes present on the same protein, for example the epidermal growth factor receptor Her-2, can be isolated from a semi-synthetic phage library (de Kruif et al., 1995a,b). It is possible to identify several of such phages and select the ones comprising the same light chain sequence, for further use according to the invention. The semi-synthetic library is formed by mixing 7 sub-libraries that each contain a different light chain (de Kruif et al, 1995a,b). It is therefore particularly practical to use such a sub-library, containing only one light chain and many heavy chains, for screening so that multiple antibodies with an identical V_L sequence are obtained, and further used for expressing the antibody mixtures according to the invention.

For the selection of phages against Her-2 several fusion proteins are generated comprising different parts of the extracellular domain of Her-2 that are fused to the CH2 and CH3 domains of human IgG1. For this purpose a pCDNA3.1zeo expression vector (Invitrogen) has been constructed that contains in its multiple cloning region an XhoI restriction site in the hinge region in frame prior to the CH2 and CH3 domains of human IgG1. Using a Her-2 cDNA clone as a template PCR fragments is generated using standard molecular biology techniques known to a person skilled in the art. These fragments consist of a unique 5' restriction site, a start codon followed by a eukaryotic leader sequence that is linked in frame to either the total

extracellular (EC) domain of Her-2 or to a part of the EC domain of Her-2 that is followed in frame by an XhoI restriction site. These PCR fragments are subsequently cloned in frame with the CH2-CH3 IgG1 region into the pCDNA3.1zeo expression vector. In addition to the fusion protein containing the total EC domain of Her-2, several smaller fusion proteins are generated containing non-overlapping fragments of the Her-2 EC domain. These constructs encoding the Her-2-Ig fusion proteins are used for transient transfection of 293T cells using the lipofectamine reagent (Gibco). Five days after transfection the supernatants of the 293T cells are harvested and Her-2-Ig fusion proteins are purified using protein A affinity chromatography according to standard procedures.

Her-2-Ig fusion proteins containing non-overlapping fragments of the Her-2 EC domain are coated for 2 hours at 37° onto the surface of Maxisorp™ plastic tubes (Nunc) at a saturating concentration (0.5 - 5 µg/ml). The tubes are blocked for 1 h in 2% fat free milk powder dissolved in PBS (MPBS). Simultaneously, 500 µl (approximately 10¹³ cfu) of a semi-synthetic phage display library (a sub-library according to the terminology used above) in which only one Vkappa1 light chain is represented prepared as described by De Kruif et al (1995a,b) and references therein, is added to two volumes of 4% MPBS. In addition, human serum is added to a final concentration of 15% and blocking is allowed to proceed for 30-60 min. The Her-2-Ig-coated tubes are emptied and the blocked phage library is added. The tube is sealed and rotated slowly for 1 h, followed by 2 h of incubation without rotation. The tubes are emptied and washed 10 times in PBS containing 0.1% Tween-20, followed by washing 5 times in PBS. 1 ml glycine-HCL, 0.05 M, pH 2.2 is added, and the tube is rotated slowly for 10 min. The eluted phages are added to 500 µl 1M Tris-HCl pH 7.4. To this mixture, 3.5 ml of exponentially growing XL-1 blue bacterial culture is added. The tubes are incubated for 30 min at 37°C without shaking. Subsequently, the bacteria are plated on 2TY agar plates containing ampicillin, tetracycline and glucose. After overnight incubation of the plates at 37°C, the colonies are scraped from the plates and used to prepare an enriched phage library, essentially as described by De Kruif et al. (1995a). Briefly, scraped bacteria are used to inoculate 2TY medium containing ampicillin, tetracycline and glucose and are grown at 37°C to an OD_{600nm} of ~0.3. Helper phages are added and allowed to infect the bacteria after which the medium is changed to 2TY containing ampicillin, tetracycline and kanamycin. Incubation is continued overnight at 30°C. The next day, the bacteria are removed from the 2TY medium by centrifugation after which the phages are precipitated using polyethylene glycol 6000/NaCl. Finally, the phages are dissolved in a small volume of PBS-1% BSA, filter-sterilized and used for a next round of selection. The selection/re-infection procedure is performed twice. After the second round of selection, individual *E.coli* colonies are used to prepare monoclonal phage antibodies. Essentially, individual colonies are grown to log-phase and infected with helper phages after which phage antibody production is allowed to proceed overnight. Phage antibody containing supernatants are tested in ELISA for binding activity to Her-2-total EC-Ig coated 96 wells plates.

[0065] Selected phage antibodies that are obtained in the screen described above, are validated by ELISA for specificity. For this purpose, Her-2-Ig fusion proteins containing non-overlapping fragments of the Her-2 EC domain are coated to Maxisorp ELISA plates. After

coating, the plates are blocked in 2% MPBS. The selected phage antibodies are incubated in an equal volume of 4% MPBS. The plates are emptied, washed once in PBS, after which the blocked phages are added. Incubation is allowed to proceed for 1 h, the plates are washed in PBS 0.1% Tween-20 and bound phages are detected using an anti-M13 antibody conjugated to peroxidase. The procedure is performed simultaneously using a control phage antibody directed against thyroglobulin (De Kruif et al. 1995a,b), which serves as a negative control.

In another assay the selected phage antibodies are analyzed for their ability to bind BT474 human breast cancer cells that express Her-2. For flow cytometry analysis, phage antibodies are first blocked in an equal volume of 4% MPBS for 15 min at 4°C prior to the staining of the BT474 cells. The binding of the phage antibodies to the cells is visualized using a biotinylated anti-M13 antibody (Santa Cruz Biotechnology) followed by streptavidin-phycoerythrin (Caltag).

[0066] Alternatively, phage antibodies recognizing multiple epitopes on Her-2 are selected using a method based upon competition of phage binding to Her-2 with binding of the well characterized murine anti-Her-2 antibodies HER50, HER66 and HER70 (Spiridon et al, 2002).

To this purpose 2×10^6 BT474 cells are incubated at 4°C with approximately 10^{13} cfu (0.5 ml) of a semi-synthetic phage display library in which only one Vkappa1 light chain is represented prepared as described supra and blocked with 2 volumes of medium containing 10% of FBS. The mixture is slowly rotated at 4°C for 2 hours in a sealed tube. Subsequently, non-bound phages are removed by two washes with 50 ml of cold medium containing 10% FBS. Hereafter, phages recognizing multiple epitopes on Her-2 are eluted by resuspending the BT474 cells in 1 ml of cold medium containing saturating concentrations (5-20 µg/ml) of the HER50, HER66 and HER70 murine anti-Her-2 antibodies. The cells are left on ice for 10 min, spun down and the supernatant containing the anti-Her-2 phage antibodies is used to reinfect XL1-Blue cells as described supra.

[0067] From the panel of Her-2-specific phage antibodies generated by de screens described above, three phage antibodies are selected that are recognizing three different non-overlapping epitopes on the Her-2 protein. The V_H sequences and the unique Vkappa light chain sequence of these clones, provisionally designated VK1HER2-1, VK1HER2-2 and VK1HER2-3, are cloned behind the HAVT20 leader sequences of expression plasmid pCRU-K01 (ECACC deposit 03041601), or a similar expression plasmid, to obtain plasmids encoding a full length human IgG1-kappa with binding specificities for Her-2. These plasmids are provisionally designated as pCRU-VK1HER2-1, pCRU-VK1HER2-2 and pCRU-VK1HER2-3, respectively. Stable PER.C6™ derived cell lines are generated, according to methods known to the person skilled in the art, the cell lines expressing antibodies encoded by genetic information on either pCRU-VK1HER2-1, pCRU-VK1HER2-2 or pCRU-VK1HER2-3 and a cell line expressing antibodies encoded by all three plasmids. Therefore, PER.C6™ cells are seeded in DMEM plus 10% FBS in tissue culture dishes (10 cm diameter) or T80 flasks with approximately 2.5×10^6 cells per dish and kept overnight under their normal culture conditions (10% CO₂ concentration and 37°C). The next day, transfections are performed in separate dishes at 37°C using Lipofectamine (Invitrogen Life Technologies) according to standard protocols provided by the manufacturer, with either 1-2 µg pCRU-VK1HER2-1, 1-2 µg pCRU-

VK1HER2-2, 1-2 µg pCRU-VK1HER2-3 or 1 µg of a mixture of pCRU-VK1HER2-1, pCRU-VK1HER2-2 and pCRU-VK1HER2-3. As a control for transfection efficiency, a few dishes are transfected with a LacZ control vector, while a few dishes are not transfected and serve as negative controls.

After 5 hours cells are washed twice with DMEM and refed with fresh medium without selection. The next day, medium is replaced with fresh medium containing 500 µg/ml G418. Cells are refreshed every 2 or 3 days with medium containing the same concentrations of G418. About 20-22 days after seeding, a large number of colonies are visible and from each transfection at least 300 are picked and grown via 96-well and/or 24-well via 6-well plates to T25 flasks. At this stage, cells are frozen (at least 1, but usually 4 vials per sub-cultured colony) and production levels of recombinant human IgG antibody are determined in the supernatant using an ELISA specific for human IgG₁. Also, at this stage G418 is removed from the culture medium and never re-applied again. For a representative number of colonies larger volumes are cultured to purify the recombinant human IgG₁ fraction from the conditioned supernatant using Protein A affinity chromatography according to standard procedures. Purified human IgG₁ from the various clones is analyzed on SDS-PAGE, Iso-electric focusing (IEF), assayed binding to Her-2-Ig fusion proteins by ELISA, and analyzed for binding to Her-2 on the surface of BT474 cells by flow cytometry.

Clones obtained from the co-transfection of pCRU-VK1HER2-1, pCRU-VK1HER2-2 and pCRU-VK1HER2-3 are screened by PCR on genomic DNA for the presence or absence of each of the three constructs. The identity of the PCR products is further confirmed by DNA sequencing.

Next, it is demonstrated that a clonal cell line accounts for the production of each of the three binding specificities. Therefore, a limited number of colonies, which screened positive for the production of each of the three binding specificities (both by PCR at the DNA level as well as in the specified binding assays against Her-2), are subjected to single cell sorting using a fluorescence activated cell sorter (FACS) (Becton & Dickinson FACS VANTAGE SE). Alternatively, colonies are seeded at 0.3 cells/well to guarantee clonal outgrowth. Clonal cell populations, hereafter designated as sub-clones, are refreshed once a week with fresh medium. Sub-clones are grown and transferred from 96-wells via 24- and 6-wells plates to T25 flasks. At this stage, sub-clones are frozen (at least 1, but usually 4 vials per sub-clone) and production levels of recombinant human IgG₁ antibody are determined in the supernatant using a human IgG₁ specific ELISA. For a representative number of sub-clones, larger volumes are cultured to purify the recombinant human IgG₁ fraction from the conditioned supernatant using Protein A affinity chromatography according to standard procedures.

Purified human IgG₁ from the various sub-clones is subsequently analyzed as described above for human IgG₁ obtained from the parental clones, i.e. by SDS-PAGE, Iso-electric focusing (IEF) and binding to Her-2. Sub-clones will also be screened by PCR on genomic DNA for the presence or absence of each of the three constructs pCRU-VK1HER2-1, pCRU-VK1HER2-2 and pCRU-VK1HER2-3. The identity of the PCR products is further confirmed by DNA sequencing.

Other methods such as Southern blot and/or FISH can also be used to determine whether each of the three constructs are present in the clonal cell line.

Sub-clones that are proven to be transgenic for each of the three constructs are brought into

culture for an extensive period to determine whether the presence of the transgenes is stable and whether expression of the antibody mixture remains the same, not only in terms of expression levels, but also for the ratio between the various antibodies that are secreted from the cell. Therefore, the sub-clone culture is maintained for at least 25 population doubling times either as an adherent culture or as a suspension culture. At every 4-6 population doublings, a specific production test is performed using the human IgG specific ELISA and larger volumes are cultured to obtain the cell pellet and the supernatant. The cell pellet is used to assess the presence of the three constructs in the genomic DNA, either via PCR, Southern blot and/or FISH. The supernatant is used to purify the recombinant human IgG₁ fraction as described supra. Purified human IgG₁ obtained at the various population doublings is analyzed as described, i.e. by SDS-PAGE, Iso-electric focusing (IEF) and binding to Her-2 by ELISA and by flow cytometry using BT474 cells.

[0068] Functionality of the antibody mixture of anti-Her-2 antibodies is analyzed in cell-based assays to determine whether the human IgG₁ mixture inhibits proliferation and/or induces apoptosis of BT474 cells. In addition the antibody mixtures are analyzed for their potential to induce antibody dependent cellular toxicity and complement dependent cytotoxicity of BT474 cells.

[0069] In each of the experiments described below the functionality of the antibody mixture recognizing Her-2 can be analyzed and compared to each of the individual IgG1 antibodies and to an equimolar combination of the three individual monospecific IgG1 molecules.

[0070] To assess the ability of the antibody mixtures to inhibit the proliferation of BT474 cells, these cells are allowed to adhere overnight in 96-well plates (1.5×10^5 /well) and are subsequently incubated with several concentrations (5 - 20 µg/ml) of the antibody mixtures against Her-2 for 72 hours. The proliferation of the cells is measured by ³H-thymidine incorporation during the last 6 hours of culture. Inhibition of growth is determined by plotting the percentage of ³H-thymidine incorporation compared with untreated cells (taken as 100% reference value).

[0071] To analyze apoptosis induction of BT474 cells, these cells are allowed to adhere overnight in 48-well plates (2.5×10^5 /well in 1ml) and are subsequently incubated with several concentrations (5 - 20 µg/ml) of the antibody mixtures against Her-2 for 4 hours. Hereafter the cells are harvested by trypsinization, are washed twice with PBS and are incubated at RT for 10 min with 100 µl FITC-labelled annexin V (Caltag) diluted 1:25 in annexin V binding buffer (Caltag). Prior to the analysis of the samples by flow cytometry (FACSCalibur, Becton Dickinson, San Jose, CA) propidium iodide (PI)(Sigma) is added to a final concentration of 5 µg/ml to distinguish necrotic cells (annexin V⁻/PI⁺) from apoptotic cells (annexin V⁺/PI⁻, early apoptotic cells; annexin V⁺/PI⁺, late apoptotic cells).

[0072] Antibody Dependent Cellular Cytotoxicity of the antibody mixtures is analyzed using

peripheral blood mononuclear cells as effector cells and BT474 cells as target cells in a standard ^{51}Cr release assay as described supra (Huls et al, 1999). Complement dependent cytotoxicity is determined in a similar assay. Instead of the effector cells, now 50 μl human serum is added to the target cells. Subsequently, the assay is performed as described supra. Alternatively, ADCC and CDC of the antibody mixtures is determined using a Europium release assay (Patel and Boyd, 1995) or using an LDH release assay (Shields et al, 2001).

[0073] The functionality of the antibody mixtures against Her-2 is also tested using in vivo animal models, such as for instance described in Spiridon et al, 2002.

Example 5 (for reference)

Expression of different functional human IgGs in the milk of transgenic animals

[0074] The V_H and V_H sequences of phages against proteins present on human B-cells, i.e. CD22 (clone B28), CD72 (clone II-2) and HLA-DR (clone I-2) (Fig. 7) are cloned into expression plasmid pBC1 (as provided in the pBC1 Mouse Milk Expression System, Invitrogen Life Technologies) to obtain mammary-gland and lactation-specific expression of these human IgG molecules in transgenic animals, according to the manufacturer's instructions. These mammary-gland specific expression vectors, encoding the antibody sequences for anti-CD22, anti-CD72 and anti-HLA-DR are introduced into the murine germline according to the manufacturer's instructions. Obtained pups are screened for the presence of each of the three constructs by PCR on DNA isolated from the tail. Pups, either male or female, confirmed for being transgenic for each of the three antibodies, are weaned and matured. Female transgenic mice are fertilized at the age of 6-8 weeks and milk samples are obtained at several time points after gestation. Male transgenic mice are mated with non-transgenic females and female transgenic offspring (as determined with PCR as described above) is mated and milked as described above for the female transgenic founders. Whenever needed, female or male transgenic founders are mated for another generation to be able to obtain sufficient amounts of transgenic milk for each founder line. Transgenic milk is analyzed for the presence of human IgG with a human IgG specific ELISA, which does not cross-react with mouse IgG or other mouse milk components. Human IgG is purified from transgenic mouse milk using Protein A affinity chromatography according to standard procedures. Purified human IgG is analyzed on SDS-PAGE, Isoelectric focusing and binding on the targets CD22, CD72 and HLA-DR. Functionality of the antibody mixture is analyzed as described supra.

Example 6 Production of an IgA/IgG mixture against a predefined target in a PER.C6TM derived clone.

[0075] The V_H - V_L sequences of the phage UBS-54 directed against the homotypic adhesion molecule EP-CAM (Huls et al., 1999) was not only cloned into a vector encoding the constant domains of a human IgG1 with Kappa light chain (expression vector pUBS3000Neo), but also into an expression vector encoding the constant domains of a human IgA1 with Kappa light chain (expression vector pUBS54-IgA, Fig. 8). Hence, antibodies derived from pUBS3000Neo and pUBS54-IgA do bind to the same epitope on EPCAM. The only differences antibodies derived from pUBS3000Neo and pUBS54-IgA are in the sequences encoding the constant domains of the heavy chain, resulting in either an IgG₁ or IgA₁ isotype. The Kappa light chain sequences of these two vectors are identical.

Stable PER.C6[™] derived cell lines expressing antibodies encoded by genetic information on pUBS3000Neo and pUBS54-IgA are generated by procedures well known to persons skilled in the art. Therefore, PER.C6[™] cells are seeded in DMEM plus 10% FBS in tissue culture dishes (10 cm diameter) or T80 flasks with approximately 2.5×10^6 cells per dish and kept overnight under their normal culture conditions (10% CO₂ concentration and 37°C). The next day, transfections are performed in separate dishes at 37°C using Lipofectamine (Invitrogen Life Technologies) according to standard protocols provided by the manufacturer, with either 1-2 µg pUBS3000Neo and pUBS54-IgA. As a control for transfection efficiency, a few dishes are transfected with a LacZ control vector, while a few dishes are not transfected and serve as negative controls.

After 4-5 hours, cells are washed twice with DMEM and refed with fresh medium without selection. The next day, medium is replaced with fresh medium containing 500 µg/ml G418. Cells are refreshed every 2 or 3 days with medium containing the same concentrations of G418. About 20-22 days after seeding, a large number of colonies is visible and from each transfection at least 300 are picked and grown via 96-well and/or 24-well via 6-well plates to T25 flasks. At this stage, cells are frozen (at least 1, but usually 4 vials per sub-cultured colony) and production levels of recombinant human IgG and human IgA antibody are determined in the supernatant using an ELISA specific for human IgG1 as well as an ELISA specific for human IgA. Also, at this stage G418 is removed from the culture medium and never re-applied again. For a representative number of colonies larger volumes are cultured to purify the recombinant human IgG₁ and human IgA fraction from the conditioned supernatant using for instance (a combination of) Protein L or LA affinity chromatography, cation exchange chromatography, hydrophobic interaction chromatography and gel filtration. Purified human immunoglobulins from the various clones are analyzed on SDS-PAGE, Iso-electric focusing (IEF) and binding to the target EPCAM using cell lines having a high expression of this molecule. The clones will also be screened by PCR on genomic DNA for the presence or absence of pUBS3000Neo and pUBS54-IgA. The identity of the PCR products is further confirmed by DNA sequencing.

A limited number of clones, which are screened positive for the production of both EPCAM IgG₁ and EPCAM IgA, are subjected to single cell sorting using a fluorescence activated cell sorter (FACS) (Becton Dickinson FACS VANTAGE SE). Alternatively, colonies are seeded at 0.3 cells/well to guarantee clonal outgrowth. Clonal cell populations, hereafter designated as sub-clones, are refreshed once a week with fresh medium. Sub-clones are grown and transferred from 96-wells via 24- and 6-wells plates to T25 flasks. At this stage, sub-clones are frozen (at

least 1, but usually 4 vials per sub-clone) and production levels of recombinant human IgG₁ and IgA antibody are determined in the supernatant using a human IgG₁ specific ELISA and a human IgA specific ELISA. For a representative number of sub-clones, larger volumes are cultured to purify the recombinant human IgG₁ and human IgA₁ fraction from the conditioned supernatant using for instance (a combination of) Protein L or LA affinity chromatography, cation exchange chromatography, hydrophobic interaction chromatography and gel filtration. Purified human immunoglobulins from the various clones are analyzed on SDS-PAGE, Iso-electric focusing (IEF) and binding to the target EPCAM using cell lines having a high expression of this molecule.

Sub-clones will also be screened by PCR on genomic DNA for the presence or absence of pUBS3000Neo and pUBS54-IgA. The identity of the PCR products is further confirmed by DNA sequencing.

[0076] Other methods such as Southern blot and/or FISH may also be used to determine whether both constructs are present in the clonal cell line.

Example 7 Production of a human IgG₁/IgG₃ mixture against multiple targets in a clonal PER.C6TM cell line

[0077] Phage clone UBS-54 and Clone K53 (Fig. 3) were obtained as described in Example 1. The V_H and V_L of clone UBS-54 was inserted into an expression vector containing the HAVT20 leader sequence and all the coding sequences for the constant domains of a human IgG₁ with a Kappa light chain by a method essentially as described (Boel et al, 2000). The resulting plasmid was designated as pUBS3000Neo (Fig. 4). It will be clear that expression vectors containing heavy chain constant domains of any desired isotype can be constructed by routine methods of molecular biology, using the sequences of these regions that are all available in the art. The V_H and V_L sequences of Phage clone K53 are cloned into an expression vector containing the HAVT20 leader sequence and all the coding sequences for the constant domains of a heavy chain of a human IgG₃ with a Kappa light chain by a method essentially as described (Boel et al, 2000). This expression vector is designated as pK53IgG3.

These plasmids are transiently expressed either alone or in combination in PER.C6TM cells. In brief, each 80 cm² flask is transfected by incubation for 4 hours with 140 µl lipofectamine + 10 µg DNA (either pUBS3000Neo, pK53IgG3 or 10 µg of both) in serum-free DMEM medium at 37°C. After 4 hours, this is replaced with DMEM + 10% FBS, and the cells are grown overnight at 37°C. Cells are then washed with PBS and the medium is replaced with Excell 525 medium (JRH Bioscience). The cells are allowed to grow at 37°C for 6 days, after which the cell culture supernatant is harvested. Human IgG specific ELISA analysis, i.e. measuring all IgG sub-types, is done to determine the IgG concentration in transfected and non-transfected PER.C6TM cells. Human IgG from each supernatant is subsequently purified using Protein A affinity chromatography (Hightrap Protein A HP, cat.no. 1-040203) according to standard procedures,

following recommendations of the manufacturer (Amersham Biosciences). After elution, samples are concentrated in a Microcon YM30 concentrator (Amicon) and buffer exchanged to 10 mM sodium phosphate, pH 6.7. Samples are analysed for binding to the targets EPCAM and CD46 using cell lines having a high expression of these molecules such as LS174T cells. Twelve µg of purified IgG, either transiently expressed UBS-54 IgG1, K53 IgG3 or IgG from the cells in which both antibodies were co-transfected, is subsequently analyzed on Isoelectric focusing gels (Serva Pre-cast IEF gels, pH range 3-10, cat.no. 42866). Samples are loaded on the low pH side and after focussing stained with colloidal blue. The pI values of the major isoforms for each sample are determined to illustrate whether there has been expression of UBS-54 IgG1, K53 IgG3 or bispecific heterodimers, depending on how the cells were transfected. The identification of heterodimers would indicate that single cells have translated both the IgG3 heavy chain of K53 and the IgG1 heavy chain of UBS-54 and assembled these into a full length IgG molecule together with the common light chain. The absence of bispecific heterodimers indicates that it is possible to translate both the IgG3 heavy chain of K53 and the IgG1 heavy chain of UBS-54 in single cells, but that these do not assemble into a full length IgG molecule together with the common light chain, i.e. there is preferential binding of IgG1 and IgG3 heavy chains. This could however also be explained by the lack of co-expression of UBS-54 IgG₁ and K53 IgG₃. Therefore, stable clonal cell lines expressing both pUBS3000Neo and pK53IgG3 are generated by procedures as such well known to persons skilled in the art. PER.C6[™] cells are seeded in DMEM plus 10% FBS in tissue culture dishes (10 cm diameter) or T80 flasks with approximately 2.5×10^6 cells per dish and kept overnight under their normal culture conditions (10% CO₂ concentration and 37°C). The next day, transfections are performed in separate dishes at 37°C using Lipofectamine (Invitrogen Life Technologies) according to standard protocols provided by the manufacturer, with either 1-2 µg pUBS3000Neo, pK53IgG3 or both. As a control for transfection efficiency, a few dishes are transfected with a LacZ control vector, while a few dishes will be not transfected and serve as negative controls.

After 4-5 hours, cells are washed twice with DMEM and refed with fresh medium without selection. The next day, medium is replaced with fresh medium containing 500 µg/ml G418. Cells are refreshed every 2 or 3 days with medium containing the same concentrations of G418. About 20-22 days after seeding, a large number of colonies is visible and from each transfection at least 300 are picked and grown via 96-well and/or 24-well via 6-well plates to T25 flasks. At this stage, cells are frozen (at least 1, but usually 4 vials per sub-cultured colony) and production levels of recombinant human IgG antibody are determined in the supernatant using an ELISA specific for all sub-types of human IgG. Also, at this stage G418 is removed from the culture medium and never re-applied again. For a representative number of colonies larger volumes are cultured to purify the recombinant human IgG from the conditioned supernatant using Protein A affinity chromatography (Hightrap Protein A HP, cat.no. 1-040203) according to standard procedures, following recommendations of the manufacturer (Amersham Biosciences). Purified human immunoglobulins from the various clones are analyzed on SDS-PAGE, Iso-electric focusing (IEF) and binding to the targets EPCAM and CD46 using cell lines having a high expression of these molecules such as LS174T cells. The clones are also screened by PCR on genomic DNA for the presence or absence of

pUBS3000Neo and pK53IgG3. The identity of the PCR products is further confirmed by DNA sequencing.

A limited number of clones, which are screened positive for the production of both EPCAM IgG1 and K53 IgG3, are subjected to single cell sorting using a fluorescence activated cell sorter (FACS) (Becton Dickinson FACS VANTAGE SE). Alternatively, colonies are seeded at 0.3 cells/well to guarantee clonal outgrowth. Clonal cell populations, hereafter designated as sub-clones, are refreshed once a week with fresh medium. Sub-clones are grown and transferred from 96-wells via 24- and 6-wells plates to T25 flasks. At this stage, sub-clones are frozen (at least 1, but usually 4 vials per sub-clone) and production levels of recombinant human IgG antibody are determined in the supernatant using a human IgG specific ELISA. For a representative number of sub-clones, larger volumes are cultured to purify the recombinant human IgG fraction from the conditioned supernatant using Protein A affinity chromatography (Hightrap Protein A HP, cat.no. 1-040203) according to standard procedures, following recommendations of the manufacturer (Amersham Biosciences). Purified human immunoglobulins from the various clones are analyzed on SDS-PAGE, Iso-electric focusing (IEF) and binding to the targets EPCAM and CD46 using cell lines having a high expression of this molecules, such as for instance LS174T cells, or transfectants expressing these molecules.

Sub-clones are also screened by PCR on genomic DNA for the presence or absence of pUBS3000Neo and pK53IgG3. The identity of the PCR products is further confirmed by DNA sequencing.

Other methods such as Southern blot and/or FISH may also be used to determine whether both constructs are present in the clonal cell line.

Once the clonal sub-clones are available and confirmed positive for the expression of both UBS-54 IgG1 and K53 IgG3, the presence of functional K53 and UBS-54 shows that it is possible to generate a mixture of functional IgG's with different isotypes with the common light chain in a single cell. Analysis of the expression of bispecific antibodies binding both EpCAM and CD46 will reveal to what extent the different heavy chains having a different subtype will pair, which will influence the amount of bispecific antibodies produced. It is expected that no or very low levels of bispecific antibodies will be found in this case.

Example 8. Selection of phage carrying single chain Fv fragments specifically recognizing rabies virus glyco protein (RVGP) using RVGP-Ig fusion protein, and expression of mixtures of antibodies against the rabies virus.

[0078] This example describes the production of mixtures of antibodies against the rabies virus, as another potential target. As an antigen, the Rabies Virus Glycoprotein (RVGP) is chosen, but other rabies antigens may be chosen or included as well for this purpose. Several monoclonal antibodies recognizing RVGP have already been described in the art, and polyclonal antibodies have been recognized to be useful in treatment of rabies infections as well (e.g. EP0402029; EP0445625).

Antibody fragments are selected using antibody phage display libraries and MAbstract™

technology, essentially as described in US patent 6,265,150 and in WO 98/15833. All procedures are performed at room temperature unless stated otherwise. The sequence of RVGP is available to the person skilled in the art, for cloning purposes (e.g. Yelverton et al, 1983). An RVGP-Ig fusion protein consisting of whole RVGP fused genetically to the CH2 and CH3 domains of human IgG1 is produced using vector pcDNA3.1 Zeo-CH2-CH3 expressed in PER.C6™ and coated for 2 hours at 37° onto the surface of Maxisorp™ plastic tubes (Nunc) at a concentration of 1.25 µg/ml. The tubes are blocked for 1 h in 2% fat free milk powder dissolved in PBS (MPBS). Simultaneously, 500 µl (approximately 10¹³ cfu) of a phage display library expressing single chain Fv fragments (scFv's) essentially prepared as described by De Kruif et al (1995a,b) and references therein, is added to two volumes of 4% MPBS. In this experiment, selections are performed using fractions of the original library constructed using only one single variable light chain gene species (e.g. a VK1'-library). In addition, human serum is added to a final concentration of 15% and blocking is allowed to proceed for 30-60 min. The RVGP-Ig-coated tubes are emptied and the blocked phage library is added. The tube is sealed and rotated slowly for 1 h, followed by 2 h of incubation without rotation. The tubes are emptied and washed 10 times in PBS containing 0.1% Tween-20, followed by washing 5 times in PBS. 1 ml glycine-HCL, 0.05 M, pH 2.2 is added, and the tube is rotated slowly for 10 min. The eluted phages are added to 500 µl 1M Tris-HCl pH 7.4. To this mixture, 3.5 ml of exponentially growing XL-1 blue bacterial culture is added. The tubes are incubated for 30 min at 37°C without shaking. Then, the bacteria are plated on 2TY agar plates containing ampicillin, tetracycline and glucose. After overnight incubation of the plates at 37°C, the colonies are scraped from the plates and used to prepare an enriched phage library, essentially as described by De Kruif et al. (1995a,b). Briefly, scraped bacteria are used to inoculate 2TY medium containing ampicillin, tetracycline and glucose and grown at a temperature of 37°C to an OD_{600nm} of ~0.3. Helper phages are added and allowed to infect the bacteria after which the medium is changed to 2TY containing ampicillin, tetracycline and kanamycin. Incubation is continued overnight at 30°C. The next day, the bacteria are removed from the 2TY medium by centrifugation after which the phages are precipitated using polyethylene glycol 6000/NaCl. Finally, the phages are dissolved in a small volume of PBS-1% BSA, filter-sterilized and used for a next round of selection. The selection/re-infection procedure is performed twice. After the second round of selection, individual *E.coli* colonies are used to prepare monoclonal phage antibodies. Essentially, individual colonies are grown to log-phase and infected with helper phages after which phage antibody production is allowed to proceed overnight. Phage antibody containing supernatants are tested in ELISA for binding activity to human RVGP-Ig coated 96 wells plates.

[0079] Selected phage antibodies that are obtained in the screen described above, are validated in ELISA for specificity. For this purpose, human RVGP-Ig is coated to Maxisorp ELISA plates. After coating, the plates are blocked in 2% MPBS. The selected phage antibodies are incubated in an equal volume of 4% MPBS. The plates are emptied, washed once in PBS, after which the blocked phages are added. Incubation is allowed to proceed for 1 h, the plates are washed in PBS 0.1% Tween-20 and bound phages are detected using an anti-M13 antibody conjugated to peroxidase. As a control, the procedure is performed

simultaneously using a control phage antibody directed against thyroglobulin (De Kruif et al. 1995a,b), which serves as a negative control.

[0080] The phage antibodies that bind to human RVGP-Ig are subsequently tested for binding to human serum IgG to exclude the possibility that they recognized the Fc part of the fusion protein.

[0081] In another assay the phage antibodies are analyzed for their ability to bind PER.C6TM cells that express RVGP. To this purpose PER.C6TM cells are transfected with a plasmid carrying a cDNA sequence encoding RVGP or with the empty vector and stable transfectants are selected using standard techniques known to a person skilled in the art (e.g. COLIGAN, J.E. et al. (2001) Current protocols in protein science, volume I. John Wiley & Sons, Inc. New York). For flow cytometry analysis, phage antibodies are first blocked in an equal volume of 4% MPBS for 15 min at 4°C prior to the staining of the RVGP- and control transfected PER.C6TM cells. The blocked phages are added to a mixture of unlabelled control transfected PER.C6TM cells and RVGP transfected PER.C6TM cells that have been labelled green using a lipophilic dye (PKH67, Sigma). The binding of the phage antibodies to the cells is visualized using a biotinylated anti-M13 antibody (Santa Cruz Biotechnology) followed by streptavidin-phycoerythrin (Caltag). Anti RVGP scFv selectively stains the PER.C6TM RVGP transfectant while they do not bind the control transfectant.

[0082] An alternative way of screening for phages carrying single chain Fv fragments specifically recognizing human RVGP, is by use of RVGP-transfected PER.C6TM cells. PER.C6TM cells expressing membrane bound RVGP are produced as described supra. Phage selection experiments are performed as described supra, using these cells as target. A fraction of the phage library comprised of scFv-phage particles using only one single scFv species (500 µl, approximately 10¹³cfu) is blocked with 2 ml RPMI/10%FCS/1%NHS for 15' at RT. Untransfected PER.C6TM cells (~10*10⁶ cells) are added to the PER.C6-RVGP cells (~1.0*10⁶ cells). This mixture is added to the blocked light chain restricted phage-library and incubated for 2,5 hr while slowly rotating at 4°C. Subsequently, the cells are washed twice and were resuspended in 500µl RPMI/10%FCS and incubated with a murine anti-RVGP antibody (Becton Dickinson) followed by a phycoerythrin (PE)-conjugated anti-mouse-IgG antibody (Caltag) for 15' on ice. The cells are washed once and transferred to a 4 ml tube. Cell sorting is performed on a FACSvantage fluorescence-activated cell sorter (Becton Dickinson) and RVGP (PE positive) cells are sorted. The sorted cells are spun down, the supernatant is saved and the bound phages are eluted from the cells by resuspending the cells in 500µl 50mM Glycin pH2.2 followed by incubation for 5 min. at room temperature. The mixture is neutralized with 250µl 1M Tris-HCl pH 7.4 and added to the rescued supernatant. Collectively these phages are used to prepare an enriched phage library as described above. The selection/re-infection procedure is performed twice. After the second round of selection, monoclonal phage antibodies are prepared and tested for binding to RVGP-PER.C6TM cells and untransfected PER.C6TM cells as described supra. Phages that are positive on RVGP-transfected cells are subsequently tested

for binding to the RVGP-IgG fusion protein in ELISA as described supra.

[0083] The selected scFv fragments are cloned in a human IgG1 format, according to methods known in the art (e.g. Boel et al, 2000). To this purpose, the VL fragment shared by the selected scFv is PCR amplified using oligo's that add appropriate restriction sites. A similar procedure is used for the VH genes. Thus modified genes are cloned in expression pCRU-K01 (ECACC deposit 03041601), which results in expression vectors encoding a complete hulgG1 heavy chain and a complete human light chain gene having the same specificity as the original phage clone. By this method, three different heavy chains are cloned into separate expression vectors, while only one of the vectors needs to comprise the common light chain sequence. These expression vectors are provisionally designated pCRU-RVGP-1, pCU-RVGP-2, and pCRU-RVGP-3. Alternatively, these three vectors may lack DNA encoding the V_L region, which can then be encoded in a fourth, separate expression vector not encoding a heavy chain. It is also possible to have V_L sequences present in all three or two of the three vectors comprising the different V_H sequences.

Stable PER.C6TM derived cell lines are generated, according to methods known to the person skilled in the art (see e.g. WO 00/63403), the cell lines expressing antibodies encoded by genetic information on either pCRU-RVGP-1, pCRU-RVGP-2 or pCRU-RVGP-3 and a cell line expressing antibodies encoded by all three plasmids. Therefore, PER.C6TM cells are seeded in DMEM plus 10% FBS in tissue culture dishes (10 cm diameter) or T80 flasks with approximately 2.5×10^6 cells per dish and kept overnight under their normal culture conditions (10% CO₂ concentration and 37°C). The next day, transfections are performed in separate dishes at 37°C using Lipofectamine (Invitrogen Life Technologies) according to standard protocols provided by the manufacturer, with either 1-2 µg pCRU-RVGP-1, 1-2 µg pCRU-RVGP-2, 1-2 µg pCRU-RVGP-3 or 1 µg of a mixture of pCRU-RVGP-1, pCRU-RVGP-2 and pCRU-RVGP-3. As a control for transfection efficiency, a few dishes are transfected with a LacZ control vector, while a few dishes will not be transfected and serve as negative controls. After 4 to 5 hours, cells are washed twice with DMEM and refed with fresh medium without selection. The next day, medium are replaced with fresh medium containing 500 µg/ml G418. Cells are refreshed every 2 or 3 days with medium containing the same concentrations of G418. About 20-22 days after seeding, a large number of colonies are visible and from each transfection at least 300 are picked and grown via 96-well and/or 24-well via 6-well plates to T25 flasks. At this stage, cells are frozen (at least 1, but usually 4 vials per sub-cultured colony) and production levels of recombinant human IgG antibody are determined in the supernatant using an ELISA specific for human IgG₁ (described in WO 00/63403). Also, at this stage G418 is removed from the culture medium and never re-applied again. For a representative number of colonies larger volumes will be cultured to purify the recombinant human IgG₁ fraction from the conditioned supernatant using Protein A affinity chromatography according to standard procedures. Purified human IgG₁ from the various clones is analyzed on SDS-PAGE, Iso-electric focusing (IEF) and binding to the target RVGP using an RVGP PER.C6-transfectant described above.

Colonies obtained from the co-transfection with pCRU-RVGP-1, pCRU-RVGP-2 and pCRU-

RVGP-3 are screened by PCR on genomic DNA for the presence or absence of each of the three constructs. The identity of the PCR products is further confirmed by DNA sequencing.

A limited number of colonies, which screened positive for the production of each of the three binding specificities (both by PCR at the DNA level as well as in the specified binding assays against RVGP), are subjected to single cell sorting using a fluorescence activated cell sorter (FACS) (Becton & Dickinson FACS VANTAGE SE). Alternatively, colonies are seeded at 0.3 cells/well to guarantee clonal outgrowth. Clonal cell populations, hereafter designated as sub-clones, are refreshed once a week with fresh medium. Sub-clones are grown and transferred from 96-wells via 24- and 6-wells plates to T25 flasks. At this stage, sub-clones are frozen (at least 1, but usually 4 vials per sub-clone) and production levels of recombinant human IgG₁ antibody are determined in the supernatant using a human IgG₁ specific ELISA. For a representative number of sub-clones, larger volumes are cultured to purify the recombinant human IgG₁ fraction from the conditioned supernatant using Protein A affinity chromatography according to standard procedures.

Purified human IgG₁ from the various sub-clones is subsequently analyzed as described above for human IgG₁ obtained from the parental clones, i.e. by SDS-PAGE, Iso-electric focusing (IEF) and binding to the target RVGP. Sub-clones are also screened by PCR on genomic DNA for the presence or absence of each of the three constructs pCRU-RVGP-1, pCRU-RVGP-2 and pCRU-RVGP-3. The identity of the PCR products is further confirmed by DNA sequencing. Other methods such as Southern blot and/or FISH can also be used to determine whether each of the three constructs are present in the clonal cell line.

Sub-clones that are proven to be transgenic for each of the three constructs are brought into culture for an extensive period to determine whether the presence of the transgenes is stable and whether expression of the antibody mixture remains the same, not only in terms of expression levels, but also for the ratio between the various antibody isoforms that are secreted from the cell. Therefore, the sub-clone culture is maintained for at least 25 population doublings either as an adherent culture or as a suspension culture. At every 4-6 population doublings, a specific production test is performed using the human IgG specific ELISA and larger volumes are cultured to obtain the cell pellet and the supernatant. The cell pellet is used to assess the presence of the three constructs in the genomic DNA, either via PCR, Southern blot and/or FISH. The supernatant is used to purify the recombinant human IgG₁ fraction as described supra. Purified human IgG₁ obtained at the various population doublings is analyzed as described, i.e. by SDS-PAGE, Iso-electric focusing (IEF) and binding to the target RVGP.

The efficacy of the antibody mixtures against rabies is tested in in vitro cell culture assays where the decrease in spread of rabies virus is measured, as well as in in vivo animal models infected by rabies. Such models are known to the person skilled in the art, and are e.g. described in EP0402029.

Example 9 (for reference)

Production of a mixture of antibodies with a common light chain and three different

heavy chain variable regions in a single cell.

[0084] A method for producing a mixture of antibodies, using expression in a recombinant host cell of a single light chain and three different heavy chains capable of pairing to the single light chain to form functional antibodies, is exemplified herein and is schematically shown in Fig. 6. Human IgG's UBS54 and K53 against the EP-CAM homotypic adhesion molecule (Huls et al., 1999) and the membrane cofactor protein CD46 (WO 02/18948), respectively, are described in Example 1. Another clone that was identified to bind to cofactor protein CD46 was clone 02-237 (sequence of VH provided in Fig. 12). DNA sequencing of this clone revealed that it contained the same light chain as UBS54 and K53, but a unique heavy chain variable sequence (see alignment in Fig. 3). As a result, the CDR3 of the heavy chain of 02-237 differs at 4 positions from that of K53 (see alignment in Fig. 13). The heavy and light chain variable sequences of phage 02-237 were cloned into the expression plasmid pCRU-K01, (pCRU-K01 is deposited at the European Collection of Cell Cultures (ECACC) under number 03041601), which contains the heavy and light chain constant domains for an IgG1 antibody. The resulting plasmid was designated pgG102-237. Due to the cloning strategy followed, the resulting N-terminus of the light chain of 02-237 as encoded by pgG102-237 differed slightly from the N-terminus of UBS54 and K53 as present by pUBS3000Neo, pCD46_3000(Neo), respectively (Fig. 3). Plasmid pgG102-237 was transiently produced in human 293(T) cells or stably in PER.C6 cells. It appeared that purified 02-237 IgG had a much higher affinity for purified CD46 (Fig. 14) than K53 IgG, i.e. the affinity had increased from 9.1×10^{-7} M to 2.2×10^{-8} M for K53 and 02-237, respectively. Also, 02-237 bound much better to CD46 on human coloncarcinoma LS174T cells than K53 (Fig. 15).

[0085] Stable PER.C6TM derived cell lines expressing a combination of the plasmids pUBS3000Neo, pCD46_3000(Neo) and pgG102-237 encoding human IgG 02-237 were generated according to methods known as such to the person skilled in the art (see e.g. WO 00/63403). Therefore, PER.C6TM cells were seeded in DMEM plus 10% FBS in tissue culture dishes (10 cm diameter) with approximately 2.5×10^6 cells per dish and kept overnight under their normal culture conditions (10% CO₂ concentration and 37°C). The next day, transfections were performed in separate dishes at 37°C using Lipofectamine (Invitrogen Life Technologies) according to standard protocols provided by the manufacturer, with 2 µg of an equimolar mixture of pUBS3000Neo, pCD46_3000(Neo) and pgG102-237. As negative control for selection, a few dishes were not transfected.

After 4 to 5 hours, cells were washed twice with DMEM and refed with fresh medium without selection. The next day, medium was replaced with fresh medium containing 500 µg/ml G418. Cells were refreshed every 2 or 3 days with medium containing the same concentrations of G418. About 20-22 days after seeding, a large number of colonies was visible and about 300 were picked and grown via 96-well and/or 24-well via 6-well plates to T25 flasks. During sub-culturing, production levels of recombinant human IgG antibody were determined in the supernatant using an ELISA specific for human IgG1 (described in WO 00/63403). About 25%

of all colonies appeared to be positive in this highly specific assay. The production levels measured at this stage were comparable to the levels when a single IgG is expressed in PER.C6™ cells (expression of a single IgG described in Jones et al., 2003). It is important to stress that these high expression levels were obtained without any methods for amplification of the transgene and that they occur at a low copy number of the transgene.

The 30 best producing colonies were frozen down in vials and the 19 highest producing clones were selected for purification of the IgG (Table 1). They were sub-cultured in T80 flasks and human IgG from each clone was subsequently purified using Protein A affinity chromatography. Therefore, 15-25 ml of conditioned medium was loaded on a 5 ml Protein A FF Sepharose column (Amersham Biosciences). The column was washed with 4 mM phosphate buffered saline, pH 7.4 (PBS) before elution with 0.1 M citrate pH 3.0. The eluted fraction was subsequently desalted on a Sephadex G25 Fine HiPrep Desalting column (Amersham Biotech) to PBS. The concentration of the purified IgG fraction was determined by absorbance measurement at 280 nm using a coefficient of 1.4 for a 0.1% (w/v) solution (Table 1).

The purified IgG samples were analysed on non-reduced and reduced SDS-PAGE and IEF. Non-reduced SDS-PAGE (Fig. 16A) showed that all IgG samples migrated comparable to the control K53 or 02-237, as an assembled, intact IgG molecule of approximately 150 kDa. On reduced SDS-PAGE (Fig. 16B), the IgG samples migrated as heavy and light chains of about 50 and 25 kDa, respectively, comparable to the heavy and light chain of the control K53 or 02-237.

On IEF, the purified IgG fractions were first compared to a mixture of equal amounts of K53, UBS54 and 02-237 (Fig. 17). Clearly, some of the samples contained isoforms with a unique pl profile, when compared to the mixture containing purified K53, UBS54 and 02-237. Some major unique isoforms have a pl in between the pl of K53 and 02-237 on one hand and UBS54 on the other hand. This is also anticipated on the basis of the theoretic pl when calculated with the ProtParam tool provided on the Expasy homepage (<http://www.expasy.ch>; Appel et al., 1994). K53, 02-237 and UBS54 have a theoretic pl of 8.24, 8.36 and 7.65, respectively, whereas an isoform representing a heterodimer of one UBS54 heavy chain and one K53 heavy chain has a theoretical pl of 8.01. Assembly of such a heterodimer can only occur when a single cell translates both the heavy chain of K53 and the heavy chain of UBS54 and assembles these into a full length IgG molecule together with the common light chain. Hence these results suggest that certain clones at least express two functional antibodies. To confirm the unique identity of some of the isoforms, samples of the most interesting clones were run in parallel with K53, UBS54 and 02-237, either alone or in a mixture (Fig. 18). This furthermore showed that some clones expressed at least two antibodies (241, 282, 361). Moreover, it provided evidence that some clones express all three functional antibodies (280 and 402).

To confirm that the clones expressed IgG mixtures comprising all three heavy chains, peptide mapping (Garnick, 1992; Gelpí, 1995) was used to analyse the polyclonal IgG fraction. We previously employed peptide mapping to recover 99% of the protein sequence of K53. Based on the protein sequence provided in Fig. 12, the mass of the theoretical tryptic peptides of K53, UBS54 and 02-237 was calculated (Table II and III). A few unique peptides for each IgG, could be identified, i. e. for instance the CDR3 peptides for K53, 02-237 and UBS54 with a Mw of 2116.05, 2057.99 and 2307.15 Da, respectively. Next, a tryptic digest of Poly1-280 was prepared and this was analysed using LC-MS (Fig. 19). Peptides with Mw of 2116, 2057 and

2308 Da, representing the unique CDR3 peptides of K53, 02-237 and UBS54, respectively, were detected. The precise amino acid sequence of these peptides (as listed in Table III) was confirmed by MS-MS analysis (Tables IV, V and VI). We also confirmed the presence of the two unique N-terminal light chain peptides with Mw of 2580 and 2554 Da, respectively. The peptide mapping data unequivocally showed that a mixture of antibodies comprising a common light chain and three different heavy chains was expressed by PER.C6TM clone Poly1-280. Also clones 055, 241 and 402 were screened by peptide mapping. Clones 241 and 402 were confirmed positive for all three heavy chain sequences, whereas clone 055 only showed expression of the heavy chains of K53 and 02-237, and not of UBS54. This confirms the IEF screening (Fig. 18), where no UBS54 related band was seen in sample 055.

Poly1-280 was analysed by BIACORE for binding to CD46 (Fig. 20). The affinity of poly1-280 for CD46 was 2.1×10^{-8} M, which shows that the IgG mixture contains CD46 binding molecules having the same affinity as 02-237 IgG alone.

Taken together, this experiment shows that it is possible to express a mixture of functional IgG molecules comprising three unique heavy chains in a single cell and that next to the homodimers, heterodimers consisting of two binding specificities are also formed. Furthermore, the frequency of clones expressing three different heavy chains suggests that it will also be possible to obtain clones expressing at least 4, 5 or more heavy chains, using the same procedure. In case it would be difficult to obtain clones expressing higher numbers of heavy chains, a clone expressing at least 3 heavy chains can be used to introduce more heavy chains in a separate round of transfection, for instance by using a different selection marker.

[0086] Next, it was demonstrated that a single cell is able to produce a mixture of more than two functional human IgG's. Therefore, clones 241, 280 and 402, which were screened positive for the production of each of the three IgG's, both by IEF and MS, were subjected to limiting dilution, i.e. seeded at 0.3 cells/well in 96-wells plate to guarantee clonal outgrowth.

Clonal cell populations, hereafter designated as sub-clones, were refreshed once a week with fresh medium. Sub-clones were grown and transferred from 96-wells via 24- and 6-wells plates, T25, T80 and T175 flasks. At the T80 stage, sub-clones were frozen. Production levels of recombinant human IgG₁ antibody were determined in the supernatant using a human IgG₁ specific ELISA. For each parental clone, 3 sub-clones were chosen and cultured in a few T175 flasks to obtain sufficient conditioned medium for purification using Protein A affinity chromatography as described above.

[0087] Purified human IgG₁ from the sub-clones was subsequently analyzed as described above for human IgG₁ obtained from the parental clone, by Iso-electric focusing (IEF). The result is shown in Fig. 21. Subclones from clone poly 1-241 each have the same pattern, but differ from the parental clone in that they appear to miss certain bands. Subclones from clone poly 1-280 all appear to differ from each other and from the parental clone. Patterns obtained by IEF for subclones from parental clone poly 1-402 are identical for all three subclones and the parent clone. From these data it can be concluded that clone 402 is stably producing a mixture of antibodies. This demonstrates that it is feasible to produce a mixture of antibodies according to the invention from a single cell clone. The clones have undergone about 25

population doublings (cell divisions) from the transfection procedure up to the first analysis (shown in Fig. 18) under selection pressure, and from that point on further have undergone about 30 population doublings during the sub-cloning procedure in the absence of selection pressure, before the material analysed in Fig. 21 was harvested. Therefore, the production of a mixture of antibodies from a clone from a single cell can be stable over at least 30 generations.

[0088] Purified IgG1 from the parental 241, 280 and 402 clones, and subclones, were also analysed for binding reactivity towards the CD46- and EpCAM antigens. To this end, cDNA of EpCAM, CD46 and control antigen CD38 were cloned into expression vectors pcDNA (Invitrogen). These vectors were transfected into CHO (dhfr-) cells using Fugene (Roche) according to the protocol supplied by the manufacturer. Cells were cultured in Iscove's medium containing 10% FBS and HT supplement (Gibco). After culturing for 2 days, cells were harvested by trypsinization and suspended in PBS-1%BSA (PBSB) for use in FACS analysis.

Purified IgG1 of the clones producing the mixtures of antibodies and control IgG1 samples of anti-GBSIII, an anti-CD72 antibody (02-004), as well as antibodies from anti-EpCAM clone UBS54 and anti-CD46 clones K53 and 02-237 were diluted in PBSB to a concentration of 20 µg IgG1 /ml. 20 µl of each was added to 200.000 transfected cells and incubated on ice for 1 hour. Thereafter, cells were washed once in ice-cold PBSB. Bound IgG was then detected using incubation with goat-anti-human IgG-biotin followed by streptavidin-PE. After a final washing step, cells were suspended in PBSB containing 1 µg/ml propidium iodide. The samples were analysed on a FACS (FACSVantage, Becton Dickinson). Live cells were gated and Mean Fluorescent Intensities (MFI) were calculated from the FACS plots. The results are represented in Fig. 22. As expected, UBS54 bound selectively to EpCAM transfected cells and 02-237 and K53 bound selectively to CD46 transfectants, while unrelated antibodies did not bind to these transfectants. The results demonstrate that binding activities towards both EpCAM and CD46 were present in the purified IgG1 preps of most clones expressing a mixture of antibodies according to the invention, demonstrating that a mixture of functional antibodies was produced by sub-clones that have undergone more than 30 cell divisions, and that result from a single cell. In subclone 280-015 binding patterns towards CD46 and EpCAM were similar as in the parent clone poly 1-280, in contrast to the other clones. It should be stated that the quantitative aspect of this assay is not completely clear. Routine screening, e.g. by a functional test, can be used to find a clone with the desired expression profile. Quantitative aspects may also be included in such screens. Such screening allows for the identification of desired clones, which express the mixture of antibodies with a given functionality in a quantitatively stable manner.

Table I. Overview of the clones used for purification of IgG.

Clone Polyl-	Screening ELISA (µg/ml)	Purification	
		Conc. in feed (µg/ml)	Purified (mg)
209	6.1	98	1.37
233	10.0	53	0.75
234	8.0	51	0.71
241	6.6	91	1.42

Clone Polyl-	Screening ELISA ($\mu\text{g/ml}$)	Purification	
		Conc. in feed ($\mu\text{g/ml}$)	Purified (mg)
250	12.5	117	2.10
280	6.3	36	0.80
282	8.5	67	1.48
289	8.2	33	0.64
304	7.2	161	3.91
320	6.3	43	0.83
322	15.2	168	3.27
340	6.0	109	2.64
361	10.4	71	1.73
379	9.5	78	1.75
402	39.9	135	3.14
022	16.2	83	1.69
040	7.8	67	1.43
048	6.5	43	0.94
055	11	55	1.04

Table II. Tryptic peptides of the variable domains of the light chain of K53/UBS54 and 02-237.

Peptide	First AA ¹⁾	Last AA	Monoisotopic M_w (Da) K53/UBS54	Monoisotopic M_w (Da) 02-237
L1	1	24	2580.31 ⁽²⁾	2554.28 ⁽²⁾
L2	25	59	4039.02	4039.02
L3	60	66	700.35	700.35
L4	67	79	1302.61	1302.61
L5	80	82	374.23	374.23
L6	83	107	2810.29 ⁽²⁾	2810.29 ⁽²⁾
L7	108	111	487.30	487.30
L8	112	112	174.11	174.11

1) AA, amino acid
2) One Cysteine residue alkylated

Table III. Tryptic peptides of variable domains of heavy chains of K53, 02-237 and UBS54.

K53				02-237				UBS54			
A	B	C	D	A	B	C	D	A	B	C	D
H1	1	12	1267.68	H1	1	12	1267.68	H1	1	12	1267.68
H2	13	19	685.41	H2	13	19	685.41	H2	13	19	729.41
H3	20	23	492.24	H3	20	23	492.24	H3	20	23	492.24

K53				02-237				UBS54			
A	B	C	D	A	B	C	D	A	B	C	D
H4	24	38	1693.81	H4	24	38	1693.81	H4	24	38	1587.77
H5	39	63	2783.28	H5	39	63	2783.28	H5	39	63	2646.33
H6	64	67	472.28	H6	64	67	472.28	H6	64	67	506.26
H7	68	84	1906.87	H7	68	84	1906.87	H7	68	87	2174.04
H8	85	87	374.23	H8	85	87	374.23	-	-	-	-
H9	88	98	1319.55	H9	88	98	1319.55	H8	88	98	1333.56
H10	99	102	493.21	H10	99	102	475.25	H9	99	119	2307.15
H11	103	122	2116.05	H11	103	122	2057.99	-	-	-	-

Key: A: peptide

B: first amino acid

C: last amino acid

D: monoisotopic M_w (Da)

Remarks: 1) for H1, amino acid residue 1 is a pyroglutamic acid

2) peptides H3 and H9 from K53 and 02-237, and peptides H3 and H8 of UBS54 contain one alkylated cysteine residue

3) Unique peptides that can be used to confirm the presence of the respective IgG's are indicated in bold italics

Table IV. MS/MS-data of CDR3 peptide (H11) of K53, obtained by *collision induced dissociation* of doubly charged m/z 1059.06.

Ion	m/z		Ion	m/z
Y'' ₁	147.12		B ₁	n.d.
Y'' ₂	248.18		B ₂	157.10
Y'' ₃	<u>335.21</u> (1)		B ₃	304.18
Y'' ₄	406.25		B ₄	419.22
Y'' ₅	507.30		B ₅	<u>582.31</u>
Y'' ₆	<u>594.33</u>		B ₆	768.38
Y'' ₇	693.40		B ₇	825.39
Y'' ₈	<u>794.46</u>		B ₈	953.43
Y'' ₉	<u>893.54</u>		B ₉	n.d.
Y'' ₁₀	1006.63		B ₁₀	n.d.
Y'' ₁₁	1107.67		B ₁₁	1224.65
Y'' ₁₂	<u>1164.68</u>		B ₁₂	1323.68
Y'' ₁₃	1292.81		B ₁₃	1424.79
Y'' ₁₄	<u>1349.77</u>		B ₁₄	1523.86

Ion	m/z		Ion	m/z
Y'' ₁₅	<u>1535.85</u>		B ₁₅	n.d.
Y'' ₁₆	1698.95		B ₁₆	n.d.
Y'' ₁₇	1813.95		B ₁₇	1782.96
Y'' ₁₈	1960.97		B ₁₈	n.d.
Y'' ₁₉	n.d. (2)		B ₁₉	n.d.
¹ Underlined m/z-values are main peaks in the MS/MS-spectrum. ² n.d. is not detected.				

Table V. MS/MS-data of CDR3 peptide (H11) of 02-237, obtained by *collision induced dissociation* of doubly charged m/z 1030.02.

Ion	m/z		Ion	m/z
Y'' ₁	147.12		B ₁	n.d.
Y'' ₂	248.18		B ₂	189.09
Y'' ₃	<u>335.20</u>		B ₃	n.d.
Y'' ₄	406.24		B ₄	451.22
Y'' ₅	493.30		B ₅	n.d.
Y'' ₆	<u>580.32</u>		B ₆	n.d.
Y'' ₇	679.40		B ₇	n.d.
Y'' ₈	<u>780.44</u>		B ₈	n.d.
Y'' ₉	<u>879.53</u>		B ₉	n.d.
Y'' ₁₀	992.60		B ₁₀	n.d.
Y'' ₁₁	1093.65		B ₁₁	n.d.
Y'' ₁₂	<u>1150.67</u>		B ₁₂	n.d.
Y'' ₁₃	1278.80		B ₁₃	n.d.
Y'' ₁₄	<u>1335.80</u>		B ₁₄	n.d.
Y'' ₁₅	1521.83		B ₁₅	n.d.
Y'' ₁₆	1608.90		B ₁₆	n.d.
Y'' ₁₇	1724.00		B ₁₇	n.d.
Y'' ₁₈	n.d.		B ₁₈	n.d.
Y'' ₁₉	n.d.		B ₁₉	n.d.
¹ Underlined m/z-values are main peaks in the MS/MS-spectrum. ² n.d. is not detected.				

Table VI. MS/MS-data of CDR3 peptide (H9) of UBS54, obtained by *collision induced dissociation*

dissociation of triply charged m/z 770.09.

Ion	m/z		Ion	m/z
Y'' ₁	n.d.		B ₁	n.d.
Y'' ₂	248.17		B ₂	213.17
Y'' ₃	<u>335.20</u>		B ₃	360.16
Y'' ₄	406.25		B ₄	473.27
Y'' ₅	<u>507.30</u>		B ₅	610.32
Y'' ₆	<u>594.33</u>		B ₆	773.41
Y'' ₇	<u>693.42</u>		B ₇	<u>959.48</u>
Y'' ₈	<u>794.45</u>		B ₈	<u>1016.50</u>
Y'' ₉	<u>893.53</u>		B ₉	<u>1144.57</u>
Y'' ₁₀	<u>1006.64</u>		B ₁₀	<u>1201.59</u>
Y'' ₁₁	1107.67		B ₁₁	<u>1302.68</u>
Y'' ₁₂	1164.68		B ₁₂	<u>1415.72</u>
Y'' ₁₃	n.d.		B ₁₃	1514.78
Y'' ₁₄	n.d.		B ₁₄	n.d.
Y'' ₁₅	n.d.		B ₁₅	n.d.
Y'' ₁₆	n.d.		B ₁₆	n.d.
Y'' ₁₇	n.d.		B ₁₇	n.d.
Y'' ₁₈	n.d.		B ₁₈	n.d.
Y'' ₁₉	n.d.		B ₁₉	n.d.
Y'' ₂₀	n.d.		B ₂₀	n.d.
¹ Underlined m/z-values are main peaks in the MS/MS-spectrum.				
² n.d. is not detected.				

References

[0089]

Appel RD, Bairoch A, Hochstrasser DF. 1994. A new generation of information retrieval tools for biologists: the example of the ExPASy WWW server. Trends Biochem. Sci. 19: 258-260.

Bendig MM. 1988. The production of foreign proteins in mammalian cells. Genet Eng 7: 91-127.

Boel E, Verlaan S, Poppelier MJ, Westerdal NA, Van Strijp JA, Logtenberg T. 2000. Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments. *J Immunol Methods* 239:153-166.

Brink MF, Bishop MD, Pieper FR. 2000. Developing efficient strategies for the generation of transgenic cattle which produce biopharmaceuticals in milk. *Theriogenology* 53: 139-148.

Campbell KH, McWhir J, Ritchie WA, Wilmut I. 1996. Sheep cloned by nuclear transfer from a cultured cell line. *Nature* 380: 64-66.

Casellas R, Shih TA, Kleinewietfeld M, Rakoniak J, Nemazee D, Rajewski K, Nussenzweig MC. 2001. Contribution of receptor editing to the antibody repertoire. *Science* 291: 1541-1544.

Cockett MI, Bebbington CR, Yarranton GT. 1990. High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamate synthetase gene amplification. *Bio/technology* 8: 662-667.

De Kruif J, Terstappen L, Boel E and Logtenberg T (1995a) Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library. *Proc Natl Acad Sci USA* 92:3938

De Kruif J, Boel E and Logtenberg T (1995b) Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions. *J Mol Biol* 248:97

Dinnyes A, De Sousa P, King T, Wilmut I. 2002. Somatic cell nuclear transfer: recent progress and challenges. *Cloning Stem Cells* 4: 81-90.

Flavell DJ, Noss A, Pulford KA, Ling N, Flavell SU. 1997. Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice. *Cancer Res* 57: 4824-4829.

Fishwild DM, O'Donnell SL, Bengoechea T, Hudson DV, Harding F, Bernhard SL, Jones D, Kay RM, Higgins KM, Schramm SR, Lonberg N. 1996. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. *Nat Biotechnol.*14: 845-51.

Garnick RL. 1992. Peptide mapping for detecting variants in protein products. *Develop. Biol. Standard* 76: 117-130.

Gelpí E. 1995. Biomedical and biochemical applications of liquid chromatography-mass spectrometry. *J. Chromatography A* 703: 59-80.

Ghetie M-A, Podar EM, Ilgen A, Gordon BE, Uhr JW, Vitetta, ES. 1997. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. *Proc. Natl. Acad. Sci. USA* 94: 7509-7514.

Giddings G, Allison G, Brooks D, Carter A. 2000. Transgenic plants as factories for

biopharmaceuticals. *Nat. Biotechnol.* 18: 1151-1155.

Gorman C, Bullock C. 2000. Site-specific gene targeting for gene expression in eukaryotes. *Curr Opin Biotechnol* 11: 455-460.

Hiatt A, Cafferkey R, Bowdish K (1989) Production of antibodies in transgenic plants. *Nature*. 342: 76-78.

Huls, G. A., Heijnen, I. A., Cuomo, M. E., Koningsberger, J. C., Wiegman, L., Boel, E., van der Vuurst de Vries, A. R., Loyson, S. A., Helfrich, W., van Berge Henegouwen, G. P., van Meijer, M., de Kruif, J. & Logtenberg, T. 1999. A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. *Nat Biotechnol* 17: 276-281.

Jespers LS, Roberts A, Mahler SM, Winter G, Hoogenboom HR. 1994. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. *Biotechnology (N Y)* 12: 899-903.

Jones, D., Kroos, N., Anema, R., Van Montfort, B., Vooy, A., Van Der Kraats, S., Van Der Helm, E., Smits, S., Schouten, J., Brouwer, K., Lagerwerf, F., Van Berkel, P., Opstelten, D-J., Logtenberg, T., Bout, A. (2003). High-level expression of recombinant IgG in the human cell line PER.C6™. *Biotechnol Prog.* 19, 163-168.

Kim SJ, Kim Ns, Ryu CJ, Hong HJ, Lee GM. 1998. Characterization of chimeric antibody producing CHO cells in the course of dihydrofolate reductase-mediated gene amplification and their stability in the absence of selective pressure. *Biotechnol Bioeng* 58: 73-84.

Kohler G and Millstein C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature* 256: 495-497.

Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. 1994. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. *Blood* 84: 1415-1420.

Larrick JW, Thomas DW. 2001. Producing proteins in transgenic plants and animals. *Curr. Opin. Biotechnol.* 12: 411-418.

Massengale WT, McBurney E, Gurtler J. 2002. CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy. *J. Am. Acad. Dermatol.* 46: 441-443.

Mendez MJ, Green LL, Corvalan JR, Jia XC, Maynard-Currie CE, Yang XD, Gallo ML, Louie DM, Lee DV, Erickson KL, Luna J, Roy CM, Abderrahim H, Kirschenbaum F, Noguchi M, Smith DH, Fukushima A, Hales JF, Klapholz S, Finer MH, Davis CG, Zsebo KM, Jakobovits A. 1997. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. *Nat Genet.* 15: 146-56.

Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. 1998. An efficient route to human bispecific IgG. *Nat. Biotech.* 16: 677-681.

Nemazee D. 2000. Receptor editing in B cells. *Adv. Immunol.* 74: 89-126.

Nissim A, Hoogenboom HR, Tomlinson IM, Flynn G, Midgley C, Lane D, Winter G. 1994. Antibody fragments from a "single pot" phage display library as immunological reagents. *EMBO J.* 13: 692-698.

Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks JD. 2002. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. *Proc. Natl. Acad. Sci. USA* 99: 11346-11350.

Patel AK, Boyd PN. 1995. An improved assay for antibody dependent cellular cytotoxicity based on time resolved fluorometry. *Journal of Immunological Methods* 184: 29-38.

Peeters K, De Wilde C, De Jaeger G, Angenon G, Depicker A. 2001. Production of antibodies and antibody fragments in plants. *Vaccine* 19: 2756-2761.

Pollock DP, Kutzko JP, Birck-Wilson E, Williams JL, Echelard Y, Meade HM. 1999. Transgenic milk as a method for the production of recombinant antibodies. *J Immunol Methods.* 231: 147-157.

Radic MC, Mascelli MA, Shan H, Weigert M. 1991. Ig H and L chain contributions to autoimmune specificities. *J. Immunol.* 146: 176-182.

Schnieke AE, Kind AJ, Ritchie WA, Mycock K, Scott AR, Ritchie M, Wilmut I, Colman A, Campbell KH. 1997. Human factor IX transgenic sheep produced by transfer of nuclei from transfected fetal fibroblasts. *Science.* 278: 2130-2133.

Segal DM, Weiner GJ, Weiner LM. 2001. Introduction: bispecific antibodies. *J Immunol Methods.* 248:1-6.

Shields, RL, Namenuk AK, Hong K, Gloria Meng Y, Rae J, Biggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA and Presta LG. 2001. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII and FcRn and design of IgG1 variants with improved binding to the FcγR. *J Biol Chem* 276: 6591-6604.

Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL, Vitetta ES. 2002. Targeting multiple her-2 epitopes with monoclonal antibodies results in improved antiproliferative activity of a human breast cancer cell line in vitro and in vivo. *Clin. Cancer Res.* 8: 1720-1730.

Van der Vuurst de Vries A, Logtenberg T. 1999. Dissecting the human peripheral B-cell compartment with phage display-derived antibodies. *Immunology* 98: 55-62.

Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, McCafferty J, Hodits RA, Wilton J, Johnson KS. 1996. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. *Nat. Biotech.* 14: 309-314.

Wilmut I, Clark AJ. 1991. Basic techniques for transgenesis. *J Reprod Fertil Suppl* 43: 265-275.

Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH. 1997. Viable offspring derived from

fetal and adult mammalian cells. Nature 385: 810-813.

Wilson TJ, Kola I. 2001. The LoxP/CRE system and genome modification. Methods Mol Biol. 158:83-94.

Yelverton E, Norton S, Obijeski JF, Goeddel DV. 1983. Rabies virus glycoprotein analogs: biosynthesis in Escherichia coli. Science 219: 614-620.

Yoo EM, Coloma MJ, Trinh KR, Nguyen TQ, Vuong LU, Morrison SL, Chintalacharuvu KR. 1999. Structural requirements for polymeric immunoglobulin assembly and association with J chain. J Biol Chem. 274: 33771-33777.

SEQUENCE LISTING

[0090]

<110> CRUCCELL HOLLAND B.V.

<120> Recombinant production of mixtures of antibodies

<130> 0079 WO 00 ORD

<160> 18

<170> PatentIn version 3.2

<210> 1

<211> 333

<212> DNA

<213> Artificial

<220>

<223> VL sequence of UBS54 (anti-EpCAM) and K53 (anti-CD46)

<220>

<221> CDS

<222> (1)..(333)

<400> 1

gaa att gag ctc act cag tct cca ctc tcc ctg ccc gtc acc cct gga	48
Glu Ile Glu Leu Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly	
1 5 10 15	

gag ccg gcc tcc atc tcc tgc agg tct agt cag agc ctc ctg cat agt	96
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser	
20 25 30	

aat gga tac aac tat ttg gat tgg tac ctg cag aag cca ggg cag tct	144
---	-----

```

Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
   35               40               45

cca cag ctc ctg atc tat ttg ggt tct aat cgg gcc tcc ggg gtc cct    192
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
   50               55               60

gac agg ttc agt ggc agt gga tca ggc aca gat ttt aca ctg aaa atc    240

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
   65               70               75               80

agc aga gtg gag gct gag gat gtt ggg gtt tat tac tgc atg caa gct    288
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
   85               90               95

cta caa act ttc act ttc ggc cct ggg acc aag gtg gag atc aaa    333
Leu Gln Thr Phe Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys
  100               105               110

```

<210> 2

<211> 111

<212> PRT

<213> Artificial

<220>

<223> VL sequence of UBS54 (anti-EpCAM) and K53 (anti-CD46)

<400> 2

```

Glu Ile Glu Leu Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1               5               10               15

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
   20               25               30

Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
   35               40               45

Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
   50               55               60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
   65               70               75               80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
   85               90               95

Leu Gln Thr Phe Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys
  100               105               110

```

<210> 3

<211> 333

<212> DNA

<213> Artificial

<220>

<223> VL sequence of 02-237 (anti-CD46)

<220>

<221> CDS

<222> (1)..(333)

<400> 3

```

gac atc gtg atg act cag tct cca ctc tcc ctg ccc gtc acc cct gga      48
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1           5           10          15

gag ccg gcc tcc atc tcc tgc agg tct agt cag agc ctc ctg cat agt      96
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
          20          25          30

aat gga tac aac tat ttg gat tgg tac ctg cag aag cca ggg cag tct     144
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
        35          40          45

cca cag ctc ctg atc tat ttg ggt tct aat cgg gcc tcc ggg gtc cct     192
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
        50          55          60

gac agg ttc agt ggc agt gga tca ggc aca gat ttt aca ctg aaa atc     240
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
        65          70          75          80

agc aga gtg gag gct gag gat gtt ggg gtt tat tac tgc atg caa gct     288
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
        85          90          95

cta caa act ttc act ttc ggc cct ggg acc aag gtg gag atc aaa     333
Leu Gln Thr Phe Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys
       100       105       110

```

<210> 4

<211> 111

<212> PRT

<213> Artificial

<220>

<223> VL sequence of 02-237 (anti-CD46)

<400> 4

```

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1           5           10          15

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
        20          25          30

Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
        35          40          45

Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
        50          55          60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
        65          70          75          80

```

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95

Leu Gln Thr Phe Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys
100 105 110

<210> 5

<211> 345

<212> DNA

<213> Artificial

<220>

<223> VH sequence of UBS54 (anti-EpCAM)

<220>

<221> CDS

<222> (1)..(345)

<400> 5

cag gtg cag ctg gtg cag tct ggg gct gag gtg aag aag cct ggg tcc 48
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

tcg gtg agg gtc tcc tgc aag gct tct gga ggc acc ttc agc agc tat 96
Ser Val Arg Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30

gct atc agc tgg gtg cga cag gcc cct gga caa ggg ctt gag tgg atg 144
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

gga ggg atc atc cct atc ttt ggt aca gca aac tac gca cag aag ttc 192
Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60

cag ggc aga gtc acg att acc gcg gac gaa tcc acg agc aca gcc tac 240
Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80

atg gag ctg agc agc ctg aga tct gag gac acg gct gtg tat tac tgt 288
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

gca aga gac ccg ttt ctt cac tat tgg ggc caa ggt acc ctg gtc acc 336
Ala Arg Asp Pro Phe Leu His Tyr Trp Gly Gln Gly Thr Leu Val Thr
100 105 110

gtc tcg aca 345
Val Ser Thr
115

<210> 6

<211> 115

<212> PRT

<213> Artificial

<220>

<223> VH sequence of UBS54 (anti-EpCAM)

<400> 6

```

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1           5           10           15

Ser Val Arg Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
           20           25           30

Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
           35           40           45

Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
           50           55           60

Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65           70           75           80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
           85           90           95

Ala Arg Asp Pro Phe Leu His Tyr Trp Gly Gln Gly Thr Leu Val Thr
           100          105          110

Val Ser Thr
           115

```

<210> 7

<211> 354

<212> DNA

<213> Artificial

<220>

<223> VH sequence of K53 (anti-CD46)

<220>

<221> CDS

<222> (1)..(354)

<400> 7

```

cag gtg cag ctg gtg cag tct ggg gct gag gtg aag aag cct ggg gcc      48
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1           5           10           15

tca gtg aag gtc tcc tgc aag gct tct ggt tac acc ttt acc agc tat      96
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
           20           25           30

ggc atc agc tgg gtg cga cag gcc cct gga caa ggg ctt gag tgg atg      144
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
           35           40           45

gga tgg atc agc gct tac aat ggt aac aca aac tat gca cag aag ctc      192
Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu
           50           55           60

cag ggc aga gtc acc atg acc aca gac aca tcc acg agc aca gcc tac      240
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr

```

65	70	75	80	
atg gag ctg agg agc ctg aga tct gac gac acg gcc gtg tat tac tgt				288
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys				
	85	90	95	
gca agg ggc atg atg agg ggt gtg ttt gac tac tgg ggc caa ggt acc				336
Ala Arg Gly Met Met Arg Gly Val Phe Asp Tyr Trp Gly Gln Gly Thr				
	100	105	110	
ctg gtc acc gtc tcg aca				354
Leu Val Thr Val Ser Thr				
	115			

<210> 8

<211> 118

<212> PRT

<213> Artificial

<220>

<223> VH sequence of K53 (anti-CD46)

<400> 8

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala	
1 5 10 15	
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr	
20 25 30	
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met	
35 40 45	
Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu	
50 55 60	
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr	
65 70 75 80	
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys	
85 90 95	
Ala Arg Gly Met Met Arg Gly Val Phe Asp Tyr Trp Gly Gln Gly Thr	
100 105 110	
Leu Val Thr Val Ser Thr	
115	

<210> 9

<211> 354

<212> DNA

<213> Artificial

<220>

<223> VH sequence of 02- 237 (anti-CD46)

<220>

<221> CDS

<222> (1)..(354)

<400> 9

```

cag gtg cag ctg gtg cag tct ggg gct gag gtg aag aag cct ggg gcc      48
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1           5           10          15

tca gtg aag gtc tcc tgc aag gct tct ggt tac acc ttt acc agc tat      96
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
          20          25          30

ggg atc agc tgg gtg cga cag gcc cct gga caa ggg ctt gag tgg atg      144
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
          35          40          45

gga tgg atc agc gct tac aat ggt aac aca aac tat gca cag aag ctc      192
Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu
          50          55          60

cag ggc aga gtc acc atg acc aca gac aca tcc acg agc aca gcc tac      240
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
        65          70          75          80

atg gag ctg agg agc ctg aga tct gac gac acg gcc gtg tat tac tgt      288
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
          85          90          95

gca agg ggc ttt ccg cgt acg tgg ttt gac tcc tgg ggc cag gcc acc      336
Ala Arg Gly Phe Pro Arg Thr Ser Phe Asp Ser Trp Gly Gln Gly Thr
          100          105          110

ctg gtg acc gtc tcc tca                                          354
Leu Val Thr Val Ser Ser
          115

```

<210> 10

<211> 118

<212> PRT

<213> Artificial

<220>

<223> VH sequence of 02- 237 (anti-CD46)

<400> 10

```

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1           5           10          15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
          20          25          30

Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
          35          40          45

Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu
          50          55          60

Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
          65          70          75          80

```

```

60          70          80          90
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
      85          90          95

Ala Arg Gly Phe Pro Arg Thr Ser Phe Asp Ser Trp Gly Gln Gly Thr
      100          105          110

Leu Val Thr Val Ser Ser
      115

<210> 11
<211> 369
<212> DNA
<213> Artificial

<220>
<223> VH sequence of clone B28 (anti-CD22 phage)

<220>
<221> CDS
<222> (1)..(369)

<400> 11
atg gcc gag gtg cag ctg gtg gag tct ggg gga ggt gtg gta cgg cct      48
Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Arg Pro
1          5          10          15

gga ggg tcc ctg aga ctc tcc tgt gca gcc tct gga ttc acc ttt gat      96
Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp

      20          25          30

gat tat ggc atg agc tgg gtc cgc caa gct cca ggg aag ggg ctg gag      144
Asp Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
35          40          45

tgg gtc tct ggt att aat tgg aat ggt ggt agc aca ggt tat gca gac      192
Trp Val Ser Gly Ile Asn Trp Asn Gly Gly Ser Thr Gly Tyr Ala Asp
50          55          60

tct gtg aag ggc cga ttc acc atc tcc aga gac aac gcc aag aac tcc      240
Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser
65          70          75          80

ctg tat ctg caa atg aac agt ctg aga gcc gag gac acg gcc gtg tat      288
Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85          90          95

tac tgt gca aga ggc ttt ctt cgt ttt gct tcc tcc tgg ttt gac tat      336
Tyr Cys Ala Arg Gly Phe Leu Arg Phe Ala Ser Ser Trp Phe Asp Tyr
100          105          110

tgg ggc caa ggt acc ctg gtc acc gtc tcg aga      369
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Arg
115          120

```

<210> 12

<211> 123

<212> PRT

<213> Artificial

<220>

<223> VH sequence of clone B28 (anti-CD22 phage)

<400> 12

Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Arg Pro
 1 5 10 15

Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp
 20 25 30

Asp Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
 35 40 45

Trp Val Ser Gly Ile Asn Trp Asn Gly Gly Ser Thr Gly Tyr Ala Asp
 50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser
 65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
 85 90 95

Tyr Cys Ala Arg Gly Phe Leu Arg Phe Ala Ser Ser Trp Phe Asp Tyr
 100 105 110

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Arg
 115 120

<210> 13

<211> 369

<212> DNA

<213> Artificial

<220>

<223> VH sequence of clone II-2 (anti-CD72 phage)

<220>

<221> CDS

<222> (1)..(369)

<400> 13

atg gcc cag gtg cag ctg gtg cag tct ggg gct gag gtg aag aag cct 48
 Met Ala Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro
 1 5 10 15

ggg gcc tca gtg aag gtt tcc tgc aag gca tct gga tac acc ttc acc 96
 Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr
 20 25 30

agc tac tat atg cac tgg gtg cga cag gcc cct gga caa ggg ctt gag 144

Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu

35	40	45	
tgg atg gga ata atc aac cct agt ggt ggt ggc aca agc tac gca cag			192
Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Gly Thr Ser Tyr Ala Gln			
50	55	60	
aag ttc cag ggc aga gtc acc atg acc agg gac acg tcc acg agc aca			240
Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr			
65	70	75	80
gtc tac atg gag ctg agc agc ctg aga tct gag gac acg gcc gtg tat			288
Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr			
85	90	95	
tac tgt gca aga gac tac tat gtt acg tat gat tcc tgg ttt gac tcc			336
Tyr Cys Ala Arg Asp Tyr Tyr Val Thr Tyr Asp Ser Trp Phe Asp Ser			
100	105	110	
tgg ggc caa ggt acc ctg gtc acc gtc tcg aga			369
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Arg			
115	120		

<210> 14
 <211> 123
 <212> PRT
 <213> Artificial

<220>
 <223> VH sequence of clone II-2 (anti-CD72 phage)

<400> 14

Met Ala Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro			
1	5	10	15
Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr			
20	25	30	
Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu			
35	40	45	
Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Gly Thr Ser Tyr Ala Gln			
50	55	60	
Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr			
65	70	75	80
Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr			
85	90	95	
Tyr Cys Ala Arg Asp Tyr Tyr Val Thr Tyr Asp Ser Trp Phe Asp Ser			
100	105	110	
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Arg			
115	120		

<210> 15
 <211> 360
 <212> DNA

<213> Artificial

<220>

<223> VH sequence of clone I-2 (anti-class II phage)

<220>

<221> CDS

<222> (1)..(360)

<400> 15

```

âtg gcc gag gtg cag ctg gtg gag tct ggg gga ggc ttg gta cag cct      48
Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro
1           5           10           15

```

```

ggc agg tcc ctg aga ctc tcc tgt gca gcc tct gga ttc acc ttt gat      96
Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp
           20           25           30

```

```

gat tat gcc atg cac tgg gtc cgg caa gct cca ggg aag ggc ctg gag      144
Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
           35           40           45

```

```

tgg gtc tca ggt att agt tgg aat agt ggt agc ata ggc tat gcg gac      192
Trp Val Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp
           50           55           60

```

```

tct gtg aag ggc cga ttc acc atc tcc aga gac aac gcc aag aac tcc      240
Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser
           65           70           75           80

```

```

ctg tat ctg caa atg aac agt ctg aga gct gag gac acg gcc gtg tat      288
Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
           85           90           95

```

```

tac tgt gca agg gac ctt tat ctt gcg cat ttt gac tac tgg ggc caa      336
Tyr Cys Ala Arg Asp Leu Tyr Leu Ala His Phe Asp Tyr Trp Gly Gln
           100          105          110

```

```

ggg acc ctg gtc acc gtc tcg aga      360
Gly Thr Leu Val Thr Val Ser Arg
           115          120

```

<210> 16

<211> 120

<212> PRT

<213> Artificial

<220>

<223> VH sequence of clone I-2 (anti-class II phage)

<400> 16

```

Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro
1           5           10           15

```

```

Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp
           20           25           30

```

Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
35 40 45

Trp Val Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp

50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser
65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Ala Arg Asp Leu Tyr Leu Ala His Phe Asp Tyr Trp Gly Gln
100 105 110

Gly Thr Leu Val Thr Val Ser Arg
115 120

<210> 17

<211> 336

<212> DNA

<213> Artificial

<220>

<223> common VL sequence of clones B28 (anti-CD22 phage), II-2 (anti-CD72 phage) and I-2 (anti-class II phage)

<220>

<221> CDS

<222> (1)..(336)

<400> 17

tcg tct gag ctg act cag gac cct gct gtg tct gtg gcc ttg gga cag 48
Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln
1 5 10 15

aca gtc agg atc aca tgc caa gga gac agc ctc aga agc tat tat gca 96
Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala
20 25 30

agc tgg tac cag cag aag cca gga cag gcc cct gta ctt gtc atc tat 144
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr
35 40 45

ggt aaa aac aac cgg ccc tca ggg atc cca gac cga ttc tct ggc tcc 192

Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser
50 55 60

agc tca gga aac aca gct tcc ttg acc atc act ggg gct cag gcg gaa 240
Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu
65 70 75 80

gat gag gct gac tat tac tgt aac tcc cgg gac agc agt ggt aac cat 288
Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Asn His
85 90 95

gtg gta ttc ggc gga ggg acc aag ctg acc gtc cta ggt gcg gcc gca 336
 Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ala Ala Ala
 100 105 110

<210> 18

<211> 112

<212> PRT

<213> Artificial

<220>

<223> common VL sequence of clones B28 (anti-CD22 phage), II-2 (anti-CD72 phage) and I-2 (anti-class II phage)

<400> 18

Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln
 1 5 10 15

Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala
 20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr
 35 40 45

Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser
 50 55 60

Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu
 65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Asn His
 85 90 95

Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ala Ala Ala
 100 105 110

REFERENCES CITED IN THE DESCRIPTION

Cited references

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [EP0120694A](#) [0007] [0027]
- [EP0314161A](#) [0007] [0027]
- [EP0481790A](#) [0007] [0027]
- [US4816567A](#) [0007] [0027]
- [WO0063403A](#) [0007] [0027] [0031] [0058] [0059] [0059] [0083] [0083] [0085] [0085]
- [WO0119394A](#) [0010]
- [WO9520401A](#) [0011]
- [US5789208A](#) [0011]
- [US6335163B](#) [0011]
- [WO9850431A](#) [0022] [0055]
- [WO03004704A](#) [0026]
- [EP0523949A](#) [0027]
- [US4801687A](#) [0028]
- [US5151504A](#) [0028]
- [US4399216A](#) [0030]
- [US6180357B](#) [0037]
- [WO9964582A](#) [0039]
- [WO9936569A](#) [0043]
- [US6265150B](#) [0043] [0078]
- [WO0148485A](#) [0045]
- [WO0218948A](#) [0045] [0058] [0058] [0084]
- [EP0724639A](#) [0046]
- [WO0132901A](#) [0046]
- [US5733779A](#) [0046]
- [WO9841645A](#) [0048]
- [WO9108216A](#) [0049]
- [WO9517085A](#) [0049]
- [US6291740B](#) [0049]
- [WO9517500A](#) [0049]
- [WO9839416A](#) [0049]
- [WO0164929A](#) [0050]
- [WO9742313A](#) [0050]
- [US5888789A](#) [0050]
- [US6080560A](#) [0050]
- [WO9747739A](#) [0050]
- [WO9815627A](#) [0050]
- [US5772997A](#) [0053]
- [US5783186A](#) [0053]
- [WO9627011A](#) [0055]
- [EP0402029A](#) [0078] [0083]
- [EP0445625A](#) [0078]
- [WO9815833A](#) [0078]

Non-patent literature cited in the description

- **ROITTE** Essential Immunology Blackwell Scientific Publications 1984 0000 [0002]
- **MERCHANT et al.** Nature Biotechnology, 1998, vol. 16, 7677-681 [0004]
- **LENZWEIDLE** Gene, 1990, vol. 87, 2213-218 [0005]
- **CF BARBAS III et al.** Phage Display. A laboratory manual Cold Spring Harbor Laboratory Press 2001 0000 [0006] [0043]
- **COLIGAN JEDUNN BMPLOEGH HLSPEICHER DWWINGFIELD PT** Current Protocols in Protein Science, 1995, ISBN 0-471-11184-8 [0026]
- Tissue Culture Academic Press 1973 0000 [0027]
- Mammalian Cell Biotechnology: a Practical Approach IRL Press 1991 0000 [0027]
- In vitro selection and evolution of proteins **A. PLÜCKTHUN et al.** Adv. Prot. Chem. Academic Press 2001 0000 vol. 55, 367-403 [0043]
- In vitro selection and evolution of protein-ligand interactions by ribosome display **C. SCHAFFITZEL et al.** Protein-Protein Interactions. A Molecular Cloning Manual Cold Spring Harbor Laboratory Press 2001 0000 535-567 [0043]
- **SAMBROOK FRITSCH MANIATIS** Molecular Cloning: A Laboratory Manual 1989 0000 [0046] [0057]
- Current Protocols in Molecular Biology 1987 0000 [0046] [0057]
- Methods in Enzymology Academic Press, Inc. [0046] [0057]
- **JONES H** Plant Gene Transfer And Expression Protocols Methods In Molecular Biology, 1995, vol. 49, [0050]
- PCR2: A Practical Approach 1995 0000 [0057]
- Antibodies: A Laboratory Manual 1988 0000 [0057]
- **COLIGAN, J.E. et al.** Current protocols in protein science John Wiley & Sons, Inc. 2001 0000 vol. I, [0081]
- **APPEL RDBAIROCH AHOCHSTRASSER D** A new generation of information retrieval tools for biologists: the example of the ExPASy WWW server Trends Biochem. Sci., 1994, vol. 19, 258-260 [0089]
- **BENDIG M** The production of foreign proteins in mammalian cells Genet Eng, 1988, vol. 7, 91-127 [0089]
- **BOEL EVERLAAN SPOPELIER MJ WESTERDAAL NAVAN STRIJP JALOGTENBERG T** Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments J Immunol Methods, 2000, vol. 239, 153-166 [0089]
- **BRINK MFBISHOP MDPIEPER F** Developing efficient strategies for the generation of transgenic cattle which produce biopharmaceuticals in milk Theriogenology, 2000, vol. 53, 139-148 [0089]
- **CAMPBELL K HMCWHIR JRITCHIE WAWILMUT I** Sheep cloned by nuclear transfer from a cultured cell line Nature, 1996, vol. 380, 64-66 [0089]

- **CASELLAS RSHIH TAKLEINWETFELT MRAKONIAK JNEMAZEE DRAJEWSKI KNUSSENZWEIG MC**Contribution of receptor editing to the antibody repertoireScience, 2001, vol. 291, 1541-1544 [\[0089\]](#)
- **COCKETT MIBEBBINGTON CRYARRANTON GT**High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamate synthetase gene amplificationBio/technology, 1990, vol. 8, 662-667 [\[0089\]](#)
- **DE KRUIF JTERSTAPPEN LBOEL ELOGTENBERG TR**Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody libraryProc Natl Acad Sci USA, 1995, vol. 92, 3938- [\[0089\]](#)
- **DE KRUIF JBOEL ELOGTENBERG T**Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regionsJ Mol Biol, 1995, vol. 248, 97- [\[0089\]](#)
- **DINNYES ADE SOUSA PKING TWILMUT IS**Somatic cell nuclear transfer: recent progress and challengesCloning Stem Cells, 2002, vol. 4, 81-90 [\[0089\]](#)
- **FLAVELL DJNOSS APULFORD KALING NFLAVELL SU**Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient miceCancer Res, 1997, vol. 57, 4824-4829 [\[0089\]](#)
- **FISHWILD DMO'DONNELL SLBENGOCHEA THUDSON DVHARDING FBERNHARD SLJONES DKAY RMHIGGINS KMSCHRAMM SR**High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic miceNat Biotechnol., 1996, vol. 14, 845-51 [\[0089\]](#)
- **GARNICK RL**Peptide mapping for detecting variants in protein productsDevelop. Biol. Standard, 1992, vol. 76, 117-130 [\[0089\]](#)
- **GELPÍ E.**Biomedical and biochemical applications of liquid chromatography-mass spectrometryJ. Chromatography A, 1995, vol. 703, 59-80 [\[0089\]](#)
- **GHETIE M-APODAR EMILGEN AGORDON BEUHR JWITETTA, ES**Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cellsProc. Natl. Acad. Sci. USA, 1997, vol. 94, 7509-7514 [\[0089\]](#)
- **GIDDINGS GALLISON GBROOKS DCARTER A**Transgenic plants as factories for biopharmaceuticalsNat. Biotechnol., 2000, vol. 18, 1151-1155 [\[0089\]](#)
- **GORMAN CBULLOCK CS**Site-specific gene targeting for gene expression in eukaryotesCurr Opin Biotechnol, 2000, vol. 11, 455-460 [\[0089\]](#)
- **HIATT ACAFFERKEY RBOWDISH K**Production of antibodies in transgenic plantsNature, 1989, vol. 342, 76-78 [\[0089\]](#)
- **HULS, G. A.HEIJNEN, I. A.CUOMO, M. E.KONINGSBERGER, J. C.WIEGMAN, L.BOEL, E.VAN DER VUURST DE VRIES, A. R.LOYSON, S. A.HELFRICH, W.VAN BERGE HENEGOUWEN, G. P.**A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragmentsNat Biotechnol, 1999, vol. 17, 276-281 [\[0089\]](#)
- **JESPEERS LSROBERTS AMAHLER SMWINTER GHOOGENBOOM HR**Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigenBiotechnology (N Y), 1994, vol. 12, 899-903 [\[0089\]](#)

- JONES, D.KROOS, N.ANEMA, R.VAN MONTFORT, B.VOOYS, A.VAN DER KRAATS, S.VAN DER HELM, E.SMITS, S.SCHOUTEN, J.BROUWER, K.High-level expression of recombinant IgG in the human cell line PER.C6Biotechnol Prog., 2003, vol. 19, 163-168 [0089]
- KIM SJKIM NSRYU CJHONG HJLEE GMCharacterization of chimeric antibody producing CHO cells in the course of dihydrofolate reductase-mediated gene amplification and their stability in the absence of selective pressureBiotechnol Bioeng, 1998, vol. 58, 73-84 [0089]
- KOHLER GMILLSTEIN CContinuous cultures of fused cells secreting antibody of predefined specificityNature, 1975, vol. 256, 495-497 [0089]
- KOOPMAN GREUTELINGSPERGER CPKUIJTEN GAKEEHNEN RMPALS STVAN OERS MHAnnexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosisBlood, 1994, vol. 84, 1415-1420 [0089]
- LARRICK JWTHOMAS DWProducing proteins in transgenic plants and animalsCurr. Opin. Biotechnol., 2001, vol. 12, 411-418 [0089]
- MASSENGALE WTMCBURNEY EGURTLE JCD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapyJ. Am. Acad. Dermatol., 2002, vol. 46, 441-443 [0089]
- MENDEZ MJGREEN LLCORVALAN JRJIA XCMAYNARD-CURRIE CEYANG XDGALLO MLLOUIE DMLEE DVERICKSON KLFfunctional transplant of megabase human immunoglobulin loci recapitulates human antibody response in miceNat Genet., 1997, vol. 15, 146-56 [0089]
- MERCHANT AMZHU ZYUAN JQGODDARD AADAMS CWPRESTA LGCARTER PAn efficient route to human bispecific IgGNat. Biotech., 1998, vol. 16, 677-681 [0089]
- NEMAZEE D.Receptor editing in B cellsAdv. Immunol., 2000, vol. 74, 89-126 [0089]
- NISSIM AHOOGENBOOM HRTOMLINSON IMFLYNN GMIDGLEY CLANE DWINTER GAntibody fragments from a "single pot" phage display library as immunological reagentsEMBO J., 1994, vol. 13, 692-698 [0089]
- NOWAKOWSKI AWANG CPowers DBAMERSDORFER PSMITH TJ, MONTGOMERY VASHERIDAN RBLAKE RSMITH LAMARKS JDPotent neutralization of botulinum neurotoxin by recombinant oligoclonal antibodyProc. Natl. Acad. Sci. USA, 2002, vol. 99, 11346-11350 [0089]
- PATEL AKBOYD PNAAn improved assay for antibody dependent cellular cytotoxicity based on time resolved fluorometryJournal of Immunological Methods, 1995, vol. 184, 29-38 [0089]
- PEETERS KDE WILDE CDE JAEGER GANGENON GDEPICKER AProduction of antibodies and antibody fragments in plantsVaccine, 2001, vol. 19, 2756-2761 [0089]
- POLLOCK DPKUTZKO JPBIRCK-WILSON EWilliams JLECHELARD YMEADE HMTTransgenic milk as a method for the production of recombinant antibodiesJ Immunol Methods, 1999, vol. 231, 147-157 [0089]
- RADIC MCMASCELLI MASHAN HWEIGERT MIg H and L chain contributions to autoimmune specificitiesJ. Immunol., 1991, vol. 146, 176-182 [0089]
- SCHNIEKE AEKIND AJRITCHIE WAMYCOCK KSCOTT ARRITCHIE MWILMUT ICOLMAN ACAMPBELL KHHuman factor IX transgenic sheep produced by transfer of

- nuclei from transfected fetal fibroblasts *Science*, 1997, vol. 278, 2130-2133 [0089]
- **SEGAL DMWEINER GJWEINER LM** Introduction: bispecific antibodies *J Immunol Methods*, 2001, vol. 248, 1-6 [0089]
 - **SHIELDS, RLNAMENUK AKHONG KGLORIA MENG YRAE JBIGGS JXIE DLAI JSTADLEN ALI B** High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII and FcRn and design of IgG1 variants with improved binding to the FcγRJ *Biol Chem*, 2001, vol. 276, 6591-6604 [0089]
 - **SPIRIDON CIGHETIE MAUHR JMARCHES RLI JLSHEN GLVITETTA ES** Targeting multiple her-2 epitopes with monoclonal antibodies results in improved antitumor activity of a human breast cancer cell line in vitro and in vivo *Clin. Cancer Res.*, 2002, vol. 8, 1720-1730 [0089]
 - **VAN DER VUURST DE VRIES ALOGTENBERG T** Dissecting the human peripheral B-cell compartment with phage display-derived antibodies *Immunology*, 1999, vol. 98, 55-62 [0089]
 - **VAUGHAN TJWILLIAMS AJPRITCHARD KOSBOURN JKPOPE AREARNshaw JCMCCAFFERTY JHODITS RAWILTON JJOHNSON KS** Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library *Nat. Biotech.*, 1996, vol. 14, 309-314 [0089]
 - **WILMUT I.CLARK AJ** Basic techniques for transgenesis *J Reprod Fertil Suppl*, 1991, vol. 43, 265-275 [0089]
 - **WILMUT ISCHNIEKE AEMCWHIR JKIND AJCAMPBELL KH** Viable offspring derived from fetal and adult mammalian cells *Nature*, 1997, vol. 385, 810-813 [0089]
 - **WILSON TJKOLA I** The LoxP/CRE system and genome modification *Methods Mol Biol.*, 2001, vol. 158, 83-94 [0089]
 - **YELVERTON ENORTON SOBIJESKI JFGOEDEL DV** Rabies virus glycoprotein analogs: biosynthesis in *Escherichia coli* *Science*, 1983, vol. 219, 614-620 [0089]
 - **YOO EMCOLMA MJTRINH KRNGUYEN TQVUONG LUMORRISON SLCHINTALACHARUVU KR** Structural requirements for polymeric immunoglobulin assembly and association with J chain *J Biol Chem.*, 1999, vol. 274, 33771-33777 [0089]

Patentkrav

1. Fremgangsmåde til identifikation af mindst én værtscelleklon der producerer en blanding af antistoffer, hvilken blanding af antistoffer har en ønsket virkning ifølge et funktionelt assay, hvilken fremgangsmåde omfatter trinene:

5

(i) at tilvejebringe en værtscelle med en nucleinsyresekvens der koder for én let kæde, og nucleinsyresekvenser der koder for to forskellige tunge kæder, hvilke tunge og lette kæder er i stand til at danne par med hinanden;

10

(ii) at dyrke mindst én klon af værtscellen under betingelser der fremmer ekspression af nucleinsyresekvenserne;

(iii) at screene den mindst ene klon af værtscellen for produktion af en blanding af antistoffer med den ønskede virkning ved et funktionelt assay; og

15

(iv) at identificere mindst én klon der producerer en blanding af antistoffer med den ønskede virkning.

2. Fremgangsmåden ifølge krav 1, hvor dyrkningen i trin (ii) og screeningen i trin (iii) udføres med mindst to kloner.

20

3. Fremgangsmåde til fremstilling af en blanding af antistoffer der omfatter trinnet:

(i) at dyrke en værtscelleklon der er identificeret ved en fremgangsmåde ifølge et hvilket som helst af kravene 1-2 under betingelser, der fremmer ekspression af nucleinsyrerne, som koder for den ene lette kæde og de to forskellige tunge kæder.

25

4. Fremgangsmåden ifølge krav 3 der yderligere omfatter trinnet: (ii) at genvinde blandingen af antistoffer fra værtscellen eller værtscellekulturen.

5. Fremgangsmåde ifølge et hvilket som helst af kravene 1-2, hvor nucleinsyresekvensen eller nucleinsyresekvenserne der koder for mindst én af de fælles

30


lette og/eller tunge kæder, er blevet opnået ved en fremgangsmåde, som omfatter mindst ét antistofdisplayselektionstrin.

- 5 **6.** Fremgangsmåde til fremstilling af en blanding af antistoffer i en rekombinant vært, hvilken fremgangsmåde omfatter trinnet: i en rekombinant værtscelle at udtrykke en nucleinsyresekvens der koder for en fælles let kæde, og en nucleinsyresekvens eller nucleinsyresekvenser der koder for to forskellige tunge kæder, som er forskellige i den variable region og som er i stand til at danne par med den fælles lette kæde, og hvor de tunge kæder yderligere adskiller sig til-
- 10 strækkeligt i deres konstante regioner til at reducere eller forhindre dannelse af par mellem de forskellige tunge kæder.

7. Fremgangsmåden ifølge krav 6, hvor de tunge kæder er af forskellig isotype.

- 15 **8.** Fremgangsmåden ifølge krav 1, hvor det funktionelle assay er valgt fra gruppen af: bindingsassays, apoptoseassays, antistofafhængig cellulær cytotoxicitetsassays (ADCC), komplementafhængig cytotoxicitetsassays (CDC), assays til inhibering af vækst eller proliferation (cytostatisk virkning) af celler, celledræbende assays (cytotoksisk virkning), cellesignalerende assays, assays til måling
- 20 af hæmning af binding af patogen til målcelle, assays til måling af sekretion af vaskulær endotel vækstfaktor (VEGF) eller andre sekreterede molekyler, assays til bakteriestase, bakteriedræbende aktivitet, neutralisering af vira, assays til at måle tiltrækningen af komponenter i immunsystemet til det sted, hvor antistoffer er bundet, inklusive in situ hybridiseringsfremgangsmåder, mærknings-
- 25 fremgangsmåder, in vivo assays såsom dyremodeller, herunder musetumormodeller, modeller for autoimmunsygdom, virusinficerede eller bakterieinficerede gnaver- eller primatmodeller.

DRAWINGS






Fig. 3

UBS54-VL
K53-VL
02-237-VL

GAAATTGAGCTCACTCAGTCTCCACTCTCCCTGCGGTCACTCCCTGGAGAGCGGGCC
GAAATTGAGCTCACTCAGTCTCCACTCTCCCTGCGGTCACTCCCTGGAGAGCGGGCC
GACATCGTGATGACTCAGTCTCCACTCTCCCTGCGGTCACTCCCTGGAGAGCGGGCC
** ** * * *****

UBS54-VL
K53-VL
02-237-VL

TCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACATATTGGAT
TCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACATATTGGAT
TCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACATATTGGAT

UBS54-VL
K53-VL
02-237-VL

TGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGTTCTAATCGG
TGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGTTCTAATCGG
TGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGTTCTAATCGG

UBS54-VL
K53-VL
02-237-VL

GCCTCCGGGGTCCCTGACAGGTTCACTGGCAGTGGATCAGGCACAGATTTTACACTGAAA
GCCTCCGGGGTCCCTGACAGGTTCACTGGCAGTGGATCAGGCACAGATTTTACACTGAAA
GCCTCCGGGGTCCCTGACAGGTTCACTGGCAGTGGATCAGGCACAGATTTTACACTGAAA

UBS54-VL
K53-VL
02-237-VL

ATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAACT
ATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAACT
ATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAACT

UBS54-VL
K53-VL
02-237-VL

TTCACCTTTCGGCCCTGGGACCAAGGTGGAGATCAAA
TTCACCTTTCGGCCCTGGGACCAAGGTGGAGATCAAA
TTCACCTTTCGGCCCTGGGACCAAGGTGGAGATCAAA

Fig. 3, cont'd

K53-VH	CAGGTGCAGCTGGTGCAGCTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTC
02-237-VH	CAGGTGCAGCTGGTGCAGCTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTC
UBS54-VH	CAGGTGCAGCTGGTGCAGCTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTC

K53-VH	TCCTGCAAGGCTTCTGGTTACACCTTACAGCTATGGTATCAGCTGGGTGGACACAGGCC
02-237-VH	TCCTGCAAGGCTTCTGGTTACACCTTACAGCTATGGTATCAGCTGGGTGGACACAGGCC
UBS54-VH	TCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGGACACAGGCC

K53-VH	CCTGGACAAGGGCTTGACTGGATGSGATGGATCAGGGCTTACAGCTGGTACACAACTAT
02-237-VH	CCTGGACAAGGGCTTGACTGGATGSGATGGATCAGGGCTTACAGCTGGTACACAACTAT
UBS54-VH	CCTGGACAAGGGCTTGACTGGATGSGAGGGATCATCCCTATCTTTGGTACAGCAAACTAC

K53-VH	GCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCAGCCCTAC
02-237-VH	GCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCAGCCCTAC
UBS54-VH	GCACAGAAGTTCAGGGCAGAGTCACCATGACCAGGACGAAATCCACGAGCAGCCCTAC

K53-VH	ATGGAGCTGAGGAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCAAGGGGCGATG
02-237-VH	ATGGAGCTGAGGAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCAAGGGGCTTT
UBS54-VH	ATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCTGTGTATTACTGTGCAAGAGAGACC--

K53-VH	ATGAGGGGTGTGTTTGACTACTGGGGCCCAAGGTACCCCTGGTACCCTGCTCCGACA
02-237-VH	CCGCGTACGTCGTTTGACTCTCTGGGGCCAGGGCACCCTGGTGGTCCGCTCTCCCTCA
UBS54-VH	-----CGTTTCTTCACTATTGGGGCCCAAGGTACCCCTGGTGGTCCGCTCTCCGACA
	* ** * ***** ** ***** * ** ***** * **

Fig. 4






Fig. 5

A.



B.




Fig. 6




Fig. 7Anti-CD22 V_H fragment (Phage B28)

M A E V Q L V E S G G G V V R P G G S L R L S C .
 1 ATGCCGAGGTGCAGCTGGTGGAGTGTGGGAGGTGTGTACGGCTGGAGGTCCTGAGACTCTCTG
 . A A S G F T F D D Y G M S W V R Q A P G K G L E .
 72 TGCAGCCTCTGGATTACCTTTGATGATTATGGCATGAGCTGGTCCGCCAAGCTCCAGGGAAGGGCTGG
 . W V S G I N W N G G S T G Y A D S V K G R F T
 143 AGTGGTCTCTGGTATTAAATTGGAATGGTGTAGCACAGGTTATGCAGACTCTGTGAAGGCGCGATTACAC
 I S R D N A K N S L Y L Q M N S L R A E D T A V .
 214 ATCTCCAGACACACCGCCCAAGACTCCCTGTATCTGCAATGAACAGTCTGAGAGCCGAGACACGCGCGT
 . Y Y C A R G F L R F A S S W F D Y W G Q G T L V .
 285 GTATTACTGTGCAAGAGGCTTTCTTCGTTTGTCTTCTCTCTGCTTACTATGGGGCCAGGTACCCCTGG
 . T V S R
 356 TCACCGTCTCGAGA

Anti-CD72 V_H fragment (Phage II-2)

M A Q V Q L V Q S G A E V K K P G A S V K V S C .
 1 ATGGCCGAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGACCTGGGGCTCAGTGAAGTTTCTG
 . K A S G Y T F T S Y Y M H W V R Q A P G Q G L E .
 72 CAAGGCATCTGGATACACCTTCACCAGCTACTATATGCACTGGTGGCAGACGGCCCTTGGACAAGGGCTTG
 . W M G I I N P S G G T S Y A Q K F Q G R V T
 143 AGTGGATGGGAATAATCAACCCTAGTGTGGTGGCACAGCTACGCACAGAAGTCCAGGGCAGAGTCACC
 M T R D T S T S T V Y M E L S S L R S E D T A V .
 214 ATGACCGAGGACACGTCCACGAGCACAGTCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGCGCGT
 . Y Y C A R D Y Y V T Y D S W F D S W G Q G T L V .
 285 GTATTACTGTGCAAGAGACTACTATGTTACGTATGATTCCTGTTGACTCTCTGGGGCCAGGTACCCCTGG
 . T V S R
 356 TCACCGTCTCGAGA


Fig. 7, cont'dAnti-Class II V_H fragment (Phage I-2)

M A E V Q L V E S G G L V Q P G R S L R L S C .
 1 ATGGCCGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTGGTACAGCCTGGCAGGTCCCTGAGACTCTCCTG
 . A A S G F T F D D Y A M H W V R Q A P G K G L E .
 72 TGCAGCCTCTGGATTACCTTTGATGATATGCCATGCACCTGGGTCCGGGAAGCTCCAGGGAAGGGCCCTGG
 . W V S G I S W N S G S I G Y A D S V K G R F T
 143 AGTGGTCTCAGGTATTAGTTGGAATAGTGGTAGCAGGCTATGCGGACTCTGTGAAGGCCGATTCAACC
 I S R D N A K N S L Y L Q M N S L R A E D T A V .
 214 ATCTCCAGAGACACGCCCAAGAACTCCCTGTATCTGCAATGAACAGTCTGAGAGCTGAGGACACGCGCGT
 . Y Y C A R D L Y L A H F D Y W G Q G T L V T V S .
 285 GTATTACTGTGCAAGGGACCTTTATCTTGGCCATTTTGACTACTTGGGGCCCAAGGTACCCCTGGTCACCGTCT
 . R
 356 CGAGA

Shared V_L sequence of Phages I-2, II-2 and B28

S S E L T Q D P A V S V A L G Q T V R I T C Q G .
 1 TCGTCTGAGCTGACTCAGGACCTGTGTCTGTGGCTTGGGACAGACAGTCAGGATCAGATGCCAAGG
 . D S L R S Y Y A S W Y Q Q K P G Q A P V L V I Y .
 72 AGACAGCCTCAGAGCTATTATGCAAGCTGGTACCAGCAGAGCCAGGACAGGCCCTGTACTTGTCTCT
 . G K N N R P S G I P D R F S G S S S G N T A S
 143 ATGGTAAACACCGGCCCTCAGGGATCCAGACCCGATTCTCTGGCTCCAGTCCAGGAACACAGCTTCC
 L T I T G A Q A E D E A D Y Y C N S R D S S G N .
 214 TTGACCATCACTGGGGCTCAGCGGGAAGATGAGGCTGACTATTACTGTAACTCCCGGACAGCAGTGGTAA
 . H V V F G G G T K L T V L G A A A
 285 CCATGTGGTATTCGGCGGAGGACCAAGCTGACCCGTCCTAGGTGCGGCCGCA

Fig. 8



pUBS54-IgA

Fig. 9




Fig. 10




Fig. 11




Fig. 12

V_H sequence of K53 IgG

```
1      Q V Q L V Q S G A E V K K P G A S V K V  
      CAGGTGCAGCTGGTGCAGCTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCCTCAGTGAAGGTC  
61     S C K A S G Y T F T S Y G I S W V R Q A  
      TCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGTATCAGCTGGGTGGACAGGCC  
121    P G Q G L E W M G W I S A Y N G N T N Y  
      CCTGGACAAAGGGCTTGACTGGATGGGATGGATCAGCGCTTACAAATGGTAACACAAACTAT  
181    A Q K L Q G R V T M T T D T S T S T A Y  
      GCACAGAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCAGCCTAC  
241    M E L R S L R S D D T A V Y Y C A R G M  
      ATGGAGCTCAGGAGCCTGAGATCTGACGACACGGCGGTGTATTACTGTGCAAGGGGCATG  
301    M R G V F D Y W G Q G T L V T V S T  
      ATGAGGGGTGTGTTTGACTACTGGGGCCCAAGGTACCCCTGGTCACCGTCTCGACA
```

Fig. 12, cont'dV_H sequence of 02-237 IgG

1	Q V Q L V Q S G A E V K K P G A S V K V CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTC
61	S C K A S G Y T F T S Y G I S W V R Q A TCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGTATCAGCTGGGTGGACAGGCC
121	P G Q G L E W M G W I S A Y N G N T N Y CCTGGACAAAGGCTTGAGTGGATGGGATGGATCAGCGCTTACATGGTAACACAAACTAT
181	A Q K L Q G R V T M T T D T S T S T A Y GCACAGAAGCTCCAGGCGAGAGTCACCATGACACAGACACATCCACGAGCAGCCTAC
241	M E L R S L R S D D T A V Y Y C A R G F ATGGAGCTGAGGAGCCTGAGATCTGACGACACGGCGGTGTATTACTGTGCAAGGGGCTTT
301	P R T S F D S W G Q G T L V T V S S CCGCGTACGTGCTTGTACTCTCTGGGCGCAGGGCACCCCTGGTGACCGTCTCTCTCA

Fig. 12, cont'dV_H sequence of UBS54 IgG

1 Q V Q L V Q S G A E V K K P G S S V R V
 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCTCGGTGAGGGTC

 61 S C K A S G G T F S S Y A I S W V R Q A
 TCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGGCAGAGGCC

 121 P G Q G L E W M G G I I P I F G T A N Y
 CCTGGACAAGGGCTTGAGTGGATGGAGGGATCATCCCTATCTTTGGTACAGCAAACTAC

 181 A Q K F Q G R V T I T A D E S T S T A Y
 GCACAGAAGTCCAGGGCAGAGTCACGATTACCGGGGACGAATCCACGAGCAGCCTAC

 241 M E L S S L R S E D T A V Y Y C A R D P
 ATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCTGTGTATTACTGTGCAAGAGACCCG

 301 F L H Y W G Q G T L V T V S T
 TTTCTTCACTATTGGGGCCAGGTACCCCTGGTCAACCGTCTCGACA

Fig. 12, cont'dV_L sequence of K53 and UBS54 IgG

1	E I E L T Q S P L S L P V T P G E P A GAAATTGAGCTCACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCGGCC
58	S I S C R S S Q S L L H S N G Y N Y L D TCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCAAGTAATGATACAACTATTGGAT
118	W Y L Q K P G Q S P Q L L I Y L G S N R TGGTACCTGCAGAAGCCAGGCAGTCTCCACAGTCTCTGATCTATTGGGTTCTAATCGG
178	A S G V P D R F S G S G S G T D F T L K GCCTCCGGGTCCCTGACAGGTTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAA
238	I S R V E A E D V G V Y C M Q A L Q T ATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGATGCAAGCTCTACAACT
298	F T F G P G T K V E I K TTCACTTTCGGCCCTGGGACCAAGGTGGAGATCAAA

Fig. 12, cont'dV_L sequence of 02-237 IgG

1	D I V M T Q S P L S L P V T P G E P A GACATCGTGATGACTCAGTCTCCACTCTCCCTGCCCTCACCCCTGGAGAGCGGCC
58	S I S C R S S Q S L L H S N G Y N Y L D TCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTGGAT
118	W Y L Q K P G Q S P Q L L I Y L G S N R TGGTACCTGCAGAAGCCAGGCGAGTCTCCACAGCTCCTGATCTATTGGGTTCTAATCGG
178	A S G V P D R F S G S G S G T D F T L K GCCTCGGGGTCCCTGACAGGTTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAA
238	I S R V E A E D V G V Y Y C M Q A L Q T ATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAACT
298	F T F G P G T K V E I K TTCACTTTCGGCCCTGGACCAAGGTGGAGATCAAA

FIG. 13

[illegible]

Fig. 14





Fig. 15




Fig. 16A





Fig. 16A, cont'd




Fig. 16B





Fig. 16B, cont'd




Fig. 17





Fig. 17, cont'd




Fig. 17, cont'd




Fig. 18




Fig. 19 Peptide mapping of Polyclonal Poly1-280




Fig. 20




Fig. 21






Fig. 22

A.



B.



C.

